FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Rosell-Negre, P
   Bustamante, JC
   Fuentes-Claramonte, P
   Costumero, V
   Llopis-Llacer, JJ
   Barros-Loscertales, A
AF Rosell-Negre, Patricia
   Bustamante, Juan-Carlos
   Fuentes-Claramonte, Paola
   Costumero, Victor
   Llopis-Llacer, Juan-Jose
   Barros-Loscertales, Alfonso
TI Reward Contingencies Improve Goal-Directed Behavior by Enhancing
   Posterior Brain Attentional Regions and Increasing Corticostriatal
   Connectivity in Cocaine Addicts
SO PLOS ONE
LA English
DT Article
ID IMPAIRED INHIBITORY CONTROL; STROOP-LIKE TASK; COGNITIVE CONTROL;
   PREFRONTAL CORTEX; DECISION-MAKING; DORSAL STRIATUM; PSYCHOPHYSIOLOGICAL
   INTERACTIONS; DEFICIT/HYPERACTIVITY DISORDER; FUNCTIONAL CONNECTIVITY;
   RESPONSE-INHIBITION
AB The dopaminergic system provides the basis for the interaction between motivation and cognition. It is triggered by the possibility of obtaining rewards to initiate the neurobehavioral adaptations necessary to achieve them by directing the information from motivational circuits to cognitive and action circuits. In drug addiction, the altered dopamine (DA) modulation of the meso-cortico-limbic reward circuitry, such as the prefrontal cortex (PFC), underlies the disproportionate motivational value of drug use at the expense of other non drug reinforcers and the user's loss of control over his/her drug intake. We examine how the magnitude of the reward affects goal-directed processes in healthy control (HC) subjects and abstinent cocaine dependent (ACD) patients by using functional magnetic resonance imaging (fMRI) during a counting Stroop task with blocked levels of monetary incentives of different magnitudes ((sic)0, (sic)0.01, (sic)0.5, (sic)1 or (sic)1.5). Our results showed that increasing reward magnitude enhances (1) performance facilitation in both groups; (2) left dorsolateral prefrontal cortex (DLPFC) activity in HC and left superior occipital cortex activity in ACD; and (3) left DLPFC and left putamen connectivity in ACD compared to HC. Moreover, we observed that (4) dorsal striatal and pallidum activity was associated with craving and addiction severity during the parametric increases in the monetary reward. In conclusion, the brain response to gradients in monetary value was different in HC and ACD, but both groups showed improved task performance due to the possibility of obtaining greater monetary rewards.
C1 [Rosell-Negre, Patricia; Fuentes-Claramonte, Paola; Costumero, Victor; Barros-Loscertales, Alfonso] Univ Jaume 1, Dept Psicol Basica Clin & Psicobiol, Castellon de La Plana, Castello De La, Spain.
   [Bustamante, Juan-Carlos] Univ Zaragoza, Dept Psicol & Sociol, Zaragoza, Zaragoza, Spain.
   [Fuentes-Claramonte, Paola] FIDMAG Germanes Hosp Res Fdn Barcelona, Cataluna, Spain.
   [Llopis-Llacer, Juan-Jose] Conselleria Sanitat, Hosp Gen Univ, Unidad Conductas Adict, Castellon De La Plana, Spain.
RP Barros-Loscertales, A (reprint author), Univ Jaume 1, Dept Psicol Basica Clin & Psicobiol, Castellon de La Plana, Castello De La, Spain.
EM barros@uji.es
RI Costumero, Victor/A-5784-2019; Barros-Loscertales, Alfonso/D-7069-2013
OI Costumero, Victor/0000-0002-8743-5239; Fuentes-Claramonte,
   Paola/0000-0002-1428-7976
FU Spanish Ministry of Economy and Competitiveness [PSI2012-33054]; Spanish
   National Drug Strategy [20111040]
FX This research has been supported by Grants PSI2012-33054 from the
   Spanish Ministry of Economy and Competitiveness
   (http://www.mineco.gob.es/), and by 20111040 from the Spanish National
   Drug Strategy (http://www.pnsd.msssi.gob.es/) to ABL. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Aarts E, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00163
   Aarts E, 2010, NEUROPSYCHOPHARMACOL, V35, P1943, DOI 10.1038/npp.2010.68
   Adams ZW, 2011, PSYCHOL ASSESSMENT, V23, P427, DOI 10.1037/a0022112
   Ahmed SH, 2002, NAT NEUROSCI, V5, P625, DOI 10.1038/nn872
   Arias-Carrion Oscar, 2010, Int Arch Med, V3, P24, DOI 10.1186/1755-7682-3-24
   Aron AR, 2011, BIOL PSYCHIAT, V69, pE55, DOI 10.1016/j.biopsych.2010.07.024
   Asensio S, 2010, ADDICT BIOL, V15, P504, DOI 10.1111/j.1369-1600.2010.00230.x
   Ashburner J, SPM8 MANUAL FIL METH
   Balleine BW, 2007, J NEUROSCI, V27, P8161, DOI 10.1523/JNEUROSCI.1554-07.2007
   Barros-Loscertales A, 2011, PSYCHIAT RES-NEUROIM, V194, P111, DOI 10.1016/j.pscychresns.2011.05.001
   Berridge KC, 2008, PSYCHOPHARMACOLOGY, V199, P457, DOI 10.1007/s00213-008-1099-6
   Bolla K, 2004, J NEUROPSYCH CLIN N, V16, P456, DOI 10.1176/appi.neuropsych.16.4.456
   Braver TS, 2014, COGN AFFECT BEHAV NE, V14, P443, DOI 10.3758/s13415-014-0300-0
   Brewer JA, 2008, BIOL PSYCHIAT, V64, P998, DOI 10.1016/j.biopsych.2008.05.024
   Bustamante J. C, 2012, SUBSTANCE ABUSE ASSE
   Bustamante JC, 2014, ADDICT BIOL, V19, P885, DOI 10.1111/adb.12041
   Carmona S, 2012, HUM BRAIN MAPP, V33, P2350, DOI 10.1002/hbm.21368
   Colzato LS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001143
   Cools R, 2007, J NEUROSCI, V27, P5506, DOI 10.1523/JNEUROSCI.0601-07.2007
   Cools R, 2015, CURR OPIN BEHAV SCI, V4, P152, DOI 10.1016/j.cobeha.2015.05.007
   Crunelle CL, 2012, BRAIN BEHAV, V2, P499, DOI 10.1002/brb3.65
   Engelmann JB, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.004.2009
   Everitt BJ, 2013, NEUROSCI BIOBEHAV R, V37, P1946, DOI 10.1016/j.neubiorev.2013.02.010
   Fillmore MT, 2002, DRUG ALCOHOL DEPEN, V66, P265, DOI 10.1016/S0376-8716(01)00206-X
   Fleming SM, 2012, J NEUROSCI, V32, P6117, DOI 10.1523/JNEUROSCI.6489-11.2012
   Fowler Joanna S, 2007, Sci Pract Perspect, V3, P4
   FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007
   Garavan H, 2000, AM J PSYCHIAT, V157, P1789, DOI 10.1176/appi.ajp.157.11.1789
   Garavan H, 2007, NEUROPSYCHOL REV, V17, P337, DOI 10.1007/s11065-007-9034-x
   Garavan H, 2012, PREV MED, V55, pS17, DOI 10.1016/j.ypmed.2012.05.018
   Gilbert Alison M., 2004, Cognitive Affective & Behavioral Neuroscience, V4, P540, DOI 10.3758/CABN.4.4.540
   Gitelman DR, 2003, NEUROIMAGE, V19, P200, DOI 10.1016/S1053-8119(03)00058-2
   Goldstein RZ, 2008, PSYCHOPHYSIOLOGY, V45, P705, DOI 10.1111/j.1469-8986.2008.00670.x
   Goldstein RZ, 2007, DRUG ALCOHOL DEPEN, V87, P233, DOI 10.1016/j.drugalcdep.2006.08.022
   Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119
   Goldstein RZ, 2009, TRENDS COGN SCI, V13, P372, DOI 10.1016/j.tics.2009.06.004
   Goldstein RZ, 2001, NEUROREPORT, V12, P2595, DOI 10.1097/00001756-200108080-00060
   Goldstein RZ, 2007, PSYCHIAT INTERPE JAN, P43
   Gonzalez-Saiz F, 2009, EUR ADDICT RES, V15, P87, DOI 10.1159/000189787
   Grahn JA, 2008, PROG NEUROBIOL, V86, P141, DOI 10.1016/j.pneurobio.2008.09.004
   Guitart-Masip M, 2012, NEUROIMAGE, V62, P154, DOI 10.1016/j.neuroimage.2012.04.024
   Hester R, 2004, J NEUROSCI, V24, P11017, DOI 10.1523/JNEUROSCI.3321-04.2004
   Hester R, 2013, DRUG ALCOHOL DEPEN, V133, P86, DOI 10.1016/j.drugalcdep.2013.05.027
   Hester R, 2009, NEUROPSYCHOPHARMACOL, V34, P2450, DOI 10.1038/npp.2009.67
   Hyatt CJ, 2012, REWARD RELATED DORSA, V7, P1
   Ichihara-Takeda S, 2008, J COGNITIVE NEUROSCI, V20, P563, DOI 10.1162/jocn.2008.20047
   Ikemoto S, 2014, NEUROPHARMACOLOGY, V76, P329, DOI 10.1016/j.neuropharm.2013.04.031
   Ivanov I, 2012, BRAIN BEHAV, V2, P741, DOI 10.1002/brb3.80
   Jasinska AJ, 2014, NEUROSCI BIOBEHAV R, V38, P1, DOI 10.1016/j.neubiorev.2013.10.013
   Jia Z, 2012, INITIAL STUDY NEURAL, V70, P553
   Jimura K, 2010, P NATL ACAD SCI USA, V107, P8871, DOI 10.1073/pnas.1002007107
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Kampman KM, 1998, ADDICT BEHAV, V23, P449, DOI 10.1016/S0306-4603(98)00011-2
   Konova AB, 2012, EUR J NEUROSCI, V36, P2979, DOI 10.1111/j.1460-9568.2012.08211.x
   Krebs RM, 2011, J NEUROSCI, V31, P9752, DOI 10.1523/JNEUROSCI.0732-11.2011
   Kriegeskorte N, 2009, CIRCULAR ANAL SYSTEM, P1
   Leung HC, 2000, CEREB CORTEX, V10, P552, DOI 10.1093/cercor/10.6.552
   Li CSR, 2008, NEUROPSYCHOPHARMACOL, V33, P1798, DOI 10.1038/sj.npp.1301568
   Liu X, 2004, NEUROIMAGE, V22, P1097, DOI 10.1016/j.neuroimage.2004.02.033
   LOGAN GD, 1979, MEM COGNITION, V7, P166, DOI 10.3758/BF03197535
   LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295
   MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163
   Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1
   McFarland K, 2001, J NEUROSCI, V21, P8655
   McLaren DG, 2012, NEUROIMAGE, V61, P1277, DOI 10.1016/j.neuroimage.2012.03.068
   Mitchell Marci R., 2013, PRELIMINARY INVESTIG, V39, P1
   Modesto-Lowe V, 1997, DRUG ALCOHOL DEPEN, V49, P9, DOI 10.1016/S0376-8716(97)00134-8
   Moeller SJ, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.110
   Moeller SJ, 2014, J PSYCHIATR RES, V58, P55, DOI 10.1016/j.jpsychires.2014.07.016
   Moeller SJ, 2014, CEREB CORTEX, V24, P643, DOI 10.1093/cercor/bhs345
   Moeller SJ, 2010, BRAIN, V133, P1484, DOI 10.1093/brain/awq066
   Garcia MAM, 2008, PSICOTHEMA, V20, P545
   Noel X, 2013, CURR OPIN NEUROBIOL, V23, P632, DOI 10.1016/j.conb.2013.01.018
   Noudoost B, 2011, NATURE, V474, P372, DOI 10.1038/nature09995
   Nutt DJ, 2015, NAT REV NEUROSCI, V16, P305, DOI 10.1038/nrn3939
   Panadero A, 2015, CONSCIOUS COGN, V31, P35, DOI 10.1016/j.concog.2014.09.016
   Petty NM, 2002, J CONSULT CLIN PSYCH, V70, P398, DOI 10.1037//0022-006X.70.2.398
   Pochon JB, 2002, P NATL ACAD SCI USA, V99, P5669, DOI 10.1073/pnas.082111099
   Poldrack RA, 2007, SOC COGN AFFECT NEUR, V2, P67, DOI 10.1093/scan/nsm006
   Preacher K. J, 2002, CALCULATION TEST DIF
   Robinson TE, 2003, ANNU REV PSYCHOL, V54, P25, DOI 10.1146/annurev.psych.54.101601.145237
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Rogers RE, 2010, DRUG RELATED ACTIVIT, V22, P544
   Root DH, 2010, SYNAPSE, V64, P704, DOI 10.1002/syn.20792
   Ruiz MJ, 2015, PSYCHOPHARMACOLOGY, V232, P1717, DOI 10.1007/s00213-014-3806-9
   Sinha R, 2005, PSYCHOPHARMACOLOGY, V183, P171, DOI 10.1007/s00213-005-0147-8
   Small DM, 2005, CEREB CORTEX, V15, P1855, DOI 10.1093/cercor/bhi063
   Squire RF, 2013, ANNU REV NEUROSCI, V36, P451, DOI 10.1146/annurev-neuro-062111-150439
   Staudinger MR, 2011, CEREB CORTEX, V21, P2578, DOI 10.1093/cercor/bhr041
   Stefanik MT, 2013, J NEUROSCI, V33, P13654, DOI 10.1523/JNEUROSCI.1570-13.2013
   Stitzer ML, 2010, DRUG ALCOHOL DEPEN, V107, P76, DOI 10.1016/j.drugalcdep.2009.09.006
   Stoppel CM, 2011, BRAIN RES, V1383, P218, DOI 10.1016/j.brainres.2011.01.095
   Tang DW, 2012, PHYSIOL BEHAV, V106, P317, DOI 10.1016/j.physbeh.2012.03.009
   Tau GZ, 2014, NEUROPSYCHOPHARMACOL, V39, P545, DOI 10.1038/npp.2013.189
   Tomasi D, 2007, BRAIN RES, V1171, P83, DOI 10.1016/j.brainres.2007.06.102
   Tomasi D, 2007, PSYCHIAT RES-NEUROIM, V155, P189, DOI 10.1016/j.pseychresns.2007.03.002
   Tricomi E, 2009, EUR J NEUROSCI, V29, P2225, DOI 10.1111/j.1460-9568.2009.06796.x
   Vadhan NP, 2009, DRUG ALCOHOL DEPEN, V102, P95, DOI 10.1016/j.drugalcdep.2009.02.003
   Volkow ND, 2004, NEUROPHARMACOLOGY, V47, P3, DOI 10.1016/j.neuropharm.2004.07.019
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   Volkow ND, 2012, ANNU REV PHARMACOL, V52, P321, DOI 10.1146/annurev-pharmtox-010611-134625
   Watanabe M, 2007, CEREB CORTEX, V17, pI101, DOI 10.1093/cercor/bhm067
   Weiland BJ, 2013, DRUG ALCOHOL DEPEN, V128, P130, DOI 10.1016/j.drugalcdep.2012.08.019
   Wilcox CE, 2011, DRUG ALCOHOL DEPEN, V115, P137, DOI 10.1016/j.drugalcdep.2011.01.009
   Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406
   Worhunsky PD, 2013, PSYCHOL ADDICT BEHAV, V27, P477, DOI 10.1037/a0029092
   Yager LM, 2015, NEUROSCIENCE, V301, P529, DOI 10.1016/j.neuroscience.2015.06.033
NR 107
TC 2
Z9 2
U1 1
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 1
PY 2016
VL 11
IS 12
AR e0167400
DI 10.1371/journal.pone.0167400
PG 22
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EE3JC
UT WOS:000389482700144
PM 27907134
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Trotzke, P
   Starcke, K
   Muller, A
   Brand, M
AF Trotzke, Patrick
   Starcke, Katrin
   Mueller, Astrid
   Brand, Matthias
TI Pathological Buying Online as a Specific Form of Internet Addiction: A
   Model-Based Experimental Investigation
SO PLOS ONE
LA English
DT Article
ID INCENTIVE-SENSITIZATION THEORY; COGNITIVE-BEHAVIORAL MODEL;
   CUE-REACTIVITY; MENSTRUAL-CYCLE; DISORDER; COMORBIDITY; STIMULI; SAMPLE;
   SMOKING; MEMORY
AB The study aimed to investigate different factors of vulnerability for pathological buying in the online context and to determine whether online pathological buying has parallels to a specific Internet addiction. According to a model of specific Internet addiction by Brand and colleagues, potential vulnerability factors may consist of a predisposing excitability from shopping and as mediating variable, specific Internet use expectancies. Additionally, in line with models on addiction behavior, cue-induced craving should also constitute an important factor for online pathological buying. The theoretical model was tested in this study by investigating 240 female participants with a cue-reactivity paradigm, which was composed of online shopping pictures, to assess excitability from shopping. Craving (before and after the cue-reactivity paradigm) and online shopping expectancies were measured. The tendency for pathological buying and online pathological buying were screened with the Compulsive Buying Scale (CBS) and the Short Internet Addiction Test modified for shopping (s-IAT-shopping). The results demonstrated that the relationship between individual's excitability from shopping and online pathological buying tendency was partially mediated by specific Internet use expectancies for online shopping (model's R-2 = .742, p < .001). Furthermore, craving and online pathological buying tendencies were correlated (r = .556, p < .001), and an increase in craving after the cue presentation was observed solely in individuals scoring high for online pathological buying (t(28) = 2.98, p < .01, d = 0.44). Both screening instruments were correlated (r = .517, p < .001), and diagnostic concordances as well as divergences were indicated by applying the proposed cut-off criteria. In line with the model for specific Internet addiction, the study identified potential vulnerability factors for online pathological buying and suggests potential parallels. The presence of craving in individuals with a propensity for online pathological buying emphasizes that this behavior merits potential consideration within the non-substance/behavioral addictions.
C1 [Trotzke, Patrick; Starcke, Katrin; Brand, Matthias] Univ Duisburg Essen, Dept Gen Psychol Cognit, Duisburg, Germany.
   [Mueller, Astrid] Hannover Med Sch, Dept Psychosomat Med & Psychotherapy, Hannover, Germany.
   [Brand, Matthias] Erwin L Hahn Inst Magnet Resonance Imaging, Essen, Germany.
RP Brand, M (reprint author), Univ Duisburg Essen, Dept Gen Psychol Cognit, Duisburg, Germany.
EM matthias.brand@uni-due.de
CR Agarwal V, 2014, J RES MARK, V2, P119
   American Psychiatric Association, 2013, DIAGN STAT MAN MENT
   BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173
   Berridge KC, 2009, CURR OPIN PHARMACOL, V9, P65, DOI 10.1016/j.coph.2008.12.014
   Black DW, 2007, WORLD PSYCHIATRY, V6, P14
   Black DW, 2007, CNS SPECTRUMS, V12, P124, DOI 10.1017/S1092852900020630
   Black DW, 2001, CNS DRUGS, V15, P17, DOI 10.2165/00023210-200115010-00003
   Brand M, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01256
   Brand M, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00375
   Brand M, 2011, CYBERPSYCH BEH SOC N, V14, P371, DOI 10.1089/cyber.2010.0222
   Braus DF, 2001, J NEURAL TRANSM, V108, P887, DOI 10.1007/s007020170038
   Carter BL, 1999, ADDICTION, V94, P327, DOI 10.1046/j.1360-0443.1999.9433273.x
   Chen K., 2004, Human Systems Management, V23, P49
   CHRISTENSON GA, 1994, J CLIN PSYCHIAT, V55, P5
   Claes L, 2012, EUR EAT DISORD REV, V20, P126, DOI 10.1002/erv.1136
   Claes L, 2011, COMPR PSYCHIAT, V52, P50, DOI 10.1016/j.comppsych.2010.05.003
   Cohen J, 1988, STAT POWER ANAL BEHA
   Crockford DN, 2005, BIOL PSYCHIAT, V58, P787, DOI 10.1016/j.biopsych.2005.04.037
   Davenport K, 2012, INT J MENT HEALTH AD, V10, P474, DOI 10.1007/s11469-011-9332-7
   Davis RA, 2001, COMPUT HUM BEHAV, V17, P187, DOI 10.1016/S0747-5632(00)00041-8
   Dittmar H, 2007, J SOC CLIN PSYCHOL, V26, P334, DOI 10.1521/jscp.2007.26.3.334
   Drummond DC, 2000, ADDICTION, V95, pS129
   Drummond DC, 2001, ADDICTION, V96, P33, DOI 10.1046/j.1360-0443.2001.961333.x
   Duroy D, 2014, ADDICT BEHAV, V39, P1827, DOI 10.1016/j.addbeh.2014.07.028
   Faber R. J., 2011, HDB SELF REGULATION, P537
   FABER RJ, 1992, J CONSUM RES, V19, P459, DOI 10.1086/209315
   Franken IHA, 2005, EUR J PHARMACOL, V526, P199, DOI 10.1016/j.ejphar.2005.09.025
   Franken IHA, 2003, PROG NEURO-PSYCHOPH, V27, P563, DOI 10.1016/S0278-5846(03)00081-2
   Grant JE, 2010, AM J DRUG ALCOHOL AB, V36, P233, DOI 10.3109/00952990.2010.491884
   Grusser SM, 2000, J NEURAL TRANSM, V107, P715, DOI 10.1007/s007020070072
   Grusser SM, 2004, WIEN KLIN WOCHENSCHR, V116, P201
   Hollander E, 2006, AM J PSYCHIAT, V163, P1670, DOI 10.1176/appi.ajp.163.10.1670
   HORN JL, 1965, PSYCHOMETRIKA, V30, P179, DOI 10.1007/BF02289447
   Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118
   Kellett S, 2009, CLIN PSYCHOL PSYCHOT, V16, P83, DOI 10.1002/cpp.585
   Koran LM, 2006, AM J PSYCHIAT, V163, P1806, DOI 10.1176/appi.ajp.163.10.1806
   Kukar-Kinney M, 2009, J RETAILING, V85, P298, DOI 10.1016/j.jretai.2009.05.002
   Kuss DJ, 2014, CURR PHARM DESIGN, V20, P4026, DOI 10.2174/13816128113199990617
   Kyrios M, 2004, COGNITIVE THER RES, V28, P241, DOI 10.1023/B:COTR.0000021543.62799.32
   Laier C, 2014, SEX ADDICT COMPULS, V21, P305, DOI 10.1080/10720162.2014.970722
   Laier C, 2013, J BEHAV ADDICT, V2, P100, DOI 10.1556/JBA.2.2013.002
   Laier C, 2013, J SEX RES, V50, P642, DOI 10.1080/00224499.2012.716873
   LaRose R, 2002, J BROADCAST ELECTRON, V46, P549, DOI 10.1207/s15506878jobem4604_4
   LaRose R, 2006, J COMPUT-MEDIAT COMM, V6, DOI [10.1111/j.1083-6101.2001.tb00120.x, DOI 10.1111/J.1083-6101.2001.TB00120.X]
   Lawrence LM, 2014, PSYCHIAT RES-NEUROIM, V221, P97, DOI 10.1016/j.pscychresns.2013.10.005
   Leite PL, 2014, PSYCHIAT RES, V219, P411, DOI 10.1016/j.psychres.2014.05.037
   Lloyd N., 2014, J PROMOT COMMUN, V2, P87
   Love A, 1998, ADDICTION, V93, P1091, DOI 10.1046/j.1360-0443.1998.937109113.x
   Lyons B, 2000, P ANZMAC, P739
   MCELROY SL, 1994, J CLIN PSYCHIAT, V55, P242
   McVay MA, 2012, APPETITE, V59, P591, DOI 10.1016/j.appet.2012.07.011
   Miltenberger RG, 2003, J BEHAV THER EXP PSY, V34, P1, DOI 10.1016/S0005-7916(03)00002-8
   Muller A, 2015, AM J ADDICTION, V24, P132, DOI 10.1111/ajad.12111
   Muller A, 2012, PSYCHIAT RES, V200, P575, DOI 10.1016/j.psychres.2012.04.015
   Mueller A, 2010, PSYCHIAT RES, V180, P137, DOI 10.1016/j.psychres.2009.12.001
   Mueller A, 2010, PSYCHIAT RES, V178, P348, DOI 10.1016/j.psychres.2010.04.021
   Muller A., 2011, COMPR PSYCHIAT, V52, P420, DOI DOI 10.1016/J.C0MPPSYCH.2010.09.001
   Muthen L, 2011, MPLUS
   Neuner M, 2005, J ECON PSYCHOL, V26, P509, DOI 10.1016/j/joep.2004.08.002
   Pawlikowski M, 2013, COMPUT HUM BEHAV, V29, P1212, DOI 10.1016/j.chb.2012.10.014
   Pawlikowski M, 2011, PSYCHIAT RES, V188, P428, DOI 10.1016/j.psychres.2011.05.017
   Potenza MN, 2003, ARCH GEN PSYCHIAT, V60, P828, DOI 10.1001/archpsyc.60.8.828
   Ridgway NM, 2008, J CONSUM RES, V35, P622, DOI 10.1086/591108
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Rose S, 2014, J BEHAV ADDICT, V3, P83, DOI 10.1556/JBA.3.2014.003
   SCHLOSSER S, 1994, GEN HOSP PSYCHIAT, V16, P205, DOI 10.1016/0163-8343(94)90103-1
   Schultz DE, 2015, J RETAIL CONSUM SERV, V23, P99, DOI 10.1016/j.jretconser.2014.10.010
   Sodano R, 2010, J GAMBL STUD, V26, P53, DOI 10.1007/s10899-009-9146-8
   Starcke K, 2013, J BEHAV ADDICT, V2, P17, DOI 10.1556/JBA.1.2012.012
   Stippekohl B, 2010, NEUROPSYCHOPHARMACOL, V35, P1209, DOI 10.1038/npp.2009.227
   Thalemann R, 2007, BEHAV NEUROSCI, V121, P614, DOI 10.1037/0735-7055.121.3.614
   Trotzke P, 2014, PSYCHOSOM MED, V76, P694, DOI 10.1097/PSY.0000000000000126
   van Holst RJ, 2010, NEUROSCI BIOBEHAV R, V34, P87, DOI 10.1016/j.neubiorev.2009.07.007
   Weinberger AH, 2015, NICOTINE TOB RES, V17, P407, DOI 10.1093/ntr/ntu249
   Wolfling K, 2014, BIOMED RES INT, DOI 10.1155/2014/425924
   Young K, 1999, Cyberpsychol Behav, V2, P475, DOI 10.1089/cpb.1999.2.475
   Young KS, 2013, J BEHAV ADDICT, V2, P209, DOI 10.1556/JBA.2.2013.4.3
   Yuan Kai, 2011, Commun Integr Biol, V4, P637
NR 79
TC 15
Z9 15
U1 6
U2 31
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 14
PY 2015
VL 10
IS 10
AR e0140296
DI 10.1371/journal.pone.0140296
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CU0CK
UT WOS:000363183100101
PM 26465593
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Geaney, JT
   Treadway, MT
   Smillie, LD
AF Geaney, Joachim T.
   Treadway, Michael T.
   Smillie, Luke D.
TI Trait Anticipatory Pleasure Predicts Effort Expenditure for Reward
SO PLOS ONE
LA English
DT Article
ID INSTRUMENTAL RESPONSE SELECTION; AFFECTIVE-REACTIVITY HYPOTHESIS;
   INCENTIVE-SENSITIZATION THEORY; DECISION-MAKING; NUCLEUS-ACCUMBENS;
   BEHAVIORAL ACTIVATION; CONSUMMATORY PLEASURE; MOTIVATIONAL DEFICITS;
   DOPAMINE DEPLETIONS; HEDONIC EXPERIENCE
AB Research in motivation and emotion has been increasingly influenced by the perspective that processes underpinning the motivated approach of rewarding goals are distinct from those underpinning enjoyment during reward consummation. This distinction recently inspired the construction of the Temporal Experience of Pleasure Scale (TEPS), a self-report measure that distinguishes trait anticipatory pleasure (pre-reward feelings of desire) from consummatory pleasure (feelings of enjoyment and gratification upon reward attainment). In a university community sample (N = 97), we examined the TEPS subscales as predictors of (1) the willingness to expend effort for monetary rewards, and (2) affective responses to a pleasant mood induction procedure. Results showed that both anticipatory pleasure and a well-known trait measure of reward motivation predicted effort-expenditure for rewards when the probability of being rewarded was relatively low. Against expectations, consummatory pleasure was unrelated to induced pleasant affect. Taken together, our findings provide support for the validity of the TEPS anticipatory pleasure scale, but not the consummatory pleasure scale.
C1 [Geaney, Joachim T.; Smillie, Luke D.] Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic, Australia.
   [Treadway, Michael T.] Emory Univ, Dept Psychol, Atlanta, GA 30322 USA.
RP Geaney, JT (reprint author), Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic, Australia.
EM j.geaney@student.unimelb.edu.au
RI Treadway, Michael/O-9056-2017
OI Smillie, Luke/0000-0001-5148-8358
CR Aberman JE, 1999, NEUROSCIENCE, V92, P545, DOI 10.1016/S0306-4522(99)00004-4
   American Psychiatric Association, 2013, DIAGNOSTIC AND STATI
   Applegate E, 2009, PERS INDIV DIFFER, V47, P452, DOI 10.1016/j.paid.2009.04.017
   Assogna F, 2011, MOVEMENT DISORD, V26, P1825, DOI 10.1002/mds.23815
   Barbano MF, 2007, PSYCHOPHARMACOLOGY, V191, P497, DOI 10.1007/s00213-006-0521-1
   Barch DM, 2014, J ABNORM PSYCHOL, V123, P387, DOI 10.1037/a0036299
   Bardgett ME, 2009, BEHAV NEUROSCI, V123, P242, DOI 10.1037/a0014625
   Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8
   Berridge KC, 2003, TRENDS NEUROSCI, V26, P507, DOI 10.1016/S0166-2236(03)00233-9
   BERRIDGE KC, 1989, BEHAV NEUROSCI, V103, P36, DOI 10.1037/0735-7044.103.1.36
   Berridge KC, 2009, CURR OPIN PHARMACOL, V9, P65, DOI 10.1016/j.coph.2008.12.014
   Buck B, 2013, PSYCHIAT RES, V205, P30, DOI 10.1016/j.psychres.2012.09.008
   CARVER CS, 1994, J PERS SOC PSYCHOL, V67, P319, DOI 10.1037/0022-3514.67.2.319
   Cassidy CM, 2012, SCHIZOPHR RES, V137, P39, DOI 10.1016/j.schres.2012.02.028
   Chentsova-Dutton Y, 2010, PSYCHIAT RES, V179, P176, DOI 10.1016/j.psychres.2009.06.013
   COUSINS MS, 1993, PHARMACOL BIOCHEM BE, V46, P943, DOI 10.1016/0091-3057(93)90226-J
   Croxson PL, 2009, J NEUROSCI, V29, P4531, DOI 10.1523/JNEUROSCI.4515-08.2009
   Damiano CR, 2012, J NEURODEV DISORD, V4, DOI 10.1186/1866-1955-4-13
   Depue RA, 2005, BEHAV BRAIN SCI, V28, P313
   Engel M, 2013, PSYCHIAT RES, V210, P422, DOI 10.1016/j.psychres.2013.07.025
   Epstein LH, 2003, PHYSIOL BEHAV, V78, P221, DOI 10.1016/S0031-9384(02)00978-2
   Favrod J, 2009, ENCEPHALE, V35, P241, DOI 10.1016/j.encep.2008.02.013
   Fervaha G, 2013, J PSYCHIATR RES, V47, P1590, DOI 10.1016/j.jpsychires.2013.08.003
   Finlayson G, 2007, PHYSIOL BEHAV, V90, P36, DOI 10.1016/j.physbeh.2006.08.020
   Freud S, 1950, BEYOND THE PLEASURE
   Gard DE, 2006, J RES PERS, V40, P1086, DOI 10.1016/j.jrp.2005.11.001
   Gard DE, 2007, SCHIZOPHR RES, V93, P253, DOI 10.1016/j.schres.2007.03.008
   Gard DE, 2014, J ABNORM PSYCHOL, V123, P771, DOI 10.1037/abn0000005
   Gold JM, 2013, BIOL PSYCHIAT, V74, P130, DOI 10.1016/j.biopsych.2012.12.022
   Gooding DC, 2014, PSYCHIAT RES, V215, P771, DOI 10.1016/j.psychres.2013.11.009
   Gooding DC, 2014, PSYCHIAT RES, V215, P237, DOI 10.1016/j.psychres.2013.10.012
   Gs D, 2010, OPEN PSYCHIAT J, V4, P1, DOI [DOI 10.2174/1874354401004010001, 10.2174/1874354401004010001]
   Harmon-Jones E, 1998, J PERS SOC PSYCHOL, V74, P1310, DOI 10.1037/0022-3514.74.5.1310
   Harmon-Jones E, 2008, NETHERLANDS J PSYCHO, V64, P132, DOI [10.1007/BF03076416, DOI 10.1007/BF03076416]
   Harmon-Jones E, 2010, BIOL PSYCHOL, V84, P451, DOI 10.1016/j.biopsycho.2009.08.010
   Ho PM, 2015, J PERS ASSESS, V97, P200, DOI 10.1080/00223891.2014.940625
   Holst G, 1993, BERLIN PHILHARMONIC
   Hughes DM, SOC COGN AF IN PRESS, DOI [10.1093/scan/nsu149, DOI 10.1093/SCAN/NSU149]
   Knutson B, 2000, NEUROIMAGE, V12, P20, DOI 10.1006/nimg.2000.0593
   Kurniawan IT, 2013, J NEUROSCI, V33, P6160, DOI 10.1523/JNEUROSCI.4777-12.2013
   Loas G, 2009, ANN MED-PSYCHOL, V167, P641, DOI 10.1016/j.amp.2009.09.002
   Mann CL, 2013, J ABNORM PSYCHOL, V122, P745, DOI 10.1037/a0033069
   Mayer J. D., 1995, J MENTAL IMAGERY, V19, P133
   Mela DJ, 2006, APPETITE, V47, P10, DOI 10.1016/j.appet.2006.02.006
   Mote J, 2014, SCHIZOPHR RES, V159, P76, DOI 10.1016/j.schres.2014.07.048
   Pecina S, 2003, J NEUROSCI, V23, P9395
   Powell JH, 1996, J NEUROL NEUROSUR PS, V60, P416, DOI 10.1136/jnnp.60.4.416
   Revelle W, 1996, PAPER PRESENTED AT T
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   SALAMONE JD, 1994, BEHAV BRAIN RES, V65, P221, DOI 10.1016/0166-4328(94)90108-2
   Schmidt L, 2008, BRAIN, V131, P1303, DOI 10.1093/brain/awn045
   Schweiger D, 2014, SOC COGN AFFECT NEUR, V9, P1608, DOI 10.1093/scan/nst152
   Sherdell L, 2012, J ABNORM PSYCHOL, V121, P51, DOI 10.1037/a0024945
   Smillie LD, 2013, J RES PERS, V47, P580, DOI 10.1016/j.jrp.2013.04.008
   Smillie LD, 2012, J PERS SOC PSYCHOL, V103, P306, DOI 10.1037/a0028372
   SNAITH RP, 1995, BRIT J PSYCHIAT, V167, P99, DOI 10.1192/bjp.167.1.99
   Strauss GP, 2013, SCHIZOPHRENIA BULL, V39, P872, DOI 10.1093/schbul/sbs186
   Strauss GP, 2011, PSYCHIAT RES, V187, P36, DOI 10.1016/j.psychres.2011.01.012
   Treadway MT, 2015, SCHIZOPHR RES, V161, P382, DOI 10.1016/j.schres.2014.11.024
   Treadway MT, 2013, CURR DIR PSYCHOL SCI, V22, P244, DOI 10.1177/0963721412474460
   Treadway MT, 2012, J ABNORM PSYCHOL, V121, P553, DOI 10.1037/a0028813
   Treadway MT, 2012, J NEUROSCI, V32, P6170, DOI 10.1523/JNEUROSCI.6459-11.2012
   Treadway MT, 2011, NEUROSCI BIOBEHAV R, V35, P537, DOI 10.1016/j.neubiorev.2010.06.006
   Treadway MT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006598
   Triscoli C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113425
   Tso IF, 2014, PSYCHIAT RES, V219, P470, DOI 10.1016/j.psychres.2014.06.030
   Wardle MC, 2011, J NEUROSCI, V31, P16597, DOI 10.1523/JNEUROSCI.4387-11.2011
   Westermann R, 1996, EUR J SOC PSYCHOL, V26, P557, DOI 10.1002/(SICI)1099-0992(199607)26:4<557::AID-EJSP769>3.0.CO;2-4
   WHEELER RE, 1993, PSYCHOPHYSIOLOGY, V30, P82, DOI 10.1111/j.1469-8986.1993.tb03207.x
   Winer ES, 2014, J AFFECT DISORDERS, V152, P193, DOI 10.1016/j.jad.2013.09.010
   Wynn JK, 2010, INT J PSYCHOPHYSIOL, V77, P141, DOI 10.1016/j.ijpsycho.2010.05.009
   Yang XH, 2014, PSYCHIAT RES, V220, P874, DOI 10.1016/j.psychres.2014.08.056
   Yik M, 2011, EMOTION, V11, P705, DOI 10.1037/a0023980
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 75
TC 13
Z9 14
U1 3
U2 27
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 26
PY 2015
VL 10
IS 6
AR e0131357
DI 10.1371/journal.pone.0131357
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CN1AM
UT WOS:000358147500144
PM 26115223
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Machulska, A
   Zlomuzica, A
   Adolph, D
   Rinck, M
   Margraf, J
AF Machulska, Alla
   Zlomuzica, Armin
   Adolph, Dirk
   Rinck, Mike
   Margraf, Juergen
TI "A Cigarette a Day Keeps the Goodies Away": Smokers Show Automatic
   Approach Tendencies for Smoking-But Not for Food-Related Stimuli
SO PLOS ONE
LA English
DT Article
ID INCENTIVE-SENSITIZATION THEORY; APPROACH-BIAS; ADDICTION; CUES; ALCOHOL;
   DYSREGULATION; NONSMOKERS; DEPENDENCE; BEHAVIORS; RESPONSES
AB Smoking leads to the development of automatic tendencies that promote approach behavior toward smoking-related stimuli which in turn may maintain addictive behavior. The present study examined whether automatic approach tendencies toward smoking-related stimuli can be measured by using an adapted version of the Approach-Avoidance Task (AAT). Given that progression of addictive behavior has been associated with a decreased reactivity of the brain reward system for stimuli signaling natural rewards, we also used the AAT to measure approach behavior toward natural rewarding stimuli in smokers. During the AAT, 92 smokers and 51 non-smokers viewed smoking-related vs. non-smoking-related pictures and pictures of natural rewards (i.e. highly palatable food) vs. neutral pictures. They were instructed to ignore image content and to respond to picture orientation by either pulling or pushing a joystick. Within-group comparisons revealed that smokers showed an automatic approach bias exclusively for smoking-related pictures. Contrary to our expectations, there was no difference in smokers' and non-smokers' approach bias for nicotine-related stimuli, indicating that non-smokers also showed approach tendencies for this picture category. Yet, in contrast to non-smokers, smokers did not show an approach bias for food-related pictures. Moreover, self-reported smoking attitude could not predict approach-avoidance behavior toward nicotine-related pictures in smokers or non-smokers. Our findings indicate that the AAT is suited for measuring smoking-related approach tendencies in smokers. Furthermore, we provide evidence for a diminished approach tendency toward food-related stimuli in smokers, suggesting a decreased sensitivity to natural rewards in the course of nicotine addiction. Our results indicate that in contrast to similar studies conducted in alcohol, cannabis and heroin users, the AAT might only be partially suited for measuring smoking-related approach tendencies in smokers. Nevertheless, our findings are of special importance for current etiological models and smoking cessation programs aimed at modifying nicotine-related approach tendencies in the context of a nicotine addiction.
C1 [Machulska, Alla; Zlomuzica, Armin; Adolph, Dirk; Rinck, Mike; Margraf, Juergen] Ruhr Univ Bochum, Mental Hlth Res & Treatment Ctr, Univ Str 150, Bochum, Germany.
   [Rinck, Mike] Radboud Univ Nijmegen, Inst Behav Sci, NL-6525 ED Nijmegen, Netherlands.
RP Margraf, J (reprint author), Ruhr Univ Bochum, Mental Hlth Res & Treatment Ctr, Univ Str 150, Bochum, Germany.
EM juergen.margraf@rub.de
RI Margaf, Jurgen/A-6873-2008; Rinck, Mike/A-6944-2010
OI Margaf, Jurgen/0000-0001-5207-7016; Machulska, Alla/0000-0001-5968-429X
FU Alexander von Humboldt Foundation
FX This study was funded by a research grant to Jurgen Margraf by the
   Alexander von Humboldt Foundation
   (http://www.humboldt-foundation.de/web/start.html). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Bradley BP, 2008, J PSYCHOPHARMACOL, V22, P737, DOI 10.1177/0269881107083844
   Cousijn J, 2011, ADDICTION, V106, P1667, DOI 10.1111/j.1360-0443.2011.03475.x
   Crawford JR, 2003, BRIT J CLIN PSYCHOL, V42, P111, DOI 10.1348/014466503321903544
   De Houwer J, 2003, PSYCHOLOGY OF EVALUATION, P219
   Deutsch R, 2006, PSYCHOL INQ, V17, P166, DOI 10.1207/s15327965pli1703_2
   Eberl C, 2013, DEV COGN NEUROS-NETH, V4, P38, DOI 10.1016/j.dcn.2012.11.002
   Ernst LH, 2014, ADDICT BIOL, V19, P497, DOI 10.1111/adb.12005
   HEATHERTON TF, 1991, BRIT J ADDICT, V86, P1119
   HEINZ A, 1994, PHARMACOPSYCHIATRY, V27, P7, DOI 10.1055/s-2007-1014317
   Kassel JD, 2003, PSYCHOL BULL, V129, P270, DOI 10.1037/0033-2909.129.2.270
   Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0
   Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52
   Kroemer NB, 2013, NEUROPSYCHOPHARMACOL, V38, P2307, DOI 10.1038/npp.2013.133
   Lang P. J, 1995, INT AFFECTIVE PICTUR
   Lovibond SH, 1995, MANUAL DEPRESSION AN
   Lubman DI, 2009, ARCH GEN PSYCHIAT, V66, P205, DOI 10.1001/archgenpsychiatry.2008.522
   McCabe RE, 2004, J ANXIETY DISORD, V18, P7, DOI 10.1016/j.janxdis.2003.07.003
   Mogg K, 2005, PSYCHOPHARMACOLOGY, V180, P333, DOI 10.1007/s00213-005-2158-x
   Peters J, 2011, AM J PSYCHIAT, V168, P540, DOI 10.1176/appi.ajp.2010.10071024).
   Rinck M, 2007, J BEHAV THER EXP PSY, V38, P105, DOI 10.1016/j.jbtep.2006.10.001
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Rubinstein ML, 2011, NICOTINE TOB RES, V13, P751, DOI 10.1093/ntr/ntr046
   Stippekohl B, 2012, PSYCHOPHARMACOLOGY, V222, P593, DOI 10.1007/s00213-012-2670-8
   Stippekohl B, 2010, NEUROPSYCHOPHARMACOL, V35, P1209, DOI 10.1038/npp.2009.227
   Strack F, 2004, PERS SOC PSYCHOL REV, V8, P220, DOI 10.1207/s15327957pspr0803_1
   Swanson JE, 2001, COGNITION EMOTION, V15, P207, DOI 10.1080/0269993004200060
   Waters AJ, 2003, ADDICTION, V98, P1409, DOI 10.1046/j.1360-0443.2003.00465.x
   Watson P, 2013, J EXP PSYCHOPATHOL, V4, P250, DOI 10.5127/jep.030512
   Wiers CE, 2013, PSYCHOPHARMACOLOGY, V229, P187, DOI 10.1007/s00213-013-3098-5
   Wiers RW, 2009, GENES BRAIN BEHAV, V8, P101, DOI 10.1111/j.1601-183X.2008.00454.x
   Wiers RW, 2007, PHARMACOL BIOCHEM BE, V86, P263, DOI 10.1016/j.pbb.2006.09.021
   Wiers RW, 2013, CLIN PSYCHOL SCI, V1, P192, DOI 10.1177/2167702612466547
   Wiers RW, 2011, PSYCHOL SCI, V22, P490, DOI 10.1177/0956797611400615
   Wiers RW, 2010, ADDICTION, V105, P279, DOI 10.1111/j.1360-0443.2009.02775.x
   Zhou YY, 2012, PSYCHOPHARMACOLOGY, V221, P171, DOI 10.1007/s00213-011-2557-0
NR 36
TC 17
Z9 17
U1 0
U2 26
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 18
PY 2015
VL 10
IS 2
AR e0116464
DI 10.1371/journal.pone.0116464
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CC0WZ
UT WOS:000350061500015
PM 25692468
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Voon, V
   Mole, TB
   Banca, P
   Porter, L
   Morris, L
   Mitchell, S
   Lapa, TR
   Karr, J
   Harrison, NA
   Potenza, MN
   Irvine, M
AF Voon, Valerie
   Mole, Thomas B.
   Banca, Paula
   Porter, Laura
   Morris, Laurel
   Mitchell, Simon
   Lapa, Tatyana R.
   Karr, Judy
   Harrison, Neil A.
   Potenza, Marc N.
   Irvine, Michael
TI Neural Correlates of Sexual Cue Reactivity in Individuals with and
   without Compulsive Sexual Behaviours
SO PLOS ONE
LA English
DT Article
ID IMPULSE-CONTROL DISORDERS; CINGULATE CORTEX; PSYCHIATRIC-INPATIENTS;
   HYPERSEXUAL DISORDER; PARKINSONS-DISEASE; COGNITIVE CONTROL; BRAIN
   POTENTIALS; FRONTAL-CORTEX; COCAINE CUES; HUMAN MALES
AB Although compulsive sexual behaviour (CSB) has been conceptualized as a "behavioural" addiction and common or overlapping neural circuits may govern the processing of natural and drug rewards, little is known regarding the responses to sexually explicit materials in individuals with and without CSB. Here, the processing of cues of varying sexual content was assessed in individuals with and without CSB, focusing on neural regions identified in prior studies of drug-cue reactivity. 19 CSB subjects and 19 healthy volunteers were assessed using functional MRI comparing sexually explicit videos with nonsexual exciting videos. Ratings of sexual desire and liking were obtained. Relative to healthy volunteers, CSB subjects had greater desire but similar liking scores in response to the sexually explicit videos. Exposure to sexually explicit cues in CSB compared to non-CSB subjects was associated with activation of the dorsal anterior cingulate, ventral striatum and amygdala. Functional connectivity of the dorsal anterior cingulate-ventral striatum-amygdala network was associated with subjective sexual desire (but not liking) to a greater degree in CSB relative to non-CSB subjects. The dissociation between desire or wanting and liking is consistent with theories of incentive motivation underlying CSB as in drug addictions. Neural differences in the processing of sexual-cue reactivity were identified in CSB subjects in regions previously implicated in drug-cue reactivity studies. The greater engagement of corticostriatal limbic circuitry in CSB following exposure to sexual cues suggests neural mechanisms underlying CSB and potential biological targets for interventions.
C1 [Voon, Valerie; Mole, Thomas B.; Banca, Paula; Porter, Laura; Morris, Laurel; Mitchell, Simon; Lapa, Tatyana R.; Irvine, Michael] Univ Cambridge, Addenbrookes Hosp, Dept Psychiat, Cambridge CB2 2QQ, England.
   [Voon, Valerie; Morris, Laurel] Univ Cambridge, Behav & Clin Neurosci Inst, Cambridge CB2 2QQ, England.
   [Voon, Valerie; Mole, Thomas B.; Mitchell, Simon] Cambridgeshire & Peterborough Fdn Trust, Cambridge, England.
   [Karr, Judy] British Assoc Counselling & Psychotherapy, London, England.
   [Harrison, Neil A.] Brighton & Sussex Med Sch, Dept Psychiat, Brighton, E Sussex, England.
   [Potenza, Marc N.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA.
   [Potenza, Marc N.] Yale Univ, Dept Neurobiol, New Haven, CT USA.
   [Potenza, Marc N.] Yale Univ, Ctr Child Study, New Haven, CT 06520 USA.
RP Voon, V (reprint author), Univ Cambridge, Addenbrookes Hosp, Dept Psychiat, Cambridge CB2 2QQ, England.
EM vv247@cam.ac.uk
RI Voon, Valerie/O-7038-2017; Banca, Paula/G-8330-2017; Mole,
   Tom/P-7588-2015
OI Voon, Valerie/0000-0001-6790-1776; Banca, Paula/0000-0001-7617-3635;
   Mole, Tom/0000-0001-8732-8188; Harrison, Neil/0000-0002-9584-3769;
   Morris, Laurel/0000-0002-5862-6650
FU Wellcome Trust Intermediate Fellowship grant [093705/Z/10/Z]; National
   Institutes of Health [DA027844, R01 DA018647]; Connecticut State
   Department of Mental Health and Addiction Services; Connecticut Mental
   Health Center; Center of Excellence in Gambling Research Award from the
   National Center for Responsible Gaming; Medical Research Council
   [G0001354B, G0001354, G1000183B]
FX Funding provided by Wellcome Trust Intermediate Fellowship grant
   (093705/Z/10/Z). Dr. Potenza was supported in part by grants P20
   DA027844 and R01 DA018647 from the National Institutes of Health; the
   Connecticut State Department of Mental Health and Addiction Services;
   the Connecticut Mental Health Center; and a Center of Excellence in
   Gambling Research Award from the National Center for Responsible Gaming.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Arnow BA, 2002, BRAIN, V125, P1014, DOI 10.1093/brain/awf108
   Association AP, 2013, DIAGN STAT MAN MENT
   BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561
   Bocher M, 2001, NEUROIMAGE, V14, P105, DOI 10.1006/nimg.2001.0794
   Carnes P.J, 2001, SHADOWS NET BREAKING
   Chambers RA, 2003, AM J PSYCHIAT, V160, P1041, DOI 10.1176/appi.ajp.160.6.1041
   Childress A R, 1993, NIDA Res Monogr, V137, P73
   Delmonico DL, 2003, SEXUAL RELATIONSHIP, V18
   Dunning JP, 2011, EUR J NEUROSCI, V33, P1716, DOI 10.1111/j.1460-9568.2011.07663.x
   Euser AS, 2012, NEUROSCI BIOBEHAV R, V36, P572, DOI 10.1016/j.neubiorev.2011.09.002
   Ferretti A, 2005, NEUROIMAGE, V26, P1086, DOI 10.1016/j.neuroimage.2005.03.025
   Fong Timothy W, 2006, Psychiatry (Edgmont), V3, P51
   Franken IHA, 2004, J PSYCHOPHARMACOL, V18, P544, DOI 10.1177/0269881104047282
   Franken IHA, 2003, PSYCHOPHARMACOLOGY, V170, P205, DOI 10.1007/s00213-003-1542-7
   Galvan A, 2006, J NEUROSCI, V26, P6885, DOI 10.1523/JNEUROSCI.1062-06.2006
   Grant JE, 2005, AM J PSYCHIAT, V162, P2184, DOI 10.1176/appi.ajp.162.11.2184
   Grant JE, 2007, J CLIN PSYCHIAT, V68, P1584, DOI 10.4088/JCP.v68n1018
   Hamann S, 2004, NAT NEUROSCI, V7, P411, DOI 10.1038/nn1208
   Hayden BY, 2010, J NEUROSCI, V30, P3339, DOI 10.1523/JNEUROSCI.4874-09.2010
   Heinze M, 2007, CLIN NEUROPHYSIOL, V118, P856, DOI 10.1016/j.clinph.2006.12.003
   Kafka MP, 2010, ARCH SEX BEHAV, V39, P377, DOI 10.1007/s10508-009-9574-7
   Kataoka H, 2009, MOVEMENT DISORD, V24, P471, DOI 10.1002/mds.22373
   Kor A, 2013, SEX ADDICT COMPULSIV, V20
   Kuhn S, 2014, JAMA PSYCHIAT
   Kuhn S, 2011, J SEX MED, V8, P2269, DOI 10.1111/j.1743-6109.2011.02322.x
   Kuhn S, 2011, EUR J NEUROSCI, V33, P1318, DOI 10.1111/j.1460-9568.2010.07590.x
   Linden DEJ, 2005, NEUROSCIENTIST, V11, P563, DOI 10.1177/1073858405280524
   Lubman DI, 2008, J PSYCHOPHARMACOL, V22, P836, DOI 10.1177/0269881107083846
   Maldjian JA, 2003, NEUROIMAGE, V19, P1233, DOI 10.1016/S1053-8119(03)00169-1
   Martinez D, 2003, J CEREBR BLOOD F MET, V23, P285, DOI 10.1097/01.WCB.0000048520.34839.1A
   McGahuey CA, 2000, J SEX MARITAL THER, V26, P25, DOI 10.1080/009262300278623
   Meerkerk GJ, 2009, CYBERPSYCHOL BEHAV, V12, P1, DOI 10.1089/cpb.2008.0181
   Miner MH, 2009, PSYCHIAT RES-NEUROIM, V174, P146, DOI 10.1016/j.pscychresns.2009.04.008
   Mouras H, 2003, NEUROIMAGE, V20, P855, DOI 10.1016/S1053-8119(03)00408-7
   Murray GK, 2008, MOL PSYCHIATR, V13, P267, DOI 10.1038/sj.mp.4002058
   Nelson H.E., 1982, NATL ADULT READING T
   Odlaug BL, 2010, PRIM CARE COMPANION, P12
   Odlaug BL, 2013, ANN CLIN PSYCHIATRY, V25, P193
   Paul T, 2008, HUM BRAIN MAPP, V29, P726, DOI 10.1002/hbm.20435
   Perry DC, 2014, BRAIN
   Petry NM, 2013, ADDICTION, V108, P1186, DOI 10.1111/add.12162
   Poldrack RA, 2008, NEUROIMAGE, V40, P409, DOI 10.1016/j.neuroimage.2007.11.048
   Politis M, 2013, BRAIN, V136, P400, DOI 10.1093/brain/aws326
   Redoute J, 2000, HUM BRAIN MAPP, V11, P162, DOI 10.1002/1097-0193(200011)11:3<162::AID-HBM30>3.0.CO;2-A
   Reid RC, 2013, SEXUAL ADDICTION COM, V20, P14
   Reid RC, 2012, J SEX MED, V9, P2868, DOI 10.1111/j.1743-6109.2012.02936.x
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Rudebeck PH, 2008, J NEUROSCI, V28, P13775, DOI 10.1523/JNEUROSCI.3541-08.2008
   Rushworth MFS, 2011, NEURON, V70, P1054, DOI 10.1016/j.neuron.2011.05.014
   SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x
   Sescousse G, 2013, NEUROSCI BIOBEHAV R, V37, P681, DOI 10.1016/j.neubiorev.2013.02.002
   Shackman AJ, 2011, NAT REV NEUROSCI, V12, P154, DOI 10.1038/nrn2994
   Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi
   Shenhav A, 2013, NEURON, V79, P217, DOI 10.1016/j.neuron.2013.07.007
   Smith DG, 2014, BIOL PSYCHIAT, V75, P124, DOI 10.1016/j.biopsych.2013.05.019
   Somerville LH, 2010, CURR OPIN NEUROBIOL, V20, P236, DOI 10.1016/j.conb.2010.01.006
   Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154
   Spielberger CD, 1983, MANUAL STATE TRAIT A
   Steele VR, 2013, SOCIOAFFECTIVE NEURO, V3, DOI 10.3402/snp.v3i0.20770
   Stoleru S, 1999, ARCH SEX BEHAV, V28, P1, DOI 10.1023/A:1018733420467
   van de Laar MC, 2004, PSYCHOPHARMACOLOGY, V177, P121, DOI 10.1007/s00213-004-1928-1
   Voon V, 2006, NEUROLOGY, V67, P1254, DOI 10.1212/01.wnl.0000238503.20816.13
   Wallis JD, 2010, CURR OPIN NEUROBIOL, V20, P191, DOI 10.1016/j.conb.2010.02.009
   Warren CA, 1999, CLIN NEUROPHYSIOL, V110, P1570, DOI 10.1016/S1388-2457(99)00089-9
   Weintraub D, 2010, ARCH NEUROL-CHICAGO, V67, P589, DOI 10.1001/archneurol.2010.65
   Whiteside SP, 2001, PERS INDIV DIFFER, V30, P669, DOI 10.1016/S0191-8869(00)00064-7
   Williams SM, 1998, CEREB CORTEX, V8, P321, DOI 10.1093/cercor/8.4.321
   Young KS, 1998, CYBERPSYCHOL BEHAV, V1, P237, DOI DOI 10.1089/CPB.1998.1.237
NR 68
TC 98
Z9 98
U1 2
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 11
PY 2014
VL 9
IS 7
AR e102419
DI 10.1371/journal.pone.0102419
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AL8HH
UT WOS:000339378400094
PM 25013940
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Forbes, EE
   Rodriguez, EE
   Musselman, S
   Narendran, R
AF Forbes, Erika E.
   Rodriguez, Eric E.
   Musselman, Samuel
   Narendran, Rajesh
TI Prefrontal Response and Frontostriatal Functional Connectivity to
   Monetary Reward in Abstinent Alcohol-Dependent Young Adults
SO PLOS ONE
LA English
DT Article
ID ORBITOFRONTAL CORTEX; DECISION-MAKING; HEALTHY ADOLESCENTS; STRIATAL
   ACTIVATION; BRAIN ACTIVATION; VENTRAL STRIATUM; POSITIVE AFFECT; NEURAL
   BASIS; RISK-TAKING; ADDICTION
AB Although altered function in neural reward circuitry is widely proposed in models of addiction, more recent conceptual views have emphasized the role of disrupted response in prefrontal regions. Changes in regions such as the orbitofrontal cortex, medial prefrontal cortex, and dorsolateral prefrontal cortex are postulated to contribute to the compulsivity, impulsivity, and altered executive function that are central to addiction. In addition, few studies have examined function in these regions during young adulthood, when exposure is less chronic than in typical samples of alcohol-dependent adults. To address these issues, we examined neural response and functional connectivity during monetary reward in 24 adults with alcohol dependence and 24 psychiatrically healthy adults. Adults with alcohol dependence exhibited less response to the receipt of monetary reward in a set of prefrontal regions including the medial prefrontal cortex, lateral orbitofrontal cortex, and dorsolateral prefrontal cortex. Adults with alcohol dependence also exhibited greater negative correlation between function in each of these regions and that in the nucleus accumbens. Within the alcohol-dependent group, those with family history of alcohol dependence exhibited lower mPFC response, and those with more frequent drinking exhibited greater negative functional connectivity between the mPFC and the nucleus accumbens. These findings indicate that alcohol dependence is associated with less engagement of prefrontal cortical regions, suggesting weak or disrupted regulation of ventral striatal response. This pattern of prefrontal response and frontostriatal connectivity has consequences for the behavior patterns typical of addiction. Furthermore, brain-behavior findings indicate that the potential mechanisms of disruption in frontostriatal circuitry in alcohol dependence include family liability to alcohol use problems and more frequent use of alcohol. In all, these findings build on the extant literature on reward-circuit function in addiction and suggest mechanisms for disrupted function in alcohol dependence.
C1 [Forbes, Erika E.; Rodriguez, Eric E.; Musselman, Samuel; Narendran, Rajesh] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA.
   [Forbes, Erika E.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA.
   [Forbes, Erika E.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA.
   [Narendran, Rajesh] Univ Pittsburgh, Sch Med, Dept Radiol, Pittsburgh, PA USA.
RP Forbes, EE (reprint author), Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA.
EM forbese@upmc.edu
RI Forbes, Erika/J-2445-2015
OI Forbes, Erika/0000-0003-0659-7744
FU NIH [R01 AA018330]; National Institutes of Health [R01 DA026222, R01
   MH093605, R21DA 033612]
FX This study was funded by NIH R01 AA018330 (www.niaaa.nih.gov). The
   authors' work on this project was also supported by National Institutes
   of Health grants R01 DA026222 (Dr. Forbes, PI), R01 MH093605 (Dr.
   Forbes, PI), and R21DA 033612 ( Dr. Forbes, PI). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Alfonso-Loeches S, 2011, CRIT REV CL LAB SCI, V48, P19, DOI 10.3109/10408363.2011.580567
   Bari A, 2013, PROG NEUROBIOL, V108, P44, DOI 10.1016/j.pneurobio.2013.06.005
   Beck A, 2012, ARCH GEN PSYCHIAT, V69, P842, DOI 10.1001/archgenpsychiatry.2011.2026
   Beck A, 2009, BIOL PSYCHIAT, V66, P734, DOI 10.1016/j.biopsych.2009.04.035
   Bjork JM, 2008, ADDICTION, V103, P1308, DOI 10.1111/j.1360-0443.2008.02250.x
   Bjork JM, 2004, J NEUROSCI, V24, P1793, DOI 10.1523/JNEUROSCI.4862-03.2004
   Braskie MN, 2008, J NEUROSCI, V28, P14320, DOI 10.1523/JNEUROSCI.3729-08.2008
   Braus DF, 2001, J NEURAL TRANSM, V108, P887, DOI 10.1007/s007020170038
   Claus ED, 2011, NEUROPSYCHOPHARMACOL, V36, P2086, DOI 10.1038/npp.2011.99
   Crunelle CL, 2012, BRAIN BEHAV, V2, P499, DOI 10.1002/brb3.65
   Cservenka A, 2012, ALCOHOL CLIN EXP RES, V36, P604, DOI 10.1111/j.1530-0277.2011.01650.x
   Dixon ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051637
   Dreher JC, 2008, P NATL ACAD SCI USA, V105, P15106, DOI 10.1073/pnas.0802127105
   Elliott R, 2000, CEREB CORTEX, V10, P308, DOI 10.1093/cercor/10.3.308
   Elliott R, 2010, CEREB CORTEX, V20, P198, DOI 10.1093/cercor/bhp092
   Etkin A, 2011, TRENDS COGN SCI, V15, P85, DOI 10.1016/j.tics.2010.11.004
   Everitt BJ, 2013, NEUROSCI BIOBEHAV R, V37, P1946, DOI 10.1016/j.neubiorev.2013.02.010
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Fecteau S, 2010, SUBST USE MISUSE, V45, P1766, DOI 10.3109/10826084.2010.482434
   First M. B., 2002, STRUCTURED CLIN INTE
   Forbes EE, 2009, MOL PSYCHIATR, V14, P60, DOI 10.1038/sj.mp.4002086
   Forbes EE, 2010, J AM ACAD CHILD PSY, V49, P162, DOI 10.1016/j.jaac.2009.11.006
   Forbes EE, 2009, AM J PSYCHIAT, V166, P64, DOI 10.1176/appi.ajp.2008.07081336
   Galvan A, 2006, J NEUROSCI, V26, P6885, DOI 10.1523/JNEUROSCI.1062-06.2006
   George MS, 2001, ARCH GEN PSYCHIAT, V58, P345, DOI 10.1001/archpsyc.58.4.345
   Goldstein RZ, 2011, NAT REV NEUROSCI, V12, P652, DOI 10.1038/nrn3119
   Grusser SM, 2004, PSYCHOPHARMACOLOGY, V175, P296, DOI 10.1007/s00213-004-1828-4
   Haber SN, 2010, NEUROPSYCHOPHARMACOL, V35, P4, DOI 10.1038/npp.2009.129
   Hare TA, 2009, SCIENCE, V324, P646, DOI 10.1126/science.1168450
   Heinz A, 2004, AM J PSYCHIAT, V161, P1783, DOI 10.1176/appi.ajp.161.10.1783
   Hingson RW, 2006, ARCH PEDIAT ADOL MED, V160, P739, DOI 10.1001/archpedi.160.7.739
   Kalivas PW, 2005, AM J PSYCHIAT, V162, P1403, DOI 10.1176/appi.ajp.162.8.1403
   Koob GF, 2013, CURR TOP BEHAV NEURO, V13, P3, DOI 10.1007/7854_2011_129
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Levy DJ, 2012, CURR OPIN NEUROBIOL, V22, P1027, DOI 10.1016/j.conb.2012.06.001
   Li CSR, 2009, ALCOHOL CLIN EXP RES, V33, P740, DOI 10.1111/j.1530-0277.2008.00891.x
   Liu X, 2011, NEUROSCI BIOBEHAV R, V35, P1219, DOI 10.1016/j.neubiorev.2010.12.012
   Lodge DJ, 2011, NEUROPSYCHOPHARMACOL, V36, P1227, DOI 10.1038/npp.2011.7
   Muller KU, 2013, JAMA PSYCHIAT, V70, P847, DOI 10.1001/jamapsychiatry.2013.44
   Murphy A, 2012, FRONT INTEGR NEUROSC, V6, DOI 10.3389/fnint.2012.00101
   Nees F, 2012, NEUROPSYCHOPHARMACOL, V37, P986, DOI 10.1038/npp.2011.282
   Park SQ, 2010, J NEUROSCI, V30, P7749, DOI 10.1523/JNEUROSCI.5587-09.2010
   Peters J, 2011, AM J PSYCHIAT, V168, P540, DOI 10.1176/appi.ajp.2010.10071024).
   Phillips M, 2008, MOL PSYCHIATR, V13, P833, DOI 10.1038/mp.2008.65
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Rudebeck PH, 2011, ANN NY ACAD SCI, V1239, P1, DOI 10.1111/j.1749-6632.2011.06267.x
   Rushworth MFS, 2011, NEURON, V70, P1054, DOI 10.1016/j.neuron.2011.05.014
   Schneider S, 2012, AM J PSYCHIAT, V169, P39, DOI 10.1176/appi.ajp.2011.11030489
   Selemon LD, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.7
   Skinner H, 1984, ALCOHOL DEPENDENCE S
   Spear LP, 2014, NEUROTOXICOL TERATOL, V41, P51, DOI 10.1016/j.ntt.2013.11.006
   Stoltenberg SF, 1998, ADDICTION, V93, P1511, DOI 10.1046/j.1360-0443.1998.931015117.x
   Vago DR, 2012, FRONT HUM NEUROSCI, V6, DOI 10.3389/fnhum.2012.00296
   Volkow ND, 2011, MOL PSYCHIATR, V16, P818, DOI 10.1038/mp.2011.30
   Volkow ND, 2009, NEUROPHARMACOLOGY, V56, P3, DOI 10.1016/j.neuropharm.2008.05.022
   Volkow ND, 2007, J NEUROSCI, V27, P12700, DOI 10.1523/JNEUROSCI.3371-07.2007
   Wallis JD, 2007, ANNU REV NEUROSCI, V30, P31, DOI 10.1146/annurev.neuro.30.051606.094334
   Weiland BJ, 2013, DRUG ALCOHOL DEPEN, V128, P130, DOI 10.1016/j.drugalcdep.2012.08.019
   Wrase J, 2002, EUR PSYCHIAT, V17, P287, DOI 10.1016/S0924-9338(02)00676-4
   Wrase J, 2007, NEUROIMAGE, V35, P787, DOI 10.1016/j.neuroimage.2006.11.043
   Yau WYW, 2012, J NEUROSCI, V32, P2544, DOI 10.1523/JNEUROSCI.1390-11.2012
   ZUCKER RA, 1994, ANN NY ACAD SCI, V708, P134, DOI 10.1111/j.1749-6632.1994.tb24706.x
NR 62
TC 29
Z9 29
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 7
PY 2014
VL 9
IS 5
AR e94640
DI 10.1371/journal.pone.0094640
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AG9HB
UT WOS:000335728900013
PM 24804780
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU O'Daly, OG
   Joyce, D
   Tracy, DK
   Azim, A
   Stephan, KE
   Murray, RM
   Shergill, SS
AF O'Daly, Owen G.
   Joyce, Daniel
   Tracy, Derek K.
   Azim, Adnan
   Stephan, Klaas E.
   Murray, Robin M.
   Shergill, Sukhwinder S.
TI Amphetamine Sensitization Alters Reward Processing in the Human Striatum
   and Amygdala
SO PLOS ONE
LA English
DT Article
ID POSITRON-EMISSION-TOMOGRAPHY; INDUCED DOPAMINE RELEASE; COCAINE-SEEKING
   BEHAVIOR; CENTER INVENTORY ARCI; NUCLEUS-ACCUMBENS; ORBITOFRONTAL
   CORTEX; INCENTIVE-SENSITIZATION; EXTRACELLULAR DOPAMINE; BASOLATERAL
   AMYGDALA; DECISION-MAKING
AB Dysregulation of mesolimbic dopamine transmission is implicated in a number of psychiatric illnesses characterised by disruption of reward processing and goal-directed behaviour, including schizophrenia, drug addiction and impulse control disorders associated with chronic use of dopamine agonists. Amphetamine sensitization (AS) has been proposed to model the development of this aberrant dopamine signalling and the subsequent dysregulation of incentive motivational processes. However, in humans the effects of AS on the dopamine-sensitive neural circuitry associated with reward processing remains unclear. Here we describe the effects of acute amphetamine administration, following a sensitising dosage regime, on blood oxygen level dependent (BOLD) signal in dopaminoceptive brain regions during a rewarded gambling task performed by healthy volunteers. Using a randomised, double-blind, parallel-groups design, we found clear evidence for sensitization to the subjective effects of the drug, while rewarded reaction times were unchanged. Repeated amphetamine exposure was associated with reduced dorsal striatal BOLD signal during decision making, but enhanced ventromedial caudate activity during reward anticipation. The amygdala BOLD response to reward outcomes was blunted following repeated amphetamine exposure. Positive correlations between subjective sensitization and changes in anticipation-and outcome-related BOLD signal were seen for the caudate nucleus and amygdala, respectively. These data show for the first time in humans that AS changes the functional impact of acute stimulant exposure on the processing of reward-related information within dopaminoceptive regions. Our findings accord with pathophysiological models which implicate aberrant dopaminergic modulation of striatal and amygdala activity in psychosis and drug-related compulsive disorders.
C1 [O'Daly, Owen G.; Joyce, Daniel; Tracy, Derek K.; Azim, Adnan; Shergill, Sukhwinder S.] Kings Coll London, Inst Psychiat, Dept Psychosis Studies, Cognit Schizophrenia & Imaging Lab, London, England.
   [O'Daly, Owen G.] Kings Coll London, Inst Psychiat, Ctr Neuroimaging Sci, Dept Neuroimaging, London, England.
   [Tracy, Derek K.] Oxleas NHS Fdn Trust, London, England.
   [Stephan, Klaas E.] Univ Zurich, Dept Econ, Lab Social & Neural Syst Res, Zurich, Switzerland.
   [Stephan, Klaas E.] UCL, Inst Neurol, Wellcome Trust Ctr Neuroimaging, London, England.
   [Murray, Robin M.] Kings Coll London, Inst Psychiat, Dept Psychosis Studies, London, England.
   [Shergill, Sukhwinder S.] South London & Maudsley NHS Fdn, Natl Psychosis Unit, London, England.
RP O'Daly, OG (reprint author), Kings Coll London, Inst Psychiat, Dept Psychosis Studies, Cognit Schizophrenia & Imaging Lab, London, England.
EM o.o'daly@kcl.ac.uk
RI ; murray, robin/F-8658-2012
OI Tracy, Derek/0000-0002-3609-9407; shergill, sukhi/0000-0003-4928-9100;
   Stephan, Klaas Enno/0000-0002-8594-9092; murray,
   robin/0000-0003-0829-0519; Azim, Adnan/0000-0001-5960-1159
FU Wellcome grant; Medical Research Council [G0901868]; National Institute
   for Health Research [1776]
FX This work was supported by a Wellcome grant. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Andersson JLR, 2001, NEUROIMAGE, V13, P903, DOI 10.1006/nimg.2001.0746
   Angrist B M, 1970, Biol Psychiatry, V2, P95
   ANTELMAN SM, 1980, SCIENCE, V207, P329, DOI 10.1126/science.7188649
   Anticevic A, 2010, SCHIZOPHR B
   Balleine BW, 2006, TRENDS NEUROSCI, V29, P272, DOI 10.1016/j.tins.2006.03.002
   Baxter MG, 2002, NAT REV NEUROSCI, V3, P563, DOI 10.1038/nrn875
   Belin D, 2008, NEURON, V57, P432, DOI 10.1016/j.neuron.2007.12.019
   Belin D, 2013, CURR OPIN NEUROBIOL, V23, P564, DOI 10.1016/j.conb.2013.01.025
   Boileau I, 2007, J NEUROSCI, V27, P3998, DOI 10.1523/JNEUROSCI.4370-06.2007
   Boileau I, 2006, ARCH GEN PSYCHIAT, V63, P1386, DOI 10.1001/archpsyc.63.12.1386
   Bolla KI, 2003, NEUROIMAGE, V19, P1085, DOI 10.1016/S1053-8119(03)00113-7
   Booij L, 2009, 50 ANN C SCAND COLL
   Breier A, 1997, P NATL ACAD SCI USA, V94, P2569, DOI 10.1073/pnas.94.6.2569
   Breiter HC, 2001, NEURON, V30, P619, DOI 10.1016/S0896-6273(01)00303-8
   Brotons O, 2010, MOL PSYCHIAT
   Castner SA, 2003, BIOL PSYCHIAT, V54, P105, DOI 10.1016/S0006-3223(03)00292-0
   Castner SA, 1999, NEUROPSYCHOPHARMACOL, V20, P10, DOI 10.1016/S0893-133X(98)00050-5
   Castner SA, 2000, NEUROPSYCHOPHARMACOL, V22, P4, DOI 10.1016/S0893-133X(99)00080-9
   Chambers RA, 2004, BIOL PSYCHIAT, V56, P308, DOI 10.1016/j.biopsych.2004.05.019
   De Vries TJ, 1998, EUR J NEUROSCI, V10, P3565, DOI 10.1046/j.1460-9568.1998.00368.x
   Di Ciano P, 2004, J NEUROSCI, V24, P7167, DOI 10.1523/JNEUROSCI.1581-04.2004
   Ernst M, 2004, NEUROPSYCHOLOGIA, V42, P1585, DOI 10.1016/j.neuropsychologia.2004.05.011
   Ernst M, 2005, NEUROIMAGE, V25, P1279, DOI 10.1016/j.neuroimage.2004.12.038
   Evans AH, 2006, ANN NEUROL, V59, P852, DOI 10.1002/ana.20822
   Everitt BJ, 2013, NEUROSCI BIOBEHAV R, V37, P1946, DOI 10.1016/j.neubiorev.2013.02.010
   Featherstone RE, 2007, PROG NEURO-PSYCHOPH, V31, P1556, DOI 10.1016/j.pnpbp.2007.08.025
   Ferrario CR, 2005, BIOL PSYCHIAT, V58, P751, DOI 10.1016/j.biopsych.2005.04.046
   FRISTON KJ, 1995, NEUROIMAGE, V2, P157, DOI 10.1006/nimg.1995.1018
   FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007
   Friston KJ, 1998, NEUROIMAGE, V7, P30, DOI 10.1006/nimg.1997.0306
   Goldstein RZ, 2007, AM J PSYCHIAT, V164, P43, DOI 10.1176/appi.ajp.164.1.43
   Goldstein RZ, 2007, DRUG ALCOHOL DEPEN, V87, P233, DOI 10.1016/j.drugalcdep.2006.08.022
   Guillin O., 2005, J DUAL DIAGN, V1, P11
   Guindalini C, 2006, P NATL ACAD SCI USA, V103, P4552, DOI 10.1073/pnas.0504789103
   Haber SN, 2000, J NEUROSCI, V20, P2369
   HAERTZEN CA, 1963, PSYCHOPHARMACOLOGIA, V4, P155, DOI 10.1007/BF02584088
   HAERTZEN CA, 1963, J CLIN PSYCHOL, V19, P407, DOI 10.1002/1097-4679(196310)19:4<407::AID-JCLP2270190410>3.0.CO;2-N
   Hickey J.E., 1987, METHODS ASSESSING RE, P489
   Homayoun H, 2006, J NEUROSCI, V26, P8025, DOI 10.1523/JNEUROSCI.0842-06.2006
   Hutton C, 2002, NEUROIMAGE, V16, P217, DOI 10.1006/nimg.2001.1054
   Jensen J, 2008, NEUROPSYCHOPHARMACOL, V33, P473, DOI 10.1038/sj.npp.1301437
   Jonkman Sietse, 2006, J Neurosci, V26, P7319, DOI 10.1523/JNEUROSCI.2236-06.2006
   Juckel G, 2006, NEUROIMAGE, V29, P409, DOI 10.1016/j.neuroimage.2005.07.051
   KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U
   KALIVAS PW, 1993, J NEUROSCI, V13, P266
   KALIVAS PW, 1993, J NEUROSCI, V13, P276
   KALIVAS PW, 1986, BIOL PSYCHIAT, V21, P939, DOI 10.1016/0006-3223(86)90268-4
   KALIVAS PW, 1990, SYNAPSE, V5, P48, DOI 10.1002/syn.890050104
   Kapur S, 2003, AM J PSYCHIAT, V160, P13, DOI 10.1176/appi.ajp.160.1.13
   Kilts C D, 2001, Psychopharmacol Bull, V35, P84
   Kiyatkin EA, 1996, J NEUROPHYSIOL, V75, P142
   Knutson B, 2004, NEURON, V43, P261, DOI 10.1016/j.neuron.2004.06.030
   Knutson B, 2007, PSYCHOPHARMACOLOGY, V191, P813, DOI 10.1007/s00213-006-0686-7
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Kosson DS, 2006, NEUROIMAGE, V29, P1161, DOI 10.1016/j.neuroimage.2005.07.060
   KRETTEK JE, 1977, J COMP NEUROL, V172, P687, DOI 10.1002/cne.901720408
   Kriegeskorte N, 2009, NAT NEUROSCI, V12, P535, DOI 10.1038/nn.2303
   Kumari V, 1998, BEHAV PHARMACOL, V9, P567, DOI 10.1097/00008877-199811000-00012
   Lapish CC, 2006, ALCOHOL CLIN EXP RES, V30, P1451, DOI 10.1111/j.1530-0277.2006.00176.x
   Laruelle M, 2000, BRAIN RES REV, V31, P371, DOI 10.1016/S0165-0173(99)00054-5
   Laruelle M, 1996, P NATL ACAD SCI USA, V93, P9235, DOI 10.1073/pnas.93.17.9235
   Laruelle M, 1999, BIOL PSYCHIAT, V46, P56, DOI 10.1016/S0006-3223(99)00067-0
   Malison RT, 1999, J NUCL MED, V40, p110p
   Martinez D, 2007, AM J PSYCHIAT, V164, P622, DOI 10.1176/appi.ajp.164.4.622
   Mawlawi O, 2001, J CEREBR BLOOD F MET, V21, P1034, DOI 10.1097/00004647-200109000-00002
   MCDONALD AJ, 1991, NEUROSCIENCE, V44, P1, DOI 10.1016/0306-4522(91)90247-L
   McNair D, 1992, EDITS MANUAL PROFILE
   Montague PR, 1996, J NEUROSCI, V16, P1936
   Morris RW, 2011, MOL PSYCHIAT
   Murray GK, 2008, MOL PSYCHIATR, V13, P267, DOI 10.1038/sj.mp.4002058
   Murray GK, 2010, SCHIZOPHRENIA BULL, V36, P465, DOI 10.1093/schbul/sbq005
   Nelson A, 2006, J NEUROSCI, V26, P3805, DOI 10.1523/JNEUROSCI.4305-05.2006
   Nordquist RE, 2007, EUR NEUROPSYCHOPHARM, V17, P532, DOI 10.1016/j.euroneuro.2006.12.005
   O'Daly OG, 2014, J PSYCH IN PRESS JAN
   O'Daly OG, 2011, ARCH GEN PSYCHIAT, V68, P545, DOI 10.1001/archgenpsychiatry.2011.3
   PIAZZA PV, 1990, BRAIN RES, V514, P22, DOI 10.1016/0006-8993(90)90431-A
   Redish AD, 2007, PSYCHOL REV, V114, P784, DOI 10.1037/0033-295X.114.3.784
   Robbins TW, 2007, PSYCHOPHARMACOLOGY, V191, P433, DOI 10.1007/s00213-006-0528-7
   Robinson TE, 2001, ADDICTION, V96, P103, DOI 10.1046/j.1360-0443.2001.9611038.x
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   ROBINSON TE, 1987, NEUROPHARMACOLOGY, V26, P679, DOI 10.1016/0028-3908(87)90228-0
   ROBINSON TE, 1986, BRAIN RES REV, V11, P157, DOI 10.1016/0165-0173(86)90002-0
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Roesch MR, 2007, J NEUROSCI, V27, P245, DOI 10.1523/JNEUROSCI.4080-06.2007
   Rosenkranz JA, 1999, J NEUROSCI, V19, P11027
   Schmidt WJ, 2006, NEUROTOX RES, V10, P161, DOI 10.1007/BF03033244
   Schoenbaum G, 2005, CEREB CORTEX, V15, P1162, DOI 10.1093/cercor/bhh216
   Schoenbaum G, 2004, EUR J NEUROSCI, V19, P1997, DOI 10.1111/j.1460.9568.2004.03274.x
   Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593
   SCHULTZ W, 1993, PROG BRAIN RES, V99, P227
   Schultz W, 1998, J NEUROPHYSIOL, V80, P1
   SCHULTZ W, 1993, J NEUROSCI, V13, P900
   See RE, 2003, ANN NY ACAD SCI, V985, P294
   Stalnaker TA, 2007, NAT NEUROSCI, V10, P949, DOI 10.1038/nn1931
   Stalnaker TA, 2006, EUR J NEUROSCI, V24, P2643, DOI 10.1111/j.1460-9568.2006.05128.x
   Steeves TDL, 2009, BRAIN, V132, P1376, DOI 10.1093/brain/awp054
   Strakowski SM, 2001, NEUROPSYCHOPHARMACOL, V25, P548, DOI 10.1016/S0893-133X(01)00253-6
   Strakowski SM, 1998, BIOL PSYCHIAT, V44, P1171, DOI 10.1016/S0006-3223(97)00454-X
   Strakowski SM, 1996, BIOL PSYCHIAT, V40, P872, DOI 10.1016/0006-3223(95)00497-1
   Stuber GD, 2011, NATURE, V475, P377, DOI 10.1038/nature10194
   Takahashi Y, 2007, FRONT INTEGR NEUROSC, V1, DOI 10.3389/neuro.07/011.2007
   Tse MTL, 2011, J NEUROSCI, V31, P11282, DOI 10.1523/JNEUROSCI.1810-11.2011
   Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978
   van Eimeren T, 2009, NEUROPSYCHOPHARMACOL, V34, P2758, DOI [10.1038/sj.npp.npp2009124, 10.1038/npp.2009.124]
   Verdejo-Garcia A, 2006, J INT NEUROPSYCH SOC, V12, P405, DOI 10.1017/S1355617706060486
   Vezina P, 2004, NEUROSCI BIOBEHAV R, V27, P827, DOI 10.1016/j.neubiorev.2003.11.001
   Volkow ND, 2006, J NEUROSCI, V26, P6583, DOI 10.1523/JNEUROSCI.1544-06.2006
   Volkow ND, 1997, NATURE, V386, P830, DOI 10.1038/386830a0
   Volkow ND, 2008, NEUROIMAGE, V39, P1266, DOI 10.1016/j.neuroimage.2007.09.059
   Voorn P, 2004, TRENDS NEUROSCI, V27, P468, DOI 10.1016/j.tins.2004.06.006
   Waltz JA, 2010, NEUROPSYCHOPHARMACOL, V35, P2427, DOI 10.1038/npp.2010.126
   WISE RA, 1980, PHARMACOL BIOCHEM BE, V13, P213, DOI 10.1016/S0091-3057(80)80033-5
   Wittmann BC, 2005, NEURON, V45, P459, DOI 10.1016/j.neuron.2005.01.010
   YOUNG IR, 1988, MAGN RESON IMAGING, V6, P585, DOI 10.1016/0730-725X(88)90133-6
   Zack Martin, 2009, Curr Drug Abuse Rev, V2, P11
   Ziauddeen H, 2010, CURR OPIN PSYCHIATR, V23, P91, DOI 10.1097/YCO.0b013e328336661b
NR 116
TC 19
Z9 19
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 9
PY 2014
VL 9
IS 4
AR e93955
DI 10.1371/journal.pone.0093955
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AE9PC
UT WOS:000334339000060
PM 24717936
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Cadet, JL
   Brannock, C
   Ladenheim, B
   McCoy, MT
   Krasnova, IN
   Lehrmann, E
   Becker, KG
   Jayanthi, S
AF Cadet, Jean Lud
   Brannock, Christie
   Ladenheim, Bruce
   McCoy, Michael T.
   Krasnova, Irina N.
   Lehrmann, Elin
   Becker, Kevin G.
   Jayanthi, Subramaniam
TI Enhanced Upregulation of CRH mRNA Expression in the Nucleus Accumbens of
   Male Rats after a Second Injection of Methamphetamine Given Thirty Days
   Later
SO PLOS ONE
LA English
DT Article
ID CORTICOTROPIN-RELEASING-FACTOR; CENTRAL-NERVOUS-SYSTEM; CONDITIONED
   PLACE PREFERENCE; MESOLIMBIC DOPAMINERGIC SYSTEM; MEDIAL PREFRONTAL
   CORTEX; PITUITARY-ADRENAL AXIS; STRESS-INDUCED RELAPSE; BEHAVIORAL
   SENSITIZATION; RIBONUCLEIC-ACID; GENE-EXPRESSION
AB Methamphetamine (METH) is a widely abused amphetamine analog. Few studies have investigated the molecular effects of METH exposure in adult animals. Herein, we determined the consequences of an injection of METH (10 mg/kg) on transcriptional effects of a second METH (2.5 mg/kg) injection given one month later. We thus measured gene expression by microarray analyses in the nucleus accumbens (NAc) of 4 groups of rats euthanized 2 hours after the second injection: saline-pretreated followed by saline-challenged (SS) or METH-challenged (SM); and METH-pretreated followed by saline-challenged (MS) or METH-challenged (MM). Microarray analyses revealed that METH (2.5 mg/kg) produced acute changes (1.8-fold; P<0.01) in the expression of 412 (352 upregulated, 60 down-regulated) transcripts including cocaine and amphetamine regulated transcript, corticotropin-releasing hormone (Crh), oxytocin (Oxt), and vasopressin (Avp) that were upregulated. Injection of METH (10 mg/kg) altered the expression of 503 (338 upregulated, 165 down-regulated) transcripts measured one month later (MS group). These genes also included Cart and Crh. The MM group showed altered expression of 766 (565 upregulated, 201 down-regulated) transcripts including Avp, Cart, and Crh. The METH-induced increased Crh expression was enhanced in the MM group in comparison to SM and MS groups. Quantitative PCR confirmed the METH-induced changes in mRNA levels. Therefore, a single injection of METH produced long-lasting changes in gene expression in the rodent NAc. The long-term increases in Crh, Cart, and Avp mRNA expression suggest that METH exposure produced prolonged activation of the endogenous stress system. The METH-induced changes in oxytocin expression also suggest the possibility that this neuropeptide might play a significant role in the neuroplastic and affiliative effects of this drug.
C1 [Cadet, Jean Lud; Brannock, Christie; Ladenheim, Bruce; McCoy, Michael T.; Krasnova, Irina N.; Jayanthi, Subramaniam] NIDA, Mol Neuropsychiat Res Branch, Intramural Res Program, NIH, Baltimore, MD USA.
   [Lehrmann, Elin; Becker, Kevin G.] NIA, Intramural Res Program, Gene Express & Genom Unit, NIH, Baltimore, MD 21224 USA.
RP Cadet, JL (reprint author), NIDA, Mol Neuropsychiat Res Branch, Intramural Res Program, NIH, Baltimore, MD USA.
EM jcadet@intra.nida.nih.gov
OI Lehrmann, Elin/0000-0002-9869-9475
FU Intramural Research Program of the DHHS/NIH/NIDA
FX This work was supported by funds of the Intramural Research Program of
   the DHHS/NIH/NIDA. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Aguilera G, 2011, EXP GERONTOL, V46, P90, DOI 10.1016/j.exger.2010.08.023
   Arima H, 2000, J NEUROENDOCRINOL, V12, P833, DOI 10.1046/j.1365-2826.2000.00528.x
   Armario A, 2010, TRENDS PHARMACOL SCI, V31, P318, DOI 10.1016/j.tips.2010.04.005
   Bale TL, 2004, ANNU REV PHARMACOL, V44, P525, DOI 10.1146/annurev.pharmtox.44.101802.121410
   Bale TL, 2000, NAT GENET, V24, P410
   Balkan B, 2012, BRAIN RES, V1432, P56, DOI 10.1016/j.brainres.2011.11.006
   Baracz SJ, 2012, BEHAV BRAIN RES, V228, P185, DOI 10.1016/j.bbr.2011.11.038
   Baskerville TA, 2010, CNS NEUROSCI THER, V16, pe92, DOI 10.1111/j.1755-5949.2010.00154.x
   Binder EB, 2010, MOL PSYCHIATR, V15, P574, DOI 10.1038/mp.2009.141
   Boutrel B, 2008, BRIT J PHARMACOL, V154, P343, DOI 10.1038/bjp.2008.133
   Burbach JPH, 1995, CELL MOL NEUROBIOL, V15, P573, DOI 10.1007/BF02071318
   Burkett JP, 2012, PSYCHOPHARMACOLOGY, V224, P1, DOI 10.1007/s00213-012-2794-x
   Bustamante D, 2002, J NEUROCHEM, V83, P645, DOI 10.1046/j.1471-4159.2002.01171.x
   Cadet JL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015643
   Cadet JL, 2010, CNS NEUROL DISORD-DR, V9, P526
   Cadet JL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007812
   Cadet JL, 2001, SYNAPSE, V41, P40, DOI 10.1002/syn.1058
   Caldwell HK, 2008, PROG NEUROBIOL, V84, P1, DOI 10.1016/j.pneurobio.2007.10.007
   Carson DS, 2013, J PSYCHOPHARMACOL, V27, P231, DOI 10.1177/0269881112473788
   Carson DS, 2010, ADDICT BIOL, V15, P448, DOI 10.1111/j.1369-1600.2010.00247.x
   Carson DS, 2010, NEUROPHARMACOLOGY, V58, P38, DOI 10.1016/j.neuropharm.2009.06.018
   Clark KH, 2013, NEUROTOX RES, V23, P174, DOI 10.1007/s12640-012-9334-7
   Cornish JL, 2001, J ADDICT DIS, V20, P43, DOI 10.1300/J069v20n03_05
   Cornish JL, 1997, NEUROSCIENCE, V81, P69, DOI 10.1016/S0306-4522(97)00157-7
   CORNISH JL, 1995, BRAIN RES, V701, P28, DOI 10.1016/0006-8993(95)00967-X
   Cox BM, 2013, PSYCHONEUROENDOCRINO
   CUMMINGS S, 1983, J NEUROSCI, V3, P1355
   Danaceau JP, 2007, EUR J PHARMACOL, V559, P46, DOI 10.1016/j.ejphar.2006.11.045
   DESOUZA EB, 1985, J NEUROSCI, V5, P3189
   DEVRY J, 1988, LIFE SCI, V42, P2709, DOI 10.1016/0024-3205(88)90247-0
   Dominguez G, 2004, ANN NY ACAD SCI, V1025, P363, DOI 10.1196/annals.1316.044
   Donaldson ZR, 2008, SCIENCE, V322, P900, DOI 10.1126/science.1158668
   Douglass J, 1996, GENE, V169, P241, DOI 10.1016/0378-1119(96)88651-3
   DOUGLASS J, 1995, J NEUROSCI, V15, P2471
   DRAGO F, 1986, PHARMACOL BIOCHEM BE, V24, P1185, DOI 10.1016/0091-3057(86)90168-1
   DUVIGNEAUD V, 1953, J BIOL CHEM, V205, P949
   Fagergren P, 2007, PHYSIOL BEHAV, V92, P218, DOI 10.1016/j.physbeh.2007.05.027
   Frankel PS, 2007, PHARMACOL BIOCHEM BE, V86, P511, DOI 10.1016/j.pbb.2007.01.012
   Giardino WJ, 2011, GENES BRAIN BEHAV, V10, P78, DOI 10.1111/j.1601-183X.2010.00641.x
   Giardino WJ, 2012, PSYCHOPHARMACOLOGY, V219, P1055, DOI 10.1007/s00213-011-2433-y
   Grignaschi G, 2004, EUR J NEUROSCI, V20, P2833, DOI 10.1111/j.1460-9568.2004.03712.x
   Gysling K, 2012, BIOCHEM PHARMACOL, V83, P1, DOI 10.1016/j.bcp.2011.07.101
   Hauger Richard L., 2006, CNS & Neurological Disorders-Drug Targets, V5, P453, DOI 10.2174/187152706777950684
   Herman JP, 2005, PROG NEURO-PSYCHOPH, V29, P1201, DOI 10.1016/j.pnpbp.2005.08.006
   Hubert GW, 2010, NEUROSCIENCE, V165, P179, DOI 10.1016/j.neuroscience.2009.10.013
   Hubert GW, 2008, BIOCHEM PHARMACOL, V75, P57, DOI 10.1016/j.bcp.2007.07.028
   Imaki T, 1996, MOL BRAIN RES, V38, P166, DOI 10.1016/0169-328X(96)00011-3
   Insel TR, 2010, NEURON, V65, P768, DOI 10.1016/j.neuron.2010.03.005
   Jankord R, 2008, ANN NY ACAD SCI, V1148, P64, DOI 10.1196/annals.1410.012
   Jayanthi S, 2005, P NATL ACAD SCI USA, V102, P868, DOI 10.1073/pnas.0404990102
   Jayanthi S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006092
   JOSEPH SA, 1983, NEUROSCI LETT, V35, P135, DOI 10.1016/0304-3940(83)90540-2
   KALIVAS PW, 1993, J PHARMACOL EXP THER, V267, P486
   KELLER RW, 1992, SYNAPSE, V11, P28, DOI 10.1002/syn.890110105
   Kelly KA, 2012, J NEUROCHEM, V122, P995, DOI 10.1111/j.1471-4159.2012.07864.x
   Kim JH, 2003, NEUROPEPTIDES, V37, P369, DOI 10.1016/j.npep.2003.10.001
   Kim S, 2007, REGUL PEPTIDES, V144, P6, DOI 10.1016/j.regpep.2007.07.003
   Koob GF, 2010, CURR OPIN INVEST DR, V11, P63
   Koshimizu TA, 2012, PHYSIOL REV, V92, P1813, DOI 10.1152/physrev.00035.2011
   KOVACS GL, 1990, NEUROPHARMACOLOGY, V29, P365, DOI 10.1016/0028-3908(90)90095-9
   Krasnova IN, 2013, NEUROBIOL DIS, V58, P132, DOI 10.1016/j.nbd.2013.05.009
   Krasnova IN, 2009, BRAIN RES REV, V60, P379, DOI 10.1016/j.brainresrev.2009.03.002
   KUCZENSKI R, 1995, J NEUROSCI, V15, P1308
   Kuhar MJ, 2005, AAPS J, V7, pE259, DOI 10.1208/aapsj070125
   Le AD, 2000, PSYCHOPHARMACOLOGY, V150, P317, DOI 10.1007/s002130000411
   Lee HJ, 2009, PROG NEUROBIOL, V88, P127, DOI 10.1016/j.pneurobio.2009.04.001
   Liberzon I, 1997, NEUROPSYCHOPHARMACOL, V17, P353, DOI 10.1016/S0893-133X(97)00070-5
   Liu J, 2005, J NEUROSCI, V25, P577, DOI 10.1523/JNEUROSCI.4196-04.2005
   Liu Y, 2003, NEUROSCIENCE, V121, P537, DOI 10.1016/S0306-4522(03)00555-4
   Locatelli V, 2010, ENDOCR DEV, V17, P108, DOI 10.1159/000262533
   MAKINO S, 1995, ENDOCRINOLOGY, V136, P4517, DOI 10.1210/en.136.10.4517
   MAKINO S, 1995, ENDOCRINOLOGY, V136, P3299, DOI 10.1210/en.136.8.3299
   Mameli M, 2011, NEUROPHARMACOLOGY, V61, P1052, DOI 10.1016/j.neuropharm.2011.01.036
   Mansi JA, 1996, ENDOCRINOLOGY, V137, P4619, DOI 10.1210/en.137.11.4619
   Martin TA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034236
   Maze I, 2010, MOL INTERV, V10, P219, DOI 10.1124/mi.10.4.5
   McCoy MT, 2011, PSYCHOPHARMACOLOGY, V215, P353, DOI 10.1007/s00213-010-2146-7
   McEwen BS, 2012, DEV NEUROBIOL, V72, P878, DOI 10.1002/dneu.20968
   McGregor IS, 2012, HORM BEHAV, V61, P331, DOI 10.1016/j.yhbeh.2011.12.001
   MERCHENTHALER I, 1982, AM J ANAT, V165, P385, DOI 10.1002/aja.1001650404
   Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044
   Muller MB, 2003, NAT NEUROSCI, V6, P1100, DOI 10.1038/nn1123
   Nestler Eric J, 2012, Clin Psychopharmacol Neurosci, V10, P136, DOI 10.9758/cpn.2012.10.3.136
   Neumann ID, 2008, J NEUROENDOCRINOL, V20, P858, DOI 10.1111/j.1365-2826.2008.01726.x
   Orozco-Cabal L, 2008, J NEUROSCI, V28, P529, DOI 10.1523/JNEUROSCI.2666-07.2008
   PAULSON PE, 1995, SYNAPSE, V19, P56, DOI 10.1002/syn.890190108
   PERIS J, 1987, PHARMACOL BIOCHEM BE, V27, P533, DOI 10.1016/0091-3057(87)90361-3
   Piechota M, 2012, GENES BRAIN BEHAV, V11, P404, DOI 10.1111/j.1601-183X.2012.00777.x
   Piechota M, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-5-r48
   POTTER E, 1994, P NATL ACAD SCI USA, V91, P8777, DOI 10.1073/pnas.91.19.8777
   Qi J, 2008, N-S ARCH PHARMACOL, V376, P441, DOI 10.1007/s00210-007-0245-8
   Qi J, 2009, NEUROPHARMACOLOGY, V56, P856, DOI 10.1016/j.neuropharm.2009.01.010
   RabadanDiehl C, 1996, ENDOCRINOLOGY, V137, P3808, DOI 10.1210/en.137.9.3808
   RIVIER C, 1982, ENDOCRINOLOGY, V110, P272, DOI 10.1210/endo-110-1-272
   ROBINSON TE, 1982, BRAIN RES, V253, P231, DOI 10.1016/0006-8993(82)90690-4
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Rodriguez-Borrero E, 2010, NEUROPHARMACOLOGY, V58, P88, DOI 10.1016/j.neuropharm.2009.06.040
   Rogge G, 2008, NAT REV NEUROSCI, V9, P747, DOI 10.1038/nrn2493
   Sabol KE, 2001, BRAIN RES, V892, P122, DOI 10.1016/S0006-8993(00)03244-3
   SARNYAI Z, 1991, NEUROPEPTIDES, V19, P51, DOI 10.1016/0143-4179(91)90073-R
   SARNYAI Z, 1994, PSYCHONEUROENDOCRINO, V19, P85, DOI 10.1016/0306-4530(94)90062-0
   Segal DS, 2003, NEUROPSYCHOPHARMACOL, V28, P1730, DOI 10.1038/sj.npp.1300247
   Shahrokh DK, 2010, ENDOCRINOLOGY, V151, P2276, DOI 10.1210/en.2009-1271
   Shalev U, 2010, BRAIN RES, V1314, P15, DOI 10.1016/j.brainres.2009.07.028
   Skuse DH, 2009, TRENDS COGN SCI, V13, P27, DOI 10.1016/j.tics.2008.09.007
   Smith SM, 2004, ENDOCRINOLOGY, V145, P5202, DOI 10.1210/en.2004-0708
   Steketee JD, 2011, PHARMACOL REV, V63, P348, DOI 10.1124/pr.109.001933
   SWAAB DF, 1975, J NEURAL TRANSM, V36, P195, DOI 10.1007/BF01253126
   Thomas DM, 2004, J NEUROCHEM, V88, P380, DOI 10.1046/j.1471-4159.2003.02182.x
   Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077
   VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699
   Van Pett K, 2000, J COMP NEUROL, V428, P191, DOI 10.1002/1096-9861(20001211)428:2<191::AID-CNE1>3.0.CO;2-U
   Vanderschuren LJMJ, 1999, J NEUROSCI, V19, P9579
   VANREE JM, 1988, LIFE SCI, V42, P1091, DOI 10.1016/0024-3205(88)90565-6
   Waselus M, 2009, BIOL PSYCHIAT, V66, P76, DOI 10.1016/j.biopsych.2009.02.014
   Willuhn I, 2010, CURR TOP BEHAV NEURO, V3, P29, DOI 10.1007/7854_2009_27
   Wise RA, 2009, TRENDS NEUROSCI, V32, P517, DOI 10.1016/j.tins.2009.06.004
   Wood SK, 2013, BIOL PSYCHIAT, V73, P1087, DOI 10.1016/j.biopsych.2013.01.026
   Xi ZX, 2009, NEUROSCIENCE, V161, P392, DOI 10.1016/j.neuroscience.2009.03.060
   Yang MH, 2008, MOL CELLS, V26, P121
   Zhou Y, 2005, NEUROSCIENCE, V134, P1391, DOI 10.1016/j.neuroscience.2005.05.032
   Zhou Y, 2011, NEUROPSYCHOPHARMACOL, V36, P2062, DOI 10.1038/npp.2011.97
NR 122
TC 20
Z9 20
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 27
PY 2014
VL 9
IS 1
AR e84665
DI 10.1371/journal.pone.0084665
PG 22
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 301BI
UT WOS:000330507300013
PM 24475032
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Kedikian, X
   Faillace, MP
   Bernabeu, R
AF Kedikian, Ximena
   Faillace, Maria Paula
   Bernabeu, Ramon
TI Behavioral and Molecular Analysis of Nicotine-Conditioned Place
   Preference in Zebrafish
SO PLOS ONE
LA English
DT Article
ID INCENTIVE-SENSITIZATION THEORY; SUBUNIT MESSENGER-RNA;
   ACETYLCHOLINE-RECEPTORS; DANIO-RERIO; ADDICTION; MODEL; BRAIN; BINDING;
   SYSTEM; REWARD
AB Studies using mice and rats have demonstrated that nicotine induces a conditioned place preference (CPP), with more effective results obtained by using biased procedures. Zebrafish have also been used as a model system to identify factors influencing nicotine-associated reward by using an unbiased design. Here, we report that zebrafish exhibited putative nicotine biased CPP to an initially aversive compartment (nicotine-paired group). A counterbalanced nicotine-exposed control group did not show a significant preference shift, providing evidence that the preference shift in the nicotine-paired group was not due to a reduction of aversion for this compartment. Zebrafish preference was corroborated by behavioral analysis of several indicators of drug preference, such as time spent in the drug-paired side, number of entries to the drug-paired side, and distance traveled. These results provided strong evidence that zebrafish may actually develop a preference for nicotine, although the drug was administrated in an aversive place for the fish, which was further supported by molecular studies. Reverse transcription-quantitative real-time PCR analysis depicted a significant increase in the expression of alpha 7 and alpha 6 but not alpha 4 and beta 2 subunits of the nicotinic receptor in nicotine-paired zebrafish brains. In contrast, zebrafish brains from the counterbalanced nicotine group showed no significant changes. Moreover, CREB phosphorylation, an indicator of neural activity, accompanied the acquisition of nicotine-CPP. Our studies offered an incremental value to the drug addiction field, because they further describe behavioral features of CPP to nicotine in zebrafish. The results suggested that zebrafish exposed to nicotine in an unfriendly environment can develop a preference for that initially aversive place, which is likely due to the rewarding effect of nicotine. Therefore, this model can be used to screen exogenous and endogenous molecules involved in nicotine-associated reward in vertebrates.
C1 [Kedikian, Ximena; Faillace, Maria Paula; Bernabeu, Ramon] Univ Buenos Aires, Fac Med, Dept Fisiol, RA-1425 Buenos Aires, DF, Argentina.
   [Bernabeu, Ramon] Univ Buenos Aires, Fac Med, Inst Biol Celular & Neurociencias IBCN CONICET, Buenos Aires, DF, Argentina.
   [Faillace, Maria Paula] Consejo Nacl Invest Cient & Tecn, Inst Quim & Fis Quim Biol IQUIFIB, RA-1033 Buenos Aires, DF, Argentina.
RP Bernabeu, R (reprint author), Univ Buenos Aires, Fac Med, Dept Fisiol, RA-1425 Buenos Aires, DF, Argentina.
EM rbernabeu@fmed.uba.ar
FU FONCyT [PICT0170]; CONICET [PIP0169]; UBACYT [0823]
FX This work was supported by grants from the FONCyT PICT0170 2007-2012
   (RB); CONICET PIP0169 2009-2012 (MPF); and UBACYT 0823 (MPF, RB)
   2011-2014. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Agetsuma M, 2010, NAT NEUROSCI, V13, P1354, DOI 10.1038/nn.2654
   Barik Jacques, 2009, Handb Exp Pharmacol, P173, DOI 10.1007/978-3-540-69248-5_7
   Bernabeu R, 1997, P NATL ACAD SCI USA, V94, P7041, DOI 10.1073/pnas.94.13.7041
   Besson M, 2012, PSYCHOPHARMACOLOGY, V220, P1, DOI 10.1007/s00213-011-2422-1
   Brennan CH, 2011, REV NEUROSCIENCE, V22, P37, DOI 10.1515/RNS.2011.006
   Bretaud S, 2007, NEUROSCIENCE, V146, P1109, DOI 10.1016/j.neuroscience.2006.12.073
   Brielmaier JM, 2008, PHARMACOL BIOCHEM BE, V89, P94, DOI 10.1016/j.pbb.2007.11.005
   Brunzell DH, 2009, NEUROPSYCHOPHARMACOL, V34, P1993, DOI 10.1038/npp.2009.11
   Cachat J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017597
   Cachat J, 2010, NAT PROTOC, V5, P1786, DOI 10.1038/nprot.2010.140
   CALCAGNETTI DJ, 1994, PROG NEURO-PSYCHOPH, V18, P925, DOI 10.1016/0278-5846(94)90108-2
   Carlezon WA, 2005, TRENDS NEUROSCI, V28, P436, DOI 10.1016/j.tins.2005.06.005
   Changeux JP, 2010, NAT REV NEUROSCI, V11, P389, DOI 10.1038/nrn2849
   Darland T, 2001, P NATL ACAD SCI USA, V98, P11691, DOI 10.1073/pnas.191380698
   Drenan RM, 2008, NEURON, V60, P123, DOI 10.1016/j.neuron.2008.09.009
   Egan RJ, 2009, BEHAV BRAIN RES, V205, P38, DOI 10.1016/j.bbr.2009.06.022
   Feng ZY, 2006, CELL, V127, P621, DOI 10.1016/j.cell.2006.09.035
   Fowler CD, 2011, NATURE, V471, P597, DOI 10.1038/nature09797
   Gentry C. L., 2002, Current Drug Targets - CNS and Neurological Disorders, V1, P359, DOI 10.2174/1568007023339184
   Gerlai R, 2000, PHARMACOL BIOCHEM BE, V67, P773, DOI 10.1016/S0091-3057(00)00422-6
   Giniatullin R, 2005, TRENDS NEUROSCI, V28, P371, DOI 10.1016/j.tins.2005.04.009
   Guo S, 2004, GENES BRAIN BEHAV, V3, P63, DOI 10.1046/j.1601-183X.2003.00053.x
   Kily LJM, 2008, J EXP BIOL, V211, P1623, DOI 10.1242/jeb.014399
   Klee EW, 2012, HUM GENET, V131, P977, DOI 10.1007/s00439-011-1128-0
   Klee EW, 2011, NICOTINE TOB RES, V13, P301, DOI 10.1093/ntr/ntr010
   Koob G. F, 2005, NEUROBIOLOGY ADDICTI
   Lau B, 2006, GENES BRAIN BEHAV, V5, P497, DOI 10.1111/j.1601-183X.2005.00185.x
   Le Foll B, 2005, PSYCHOPHARMACOLOGY, V178, P481, DOI 10.1007/s00213-004-2015-5
   Mansvelder HD, 2002, NEURON, V33, P905, DOI 10.1016/S0896-6273(02)00625-6
   MARKS MJ, 1992, J NEUROSCI, V12, P2765
   Mathur P, 2011, NAT PROTOC, V6, DOI 10.1038/nprot.2010.201
   Miwa JM, 2011, NEURON, V70, P20, DOI 10.1016/j.neuron.2011.03.014
   Natarajan R, 2011, PHARMACOL BIOCHEM BE, V99, P519, DOI 10.1016/j.pbb.2011.05.004
   Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570
   Ninkovic J, 2006, METHODS, V39, P262, DOI 10.1016/j.ymeth.2005.12.007
   Papke RL, 2012, BIOCHEM PHARMACOL, V84, P352, DOI 10.1016/j.bcp.2012.04.022
   Pascual MM, 2009, PSYCHOPHARMACOLOGY, V207, P57, DOI 10.1007/s00213-009-1630-4
   Pastor V, 2013, PSYCHOPHARMACOLOGY, V226, P551, DOI 10.1007/s00213-012-2928-1
   Pastor V, 2011, J NEUROCHEM, V116, P636, DOI 10.1111/j.1471-4159.2010.07149.x
   Pauly JR, 1996, J PHARMACOL EXP THER, V278, P361
   Rink E, 2001, BRAIN RES, V889, P316, DOI 10.1016/S0006-8993(00)03174-7
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Ryan RE, 2001, NEUROREPORT, V12, P569, DOI 10.1097/00001756-200103050-00027
   Schultz W, 2007, ANNU REV NEUROSCI, V30, P259, DOI 10.1146/annurev.neuro.28.061604.135722
   SCHWARTZ RD, 1983, SCIENCE, V220, P214, DOI 10.1126/science.6828889
   Tzschentke TM, 1998, PROG NEUROBIOL, V56, P613, DOI 10.1016/S0301-0082(98)00060-4
   Visanji NP, 2006, NEUROPHARMACOLOGY, V50, P36, DOI 10.1016/j.neuropharm.2005.07.013
   Walters CL, 2006, PSYCHOPHARMACOLOGY, V184, P339, DOI 10.1007/s00213-005-0295-x
   Wang H, 2005, BRAIN RES REV, V48, P420, DOI 10.1016/j.brainresrev.2004.09.003
   Webb KJ, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-7-r81
   WESTERFIELD M., 2007, ZEBRAFISH BOOK GUIDE
   Wolf FW, 2003, J NEUROBIOL, V54, P161, DOI 10.1002/neu.10166
   WONNACOTT S, 1990, TRENDS PHARMACOL SCI, V11, P216, DOI 10.1016/0165-6147(90)90242-Z
   Xu XJ, 2007, NEUROBIOL LEARN MEM, V87, P72, DOI 10.1016/j.nlm.2006.06.002
NR 55
TC 17
Z9 17
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 24
PY 2013
VL 8
IS 7
AR e69453
DI 10.1371/journal.pone.0069453
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 188BY
UT WOS:000322167900072
PM 23894483
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Vanderlinden, LA
   Saba, LM
   Kechris, K
   Miles, MF
   Hoffman, PL
   Tabakoff, B
AF Vanderlinden, Lauren A.
   Saba, Laura M.
   Kechris, Katerina
   Miles, Michael F.
   Hoffman, Paula L.
   Tabakoff, Boris
TI Whole Brain and Brain Regional Coexpression Network Interactions
   Associated with Predisposition to Alcohol Consumption
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; QUANTITATIVE TRAIT LOCI; GENE-EXPRESSION;
   CANDIDATE GENES; ETHANOL; PREFERENCE; COMPLEX; MICE; PROTEINS; DRINKING
AB To identify brain transcriptional networks that may predispose an animal to consume alcohol, we used weighted gene coexpression network analysis (WGCNA). Candidate coexpression modules are those with an eigengene expression level that correlates significantly with the level of alcohol consumption across a panel of BXD recombinant inbred mouse strains, and that share a genomic region that regulates the module transcript expression levels (mQTL) with a genomic region that regulates alcohol consumption (bQTL). To address a controversy regarding utility of gene expression profiles from whole brain, vs specific brain regions, as indicators of the relationship of gene expression to phenotype, we compared candidate coexpression modules from whole brain gene expression data (gathered with Affymetrix 430 v2 arrays in the Colorado laboratories) and from gene expression data from 6 brain regions (nucleus accumbens (NA); prefrontal cortex (PFC); ventral tegmental area (VTA); striatum (ST); hippocampus (HP); cerebellum (CB)) available from GeneNetwork. The candidate modules were used to construct candidate eigengene networks across brain regions, resulting in three "meta-modules", composed of candidate modules from two or more brain regions (NA, PFC, ST, VTA) and whole brain. To mitigate the potential influence of chromosomal location of transcripts and cis-eQTLs in linkage disequilibrium, we calculated a semi-partial correlation of the transcripts in the meta-modules with alcohol consumption conditional on the transcripts' cis-eQTLs. The function of transcripts that retained the correlation with the phenotype after correction for the strong genetic influence, implicates processes of protein metabolism in the ER and Golgi as influencing susceptibility to variation in alcohol consumption. Integration of these data with human GWAS provides further information on the function of polymorphisms associated with alcohol-related traits.
C1 [Vanderlinden, Lauren A.; Saba, Laura M.; Hoffman, Paula L.; Tabakoff, Boris] Univ Colorado, Dept Pharmacol, Sch Med, Aurora, CO 80045 USA.
   [Kechris, Katerina] Univ Colorado, Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA.
   [Miles, Michael F.] Virginia Commonwealth Univ, Dept Pharmacol, Richmond, VA USA.
   [Miles, Michael F.] Virginia Commonwealth Univ, Dept Neurol, Richmond, VA USA.
   [Miles, Michael F.] Virginia Commonwealth Univ, Ctr Study Biol Complex, Richmond, VA USA.
RP Tabakoff, B (reprint author), Univ Colorado, Dept Pharmacol, Sch Med, Aurora, CO 80045 USA.
EM Boris.Tabakoff@ucdenver.edu
RI Saba, Laura/R-9533-2018
OI Saba, Laura/0000-0001-9649-1294
FU NIAAA [R24AA013162, U01AA016663, U01AA016649, U01AA016667, P20AA017828,
   K01AA016922]; National Foundation for Prevention of Chemical Dependency
   Disease (NFPCDD); Banbury Fund
FX This work was supported in part by NIAAA (R24AA013162 (BT), U01AA016663
   (BT), U01AA016649 (PLH), U01AA016667 (MFM), P20AA017828 (MFM),
   K01AA016922 (KK)), National Foundation for Prevention of Chemical
   Dependency Disease (NFPCDD) (LMS) and the Banbury Fund (BT). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Affymetrix, 2004, GENECHIP EXPR AN DAT
   Albert R, 2002, REV MOD PHYS, V74, P47, DOI 10.1103/RevModPhys.74.47
   Ardley HC, 2001, J BIOL CHEM, V276, P19640, DOI 10.1074/jbc.M011028200
   Barabasi AL, 2003, SCI AM, V288, P60, DOI 10.1038/scientificamerican0503-60
   Bassett DS, 2006, NEUROSCIENTIST, V12, P512, DOI 10.1177/1073858406293182
   Belknap JK, 2001, MAMM GENOME, V12, P893, DOI 10.1007/s00335-001-2074-2
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289
   Bierut LJ, 2010, P NATL ACAD SCI USA, V107, P5082, DOI 10.1073/pnas.0911109107
   Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575
   Carlson SL, 2013, J PHARMACOL EXP THER, V345, P317, DOI 10.1124/jpet.112.201954
   Chen G, 2008, J NEUROSCI RES, V86, P937, DOI 10.1002/jnr.21540
   Chesler EJ, 2005, NAT GENET, V37, P233, DOI 10.1038/ng1518
   CHURCHILL GA, 1994, GENETICS, V138, P963
   Clapp P, 2010, J PHARMACOL EXP THER, V332, P720, DOI 10.1124/jpet.109.158741
   Clarke C, 2011, J BIOTECHNOL, V155, P350, DOI 10.1016/j.jbiotec.2011.07.011
   Cox A, 2009, GENETICS, V182, P1335, DOI [10.1534/genetics.108.105486, 10.1534/genetics.109.105486]
   Dobrin R, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-5-r55
   Dong J, 2007, BMC SYSTEMS BIOL, V1, P24
   Doss S, 2005, GENOME RES, V15, P681, DOI 10.1101/gr.3216905
   Edenberg HJ, 2010, ALCOHOL CLIN EXP RES, V34, P840, DOI 10.1111/j.1530-0277.2010.01156.x
   Emilsson V, 2008, NATURE, V452, P423, DOI 10.1038/nature06758
   Farber CR, 2010, J BONE MINER RES, V25, P2359, DOI 10.1002/jbmr.138
   Fislage M, 2012, NUCLEIC ACIDS RES, V40, P5149, DOI 10.1093/nar/gks163
   Furlong LI, 2012, TRENDS GENETICS TIG
   GESCHWIN.N, 1965, BRAIN, V88, P585, DOI 10.1093/brain/88.3.585
   GESCHWIN.N, 1965, BRAIN, V88, P237, DOI 10.1093/brain/88.2.237
   Ghazalpour A, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-7-r59
   Ghoshal G, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1396
   Hardy J, 2009, NEW ENGL J MED, V360, P1759, DOI 10.1056/NEJMra0808700
   Heath AC, 2011, BIOL PSYCHIAT
   Honore B, 2000, FEBS LETT, V466, P11, DOI 10.1016/S0014-5793(99)01780-9
   Honore B, 2009, BIOESSAYS, V31, P262, DOI 10.1002/bies.200800186
   Howell MD, 2012, NEUROSCIENCE, V217, P6, DOI 10.1016/j.neuroscience.2012.05.034
   Hu W, 2008, J PHARMACOL EXP THER, V326, P792, DOI 10.1124/jpet.108.137521
   Iancu OD, 2012, BIOINFORMATICS, V28, P1592, DOI 10.1093/bioinformatics/bts245
   Imai S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058566
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Jain S, 2010, NEURON, V68, P207, DOI 10.1016/j.neuron.2010.10.010
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Jones DH, 2005, J BIOL CHEM, V280, P19003, DOI 10.1074/jbc.M500697200
   Kalivas PW, 2008, NEUROPSYCHOPHARMACOL, V33, P166, DOI 10.1038/sj.npp.1301564
   Karaduman R, 2008, RNA, V14, P2528, DOI 10.1261/rna.1369808
   Ke ZJ, 2011, ALCOHOL CLIN EXP RES, V35, P1574, DOI 10.1111/j.1530-0277.2011.01503.x
   Keane TM, 2011, NATURE, V477, P289, DOI 10.1038/nature10413
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Kowanetz K, 2004, J BIOL CHEM, V279, P32786, DOI 10.1074/jbc.M403759200
   Kravchenko-Balasha N, 2012, P NATL ACAD SCI USA, V109, P4702, DOI 10.1073/pnas.1200790109
   Langfelder P, 2007, BMC SYST BIOL, V1, DOI 10.1186/1752-0509-1-54
   Langfelder P, 2008, BIOINFORMATICS, V24, P719, DOI 10.1093/bioinformatics/btm563
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559
   Langfelder P, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1001057
   Larkin A, 2011, BIOCHEMISTRY-US, V50, P4411, DOI 10.1021/bi200346n
   Li LY, 2012, MOL BIOSYST, V8, P1613, DOI 10.1039/c2mb25021g
   Liang TB, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-2-r11
   Licht K, 2008, RNA, V14, P1532, DOI 10.1261/rna.1129608
   McBride WJ, 2012, PHARMACOL BIOCHEM BE, V102, P275, DOI 10.1016/j.pbb.2012.04.016
   MILES MF, 1991, J BIOL CHEM, V266, P2409
   MILES MF, 1994, MOL PHARMACOL, V46, P873
   Min JL, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002505
   Morito D, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00048
   Muller MM, 2006, P NATL ACAD SCI USA, V103, P14250, DOI 10.1073/pnas.0606668103
   Nayak RR, 2009, GENOME RES, V19, P1953, DOI 10.1101/gr.097600.109
   Neutzner M, 2012, ESSAYS BIOCHEM, V52, P37, DOI [10.1042/bse0520037, 10.1042/BSE0520037]
   Ni M, 2007, FEBS LETT, V581, P3641, DOI 10.1016/j.febslet.2007.04.045
   Oldham MC, 2008, NAT NEUROSCI, V11, P1271, DOI 10.1038/nn.2207
   Pallesen LT, 2012, MOL NEUROBIOL, V45, P379, DOI 10.1007/s12035-012-8236-2
   PHILLIPS TJ, 1994, ALCOHOL CLIN EXP RES, V18, P931, DOI 10.1111/j.1530-0277.1994.tb00062.x
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   RODRIGUEZ LA, 1994, ALCOHOL CLIN EXP RES, V18, P1416, DOI 10.1111/j.1530-0277.1994.tb01444.x
   RODRIGUEZ LA, 1995, ALCOHOL CLIN EXP RES, V19, P367, DOI 10.1111/j.1530-0277.1995.tb01517.x
   Saba L, 2006, MAMM GENOME, V17, P669, DOI 10.1007/s00335-005-0190-0
   Saris CGJ, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-405
   Schadt EE, 2009, NATURE, V461, P218, DOI 10.1038/nature08454
   Schulman BA, 2011, PROTEIN SCI, V20, P1941, DOI 10.1002/pro.750
   Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540290114450
   Silverman EK, 2012, DISCOV MED, V14, P143
   Staals RHJ, 2010, EMBO J, V29, P2358, DOI 10.1038/emboj.2010.122
   Stelzer M, 2011, INTEGR BIOL-UK, V3, P1071, DOI 10.1039/c1ib00008j
   Swisher KD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010006
   Tabakoff B, 2008, MAMM GENOME, V19, P352, DOI 10.1007/s00335-008-9115-z
   Tabakoff B, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-70
   Tomecki R, 2010, EMBO J, V29, P2342, DOI 10.1038/emboj.2010.121
   Tu ZD, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003107
   Verdone L, 2004, CURR BIOL, V14, P1487, DOI 10.1016/j.cub.2004.08.032
   Wahlsten D, 2006, P NATL ACAD SCI USA, V103, P16364, DOI 10.1073/pnas.0605342103
   WALKER JT, 1948, AM J CLIN PATHOL, V18, P451
   Wenzel DM, 2011, NATURE, V474, P105, DOI 10.1038/nature09966
   Wolen AR, 2012, ALCOHOL RES-CURR REV, V34, P306
   Wolen AR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033575
   Wu XS, 2009, NAT NEUROSCI, V12, P1003, DOI 10.1038/nn.2355
   Zhang B, 2005, STAT APPL GENET MO B, V4, DOI 10.2202/1544-6115.1128
NR 91
TC 22
Z9 22
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 23
PY 2013
VL 8
IS 7
AR e68878
DI 10.1371/journal.pone.0068878
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 228SX
UT WOS:000325211000052
PM 23894363
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU LeBlanc, KH
   Maidment, NT
   Ostlund, SB
AF LeBlanc, Kimberly H.
   Maidment, Nigel T.
   Ostlund, Sean B.
TI Repeated Cocaine Exposure Facilitates the Expression of Incentive
   Motivation and Induces Habitual Control in Rats
SO PLOS ONE
LA English
DT Article
ID INDUCED BEHAVIORAL SENSITIZATION; PAVLOVIAN-INSTRUMENTAL TRANSFER;
   ENHANCED DOPAMINE EFFLUX; SENSORY-SPECIFIC SATIETY; NUCLEUS-ACCUMBENS
   SHELL; ADDICTION-LIKE BEHAVIOR; FREELY MOVING RATS; EXTRACELLULAR
   DOPAMINE; D-AMPHETAMINE; DORSAL STRIATUM
AB There is growing evidence that mere exposure to drugs can induce long-term alterations in the neural systems that mediate reward processing, motivation, and behavioral control, potentially causing the pathological pursuit of drugs that characterizes the addicted state. The incentive sensitization theory proposes that drug exposure potentiates the influence of reward-paired cues on behavior. It has also been suggested that drug exposure biases action selection towards the automatic execution of habits and away from more deliberate goal-directed control. The current study investigated whether rats given repeated exposure to peripherally administered cocaine would show alterations in incentive motivation (assayed using the Pavlovian-to-instrumental transfer (PIT) paradigm) or habit formation (assayed using sensitivity to reward devaluation). After instrumental and Pavlovian training for food pellet rewards, rats were given 6 daily injections of cocaine (15 mg/ kg, IP) or saline, followed by a 10-d period of rest. Consistent with the incentive sensitization theory, cocaine-treated rats showed stronger cue-evoked lever pressing than saline-treated rats during the PIT test. The same rats were then trained on a new instrumental action with a new food pellet reward before undergoing a reward devaluation testing. Although saline-treated rats exhibited sensitivity to reward devaluation, indicative of goal-directed performance, cocaine-treated rats were insensitive to this treatment, suggesting a reliance on habitual processes. These findings, when taken together, indicate that repeated exposure to cocaine can cause broad alterations in behavioral control, spanning both motivational and action selection processes, and could therefore help explain aberrations of decision-making that underlie drug addiction.
C1 [LeBlanc, Kimberly H.; Maidment, Nigel T.; Ostlund, Sean B.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.
   [LeBlanc, Kimberly H.; Maidment, Nigel T.; Ostlund, Sean B.] Univ Calif Los Angeles, Brain Res Inst, Los Angeles, CA 90024 USA.
RP LeBlanc, KH (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA.
EM kahathaway@ucla.edu
RI Ostlund, Sean/D-6000-2017
OI LeBlanc, Kimberly/0000-0002-9333-5963
FU NIDA [T32-DA024635, DA09359, DA05010, DA029035]
FX This research was supported by Grant DA029035 to SO, Grants DA09359 and
   DA05010 to NM, and training fellowship T32-DA024635 to KL, all from NIDA
   (http://www.drugabuse.gov/). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR AKIMOTO K, 1990, BRAIN RES, V507, P344, DOI 10.1016/0006-8993(90)90295-M
   Balleine BW, 1998, NEUROPHARMACOLOGY, V37, P407, DOI 10.1016/S0028-3908(98)00033-1
   Belin D, 2008, NEURON, V57, P432, DOI 10.1016/j.neuron.2007.12.019
   Belin D, 2009, BIOL PSYCHIAT, V65, P863, DOI 10.1016/j.biopsych.2008.05.031
   Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9
   Berridge KC, 2003, TRENDS NEUROSCI, V26, P507, DOI 10.1016/S0166-2236(03)00233-9
   BERRIDGE KC, 1991, APPETITE, V16, P103, DOI 10.1016/0195-6663(91)90036-R
   CADOR M, 1995, NEUROSCIENCE, V65, P385, DOI 10.1016/0306-4522(94)00524-9
   Chen BT, 2008, NEURON, V59, P288, DOI 10.1016/j.neuron.2008.05.024
   Clark JJ, 2004, PHARMACOL BIOCHEM BE, V78, P691, DOI 10.1016/j.pbb.2004.05.002
   De Luca MA, 2011, PSYCHOPHARMACOLOGY, V216, P345, DOI 10.1007/s00213-011-2220-9
   De Vries TJ, 1998, EUR J NEUROSCI, V10, P3565, DOI 10.1046/j.1460-9568.1998.00368.x
   de Wit S, 2009, J EXP PSYCHOL ANIM B, V35, P382, DOI 10.1037/a0014793
   Deroche-Gamonet V, 2004, SCIENCE, V305, P1014, DOI 10.1126/science.1099020
   DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175
   DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274
   Dickinson A, 2002, Q J EXP PSYCHOL-B, V55, P331, DOI 10.1080/0272499024400016
   Dickinson A, 2000, BEHAV NEUROSCI, V114, P468, DOI 10.1037/0735-7044.114.3.468
   Everitt BJ, 2001, BRAIN RES REV, V36, P129, DOI 10.1016/S0165-0173(01)00088-1
   Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579
   Fiorino DF, 1999, J NEUROSCI, V19, P456
   Fiorino DF, 1999, PSYCHOPHARMACOLOGY, V142, P200, DOI 10.1007/s002130050880
   Harmer CJ, 1998, BEHAV PHARMACOL, V9, P299
   Harmer CJ, 1999, NEUROSCIENCE, V90, P119, DOI 10.1016/S0306-4522(98)00464-3
   Hemby SE, 1997, PSYCHOPHARMACOLOGY, V133, P7, DOI 10.1007/s002130050365
   HETHERINGTON M, 1989, APPETITE, V12, P57, DOI 10.1016/0195-6663(89)90068-8
   Holland PC, 2004, J EXP PSYCHOL ANIM B, V30, P104, DOI 10.1037/0097-7403.30.2.104
   HORGER BA, 1992, PSYCHOPHARMACOLOGY, V107, P271, DOI 10.1007/BF02245147
   Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009
   Ikemoto S, 1999, BRAIN RES REV, V31, P6, DOI 10.1016/S0165-0173(99)00023-5
   Ito R, 2002, J NEUROSCI, V22, P6247
   KALIVAS PW, 1993, J NEUROSCI, V13, P266
   Kantor L, 1999, J NEUROSCI, V19, P3801
   Klein ED, 2007, LEARN MOTIV, V38, P44, DOI 10.1016/j.lmot.2006.07.004
   KUCZENSKI R, 1991, J NEUROSCI, V11, P2703
   LeBlanc KH, 2012, BEHAV NEUROSCI, V126, P681, DOI 10.1037/a0029534
   Lex A, 2008, LEARN MEMORY, V15, P483, DOI 10.1101/lm.978708
   MAYFIELD RD, 1992, BRAIN RES, V573, P331, DOI 10.1016/0006-8993(92)90783-6
   Mendez IA, 2009, BEHAV BRAIN RES, V201, P74, DOI 10.1016/j.bbr.2009.01.034
   Mendrek A, 1998, PSYCHOPHARMACOLOGY, V135, P416, DOI 10.1007/s002130050530
   Miles FJ, 2003, BEHAV NEUROSCI, V117, P927, DOI 10.1037/0735-7044.117.5.927
   Nelson A, 2006, J NEUROSCI, V26, P3805, DOI 10.1523/JNEUROSCI.4305-05.2006
   Nocjar C, 2002, BEHAV BRAIN RES, V128, P189, DOI 10.1016/S0166-4328(01)00321-7
   Nordquist RE, 2007, EUR NEUROPSYCHOPHARM, V17, P532, DOI 10.1016/j.euroneuro.2006.12.005
   OSTLUND SB, 2010, FRONT INTEGR NEUROSC, P4
   Ostlund SB, 2012, NEUROPSYCHOPHARMACOL, V37, P508, DOI 10.1038/npp.2011.217
   Ostlund Sean B, 2008, Drug Discov Today Dis Models, V5, P235
   Ostlund SB, 2011, J NEUROSCI, V31, P200, DOI 10.1523/JNEUROSCI.4759-10.2011
   Pierce RC, 2010, NEUROSCI BIOBEHAV R, V35, P212, DOI 10.1016/j.neubiorev.2010.01.007
   Pierce RC, 1997, BRAIN RES REV, V25, P192, DOI 10.1016/S0165-0173(97)00021-0
   PIERCE RC, 1995, J PHARMACOL EXP THER, V275, P1019
   Pontieri FE, 1995, P NATL ACAD SCI USA, V92, P12304, DOI 10.1073/pnas.92.26.12304
   POST RM, 1981, LIFE SCI, V28, P755, DOI 10.1016/0024-3205(81)90157-0
   Ranaldi R, 2009, PHARMACOL BIOCHEM BE, V91, P351, DOI 10.1016/j.pbb.2008.08.006
   RESCORLA RA, 1994, ANIM LEARN BEHAV, V22, P27, DOI 10.3758/BF03199953
   ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P
   Robinson TE, 1998, NEUROSCI BIOBEHAV R, V22, P347, DOI 10.1016/S0149-7634(97)00020-1
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Saddoris MP, 2011, EUR J NEUROSCI, V33, P2274, DOI 10.1111/j.1460-9568.2011.07683.x
   Schoenbaum G, 2005, CEREB CORTEX, V15, P1162, DOI 10.1093/cercor/bhh216
   Shaham Y, 2003, PSYCHOPHARMACOLOGY, V168, P3, DOI 10.1007/s00213-002-1224-x
   Shiflett MW, 2012, PSYCHOPHARMACOLOGY, V223, P361, DOI 10.1007/s00213-012-2724-y
   SORG BA, 1993, J PHARMACOL EXP THER, V266, P424
   Stefanski R, 1999, EUR J PHARMACOL, V371, P123, DOI 10.1016/S0014-2999(99)00094-1
   Suto N, 2002, NEUROPSYCHOPHARMACOL, V27, P970, DOI 10.1016/S0893-133X(02)00379-2
   Taylor JR, 2001, BIOL PSYCHIAT, V50, P137, DOI 10.1016/S0006-3223(01)01106-4
   TIFFANY ST, 1990, PSYCHOL REV, V97, P147, DOI 10.1037/0033-295X.97.2.147
   Vanderschuren LJMJ, 2005, J NEUROSCI, V25, P8665, DOI 10.1523/JNEUROSCI.0925-05-2005
   Vanderschuren LJMJ, 2000, PSYCHOPHARMACOLOGY, V151, P99, DOI 10.1007/s002130000493
   Vanderschuren LJMJ, 2004, SCIENCE, V305, P1017, DOI 10.1126/science.1098975
   Vezina P, 2002, J NEUROSCI, V22, P4654, DOI 10.1523/JNEUROSCI.22-11-04654.2002
   Wassum KM, 2011, LEARN MEMORY, V18, P475, DOI 10.1101/lm.2229311
   WEISS SRB, 1989, PHARMACOL BIOCHEM BE, V34, P655
   White FJ, 1998, DRUG ALCOHOL DEPEN, V51, P141, DOI 10.1016/S0376-8716(98)00072-6
   WILSON JM, 1994, BRAIN RES, V668, P39, DOI 10.1016/0006-8993(94)90508-8
   Wiltgen BJ, 2007, EUR J NEUROSCI, V25, P2491, DOI 10.1111/j.1460-9568.2007.05487.x
   Wyvell CL, 2001, J NEUROSCI, V21, P7831
   Xie XH, 2012, PSYCHOPHARMACOLOGY, V223, P271, DOI 10.1007/s00213-012-2715-z
   Young PT, 1940, J GEN PSYCHOL, V22, P33, DOI 10.1080/00221309.1940.10544318
   Zapata A, 2010, J NEUROSCI, V30, P15457, DOI 10.1523/JNEUROSCI.4072-10.2010
NR 80
TC 45
Z9 45
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 30
PY 2013
VL 8
IS 4
AR e61355
DI 10.1371/journal.pone.0061355
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 146GG
UT WOS:000319077300007
PM 23646106
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU van Holst, RJ
   van der Meer, JN
   McLaren, DG
   van den Brink, W
   Veltman, DJ
   Goudriaan, AE
AF van Holst, Ruth J.
   van der Meer, Johan N.
   McLaren, Donald G.
   van den Brink, Wim
   Veltman, Dick J.
   Goudriaan, Anna E.
TI Interactions between Affective and Cognitive Processing Systems in
   Problematic Gamblers: A Functional Connectivity Study
SO PLOS ONE
LA English
DT Article
ID STOP-SIGNAL TASK; PATHOLOGICAL GAMBLERS; RESPONSE-INHIBITION;
   PSYCHOPHYSIOLOGICAL INTERACTIONS; PREFRONTAL CORTEX; BRAIN ACTIVATION;
   DECISION-MAKING; NEURAL BASIS; INCENTIVE-SENSITIZATION; ADDICTIVE
   BEHAVIORS
AB Background: Motivational and cognitive abnormalities are frequently reported in pathological gambling. However, studies simultaneously investigating motivational and cognitive processing in problematic gamblers are lacking, limiting our understanding of the interplay between these systems in problematic gambling. Studies in non-clinical samples indicate that interactions between dorsal "executive'' and ventral "affective'' processing systems are necessary for adequate responses in various emotive situations.
   Methods: We conducted a generalized Psycho-Physiological Interaction (gPPI) analysis to assess the influence of affective stimuli on changes in functional connectivity associated with response inhibition in 16 treatment seeking problematic gamblers (PRGs) and 15 healthy controls (HCs) using an affective Go-NoGo fMRI paradigm including neutral, gambling-related, positive and negative pictures as neutral and affective conditions.
   Results: Across groups, task performance accuracy during neutral inhibition trials was positively correlated with functional connectivity between the left caudate and the right middle frontal cortex. During inhibition in the gambling condition, only in PRGs accuracy of task performance was positively correlated with functional connectivity within sub-regions of the dorsal executive system. Group interactions showed that during neutral inhibition, HCs exhibited greater functional connectivity between the left caudate and occipital cortex than PRGs. In contrast, during inhibition in the positive condition, PRGs compared to HCs showed greater functional connectivity between the left caudate and occipital cortex. During inhibition trials in the negative condition, a stronger functional connectivity between the left caudate and the right anterior cingulate cortex in PRGs compared to HCs was present. There were no group interactions during inhibition in the gambling condition.
   Conclusions: During gamble inhibition PRGs seem to benefit more from functional connectivity within the dorsal executive system than HCs, because task accuracy in this condition in PRGs is positively correlated with functional connectivity, although the groups show similar connectivity patterns during gamble inhibition. Greater functional connectivity between the ventral affective system and the dorsal executive system in PRGs in the affective conditions compared to HCs, suggests facilitation of the dorsal executive system when affective stimuli are present specifically in PRGs.
C1 [van Holst, Ruth J.; van der Meer, Johan N.; van den Brink, Wim; Veltman, Dick J.; Goudriaan, Anna E.] Univ Amsterdam, Acad Med Ctr, Dept Psychiat, NL-1105 AZ Amsterdam, Netherlands.
   [van Holst, Ruth J.; van den Brink, Wim; Veltman, Dick J.; Goudriaan, Anna E.] Amsterdam Inst Addict Res, Amsterdam, Netherlands.
   [McLaren, Donald G.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
   [McLaren, Donald G.] Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Boston, MA USA.
   [Veltman, Dick J.] Vrije Univ Amsterdam, Dept Psychiat, Med Ctr, Amsterdam, Netherlands.
   [Goudriaan, Anna E.] Arkin Mental Hlth Care, Amsterdam, Netherlands.
   [McLaren, Donald G.] Geriatr Res Educ & Clin Ctr, Edith Nourse Rogers Mem Vet Affairs Med Ctr, Bedford, MA USA.
   [McLaren, Donald G.] Harvard Univ, Sch Med, Boston, MA USA.
RP van Holst, RJ (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Psychiat, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
EM ruthvan.holst@gmail.com
RI van Holst, Ruth Janke/J-1655-2012
OI van Holst, Ruth Janke/0000-0002-1184-9355; McLaren,
   Donald/0000-0002-0566-4610
FU Dutch Scientific Organization (NWO ZonMw) [91676084]; Amsterdam Brain
   Imaging Platform
FX This study was funded by a New Investigator grant to AEG from the Dutch
   Scientific Organization (NWO ZonMw, #91676084, 2007-10). Scanning costs
   were partly funded by a grant of the Amsterdam Brain Imaging Platform to
   RJH. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Agam Y, 2010, NEUROIMAGE, V52, P336, DOI 10.1016/j.neuroimage.2010.04.010
   Aron AR, 2007, J NEUROSCI, V27, P11860, DOI 10.1523/JNEUROSCI.3644-07.2007
   Aron AR, 2007, NEUROSCIENTIST, V13, P214, DOI 10.1177/1073858407299288
   Boehler CN, 2010, NEUROIMAGE, V52, P1621, DOI 10.1016/j.neuroimage.2010.04.276
   Boyer M, 2003, ADDICTION, V98, P61, DOI 10.1046/j.1360-0443.2003.00219.x
   Chambers CD, 2009, NEUROSCI BIOBEHAV R, V33, P631, DOI 10.1016/j.neubiorev.2008.08.016
   Chen CY, 2009, NEUROIMAGE, V44, P537, DOI 10.1016/j.neuroimage.2008.09.005
   Colibazzi T, 2010, EMOTION, V10, P377, DOI 10.1037/a0018484
   Crockford DN, 2005, BIOL PSYCHIAT, V58, P787, DOI 10.1016/j.biopsych.2005.04.037
   de Ruiter MB, 2009, NEUROPSYCHOPHARMACOL, V34, P1027, DOI 10.1038/npp.2008.175
   Decharms RC, 2008, NAT REV NEUROSCI, V9, P720, DOI 10.1038/nrn2414
   deCharms RC, 2005, P NATL ACAD SCI USA, V102, P18626, DOI 10.1073/pnas.0505210102
   Dolcos F, 2006, J NEUROSCI, V26, P2072, DOI 10.1523/JNEUROSI.5042-05-2006
   Duann JR, 2009, J NEUROSCI, V29, P10171, DOI 10.1523/JNEUROSCI.1300-09.2009
   Feil J, 2010, NEUROSCI BIOBEHAV R, V34, P559, DOI 10.1016/j.neubiorev.2009.11.006
   Feinstein JS, 2002, NEUROREPORT, V13, P1255, DOI 10.1097/00001756-200207190-00007
   Fichtenholtz HM, 2004, COGNITIVE BRAIN RES, V20, P67, DOI 10.1016/j.cogbrainres.2004.01.006
   Field M, 2008, DRUG ALCOHOL DEPEN, V97, P1, DOI 10.1016/j.drugalcdep.2008.03.030
   Gitelman DR, 2003, NEUROIMAGE, V19, P200, DOI 10.1016/S1053-8119(03)00058-2
   Goudriaan AE, 2008, PSYCHOL MED, V38, P41, DOI 10.1017/S0033291707000694
   Goudriaan AE, 2006, DRUG ALCOHOL DEPEN, V84, P231, DOI 10.1016/j.drugalcdep.2006.02.007
   Goudriaan AE, 2010, ADDICT BIOL, V15, P491, DOI 10.1111/j.1369-1600.2010.00242.x
   Harsay HA, 2011, J NEUROSCI, V31, P10701, DOI 10.1523/JNEUROSCI.5415-10.2011
   Holden C, 2001, SCIENCE, V294, P980, DOI 10.1126/science.294.5544.980
   Honey GD, 2003, BRAIN, V126, P1767, DOI 10.1093/brain/awg184
   Horvitz JC, 2000, NEUROSCIENCE, V96, P651, DOI 10.1016/S0306-4522(00)00019-1
   Kertzman S, 2008, PSYCHIAT RES, V161, P1, DOI 10.1016/j.psychres.2007.06.026
   Kertzman S, 2006, PSYCHIAT RES, V142, P1, DOI 10.1016/j.psychres.2005.07.027
   Kienast T, 2008, EUR J NUCL MED MOL I, V35, P1147, DOI 10.1007/s00259-007-0683-z
   Kim J, 2008, MAGN RESON IMAGING, V26, P583, DOI 10.1016/j.mri.2007.10.011
   Kim SW, 2001, PSYCHIAT RES, V104, P205
   Lang P. J., 2008, INT AFFECTIVE PICTUR
   LESIEUR HR, 1987, AM J PSYCHIAT, V144, P1184
   Li CSR, 2006, J NEUROSCI, V26, P186, DOI 10.1523/JNEUROSCI.3741-05.2006
   Locke HS, 2008, COGN AFFECT BEHAV NE, V8, P99, DOI 10.3758/CABN.8.1.99
   Lorains FK, 2011, ADDICTION, V106, P490, DOI 10.1111/j.1360-0443.2010.03300.x
   McCusker CG, 1997, BRIT J CLIN PSYCHOL, V36, P543, DOI 10.1111/j.2044-8260.1997.tb01259.x
   McLaren DG, 2012, NEUROIMAGE, V61, P1277, DOI 10.1016/j.neuroimage.2012.03.068
   Nagano-Saito A, 2008, J NEUROSCI, V28, P3697, DOI 10.1523/JNEUROSCI.3921-07.2008
   Northoff G, 2004, HUM BRAIN MAPP, V21, P202, DOI 10.1002/hbm.20002
   Ochsner KN, 2009, PSYCHOL SCI, V20, P1322, DOI 10.1111/j.1467-9280.2009.02459.x
   Ochsner KN, 2005, TRENDS COGN SCI, V9, P242, DOI 10.1016/j.tics.2005.03.010
   Park SQ, 2010, J NEUROSCI, V30, P7749, DOI 10.1523/JNEUROSCI.5587-09.2010
   Pessoa L., 2011, J COGN NEUROSCI
   Pessoa L, 2008, NAT REV NEUROSCI, V9, P148, DOI 10.1038/nrn2317
   Pessoa Luiz, 2010, Dialogues Clin Neurosci, V12, P433
   Pestilli F, 2011, NEURON, V72, P832, DOI 10.1016/j.neuron.2011.09.025
   Petry NM, 2007, AM J ADDICTION, V16, P1, DOI 10.1080/10550490601077668
   Phillips M, 2008, MOL PSYCHIATR, V13, P833, DOI 10.1038/mp.2008.65
   Picton TW, 2007, CEREB CORTEX, V17, P826, DOI 10.1093/cercor/bhk031
   Potenza MN, 2006, ADDICTION, V101, P142, DOI 10.1111/j.1360-0443.2006.01591.x
   Potenza MN, 2003, AM J PSYCHIAT, V160, P1990, DOI 10.1176/appi.ajp.160.11.1990
   Prado J, 2011, NEUROIMAGE, V54, P465, DOI 10.1016/j.neuroimage.2010.08.038
   Robbins TW, 2009, ANNU REV NEUROSCI, V32, P267, DOI 10.1146/annurev.neuro.051508.135535
   Robins L. N. C. L., 1998, DIAGNOSTIC INTERVIEW
   Robinson TE, 2001, ADDICTION, V96, P103, DOI 10.1046/j.1360-0443.2001.9611038.x
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Savine AC, 2010, COGNITION EMOTION, V24, P338, DOI 10.1080/02699930903381564
   Schultz W, 1998, J NEUROPHYSIOL, V80, P1
   Schultz W, 2006, ANNU REV PSYCHOL, V57, P87, DOI 10.1146/annurev.psych.56.091103.070229
   Schulz KP, 2009, HUM BRAIN MAPP, V30, P2821, DOI 10.1002/hbm.20706
   Siessmeier T, 2006, EUR J NEUROSCI, V24, P305, DOI 10.1111/j.1460-9568.2006.04903.x
   Steven MC, 2007, BEHAV BRAIN RES, V181, P12, DOI 10.1016/j.bbr.2007.03.023
   Tanabe J, 2007, HUM BRAIN MAPP, V28, P1276, DOI 10.1002/hbm.20344
   van Holst RJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030909
   van Holst RJ, 2010, NEUROSCI BIOBEHAV R, V34, P87, DOI 10.1016/j.neubiorev.2009.07.007
   van Steenbergen H, 2009, PSYCHOL SCI, V20, P1473, DOI 10.1111/j.1467-9280.2009.02470.x
   Wechsler D, 1981, WECHSLER ADULT INTEL
   Williams D, 2002, BRAIN, V125, P1558, DOI 10.1093/brain/awf156
NR 69
TC 13
Z9 13
U1 0
U2 25
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 28
PY 2012
VL 7
IS 11
AR e49923
DI 10.1371/journal.pone.0049923
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 057YW
UT WOS:000312601700026
PM 23209619
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Gaval-Cruz, M
   Liles, LC
   Iuvone, PM
   Weinshenker, D
AF Gaval-Cruz, Meriem
   Liles, Larry Cameron
   Iuvone, Paul Michael
   Weinshenker, David
TI Chronic Inhibition of Dopamine beta-Hydroxylase Facilitates Behavioral
   Responses to Cocaine in Mice
SO PLOS ONE
LA English
DT Article
ID PLACEBO-CONTROLLED TRIAL; INDUCED REINSTATEMENT; DISULFIRAM TREATMENT;
   LOCOMOTOR-ACTIVITY; ALCOHOL DEPENDENCE; PREFRONTAL CORTEX;
   DRUG-METABOLISM; NOREPINEPHRINE; ADDICTION; SEEKING
AB The anti-alcoholism medication, disulfiram (Antabuse), decreases cocaine use in humans regardless of concurrent alcohol consumption and facilitates cocaine sensitization in rats, but the functional targets are unknown. Disulfiram inhibits dopamine beta-hydroxylase (DBH), the enzyme that converts dopamine (DA) to norepinephrine (NE) in noradrenergic neurons. The goal of this study was to test the effects of chronic genetic or pharmacological DBH inhibition on behavioral responses to cocaine using DBH knockout (Dbh -/-) mice, disulfiram, and the selective DBH inhibitor, nepicastat. Locomotor activity was measured in control (Dbh +/-) and Dbh -/- mice during a 5 day regimen of saline+saline, disulfiram+saline, nepicastat+saline, saline+cocaine, disulfiram+cocaine, or nepicastat+cocaine. After a 10 day withdrawal period, all groups were administered cocaine, and locomotor activity and stereotypy were measured. Drug-naive Dbh -/- mice were hypersensitive to cocaine-induced locomotion and resembled cocaine-sensitized Dbh +/- mice. Chronic disulfiram administration facilitated cocaine-induced locomotion in some mice and induced stereotypy in others during the development of sensitization, while cocaine-induced stereotypy was evident in all nepicastat-treated mice. Cocaine-induced stereotypy was profoundly increased in the disulfiram+cocaine, nepicastat+cocaine, and nepicastat+saline groups upon cocaine challenge after withdrawal in Dbh +/- mice. Disulfiram or nepicastat treatment had no effect on behavioral responses to cocaine in Dbh -/- mice. These results demonstrate that chronic DBH inhibition facilitates behavioral responses to cocaine, although different methods of inhibition (genetic vs. non-selective inhibitor vs. selective inhibitor) enhance qualitatively different cocaine-induced behaviors.
C1 [Gaval-Cruz, Meriem; Liles, Larry Cameron; Weinshenker, David] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA.
   [Iuvone, Paul Michael] Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA.
RP Weinshenker, D (reprint author), Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA.
EM dweinshenker@genetics.emory.edu
FU National Institute of Drug Abuse [DA017963, DA027535, DA25040,
   DA015040]; National Eye Institute [EY004864, P30 EY06360]
FX This work was supported by the National Institute of Drug Abuse
   (DA017963 and DA027535 to DW, DA25040 and DA015040 to MGC) and the
   National Eye Institute (EY004864 and P30 EY06360 to PMI). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Baker JR, 2007, DRUG ALCOHOL DEPEN, V87, P202, DOI 10.1016/j.drugalcdep.2006.08.016
   Bourdelat-Parks BN, 2005, PSYCHOPHARMACOLOGY, V183, P72, DOI 10.1007/s00213-005-0139-8
   Brousse G, 2010, MED HYPOTHESES, V75, P600, DOI 10.1016/j.mehy.2010.07.043
   Carroll KM, 2000, ADDICTION, V95, P1335, DOI 10.1046/j.1360-0443.2000.95913355.x
   Carroll KM, 2004, ARCH GEN PSYCHIAT, V61, P264, DOI 10.1001/archpsyc.61.3.264
   Carroll KM, 1998, ADDICTION, V93, P713, DOI 10.1046/j.1360-0443.1998.9357137.x
   Carroll KM, 2012, DRUG ALCOHOL DEPEND
   Cubells JF, 2000, MOL PSYCHIATR, V5, P56, DOI 10.1038/sj.mp.4000657
   Cunningham K, 2010, COLL PROBL DRUG DEP
   Devoto P, 2012, PSYCHOPHARMACOLOGY, V219, P1153, DOI 10.1007/s00213-011-2447-5
   Erb S, 2000, NEUROPSYCHOPHARMACOL, V23, P138, DOI 10.1016/S0893-133X(99)00158-X
   EWING JA, 1978, ALCOHOL CLIN EXP RES, V2, P93, DOI 10.1111/j.1530-0277.1978.tb04701.x
   Gaval-Cruz M, 2008, PHARMACOL BIOCHEM BE, V89, P556, DOI 10.1016/j.pbb.2008.02.009
   Gaval-Cruz M, 2009, MOL INTERV, V9, P175, DOI 10.1124/mi.9.4.6
   George TP, 2000, BIOL PSYCHIAT, V47, P1080, DOI 10.1016/S0006-3223(99)00310-8
   Grassi MC, 2007, PHARMACOL RES, V55, P117, DOI 10.1016/j.phrs.2006.11.005
   Guindalini C, 2008, BEHAV BRAIN FUNCT, V4, DOI 10.1186/1744-9081-4-1
   Haile CN, 2003, BIOL PSYCHIAT, V54, P915, DOI 10.1016/S0006-3223(03)00241-5
   HAMEEDI FA, 1995, BIOL PSYCHIAT, V37, P560, DOI 10.1016/0006-3223(94)00361-6
   HEATH RG, 1965, DIS NERV SYST, V26, P99
   HIGGINS ST, 1993, AM J PSYCHIAT, V150, P675
   Kalayasiri R, 2007, BIOL PSYCHIAT, V61, P1310, DOI 10.1016/j.biopsych.2006.08.012
   Kapoor A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026509
   KUCZENSKI R, 1991, J NEUROSCI, V11, P2703
   Leri F, 2002, J NEUROSCI, V22, P5713
   MAJ J, 1968, J PHARM PHARMACOL, V20, P247, DOI 10.1111/j.2042-7158.1968.tb09735.x
   MAJOR LF, 1979, BIOL PSYCHIAT, V14, P337
   Marek GJ, 1999, EUR J PHARMACOL, V367, P197, DOI 10.1016/S0014-2999(98)00945-5
   McCance-Katz EF, 1998, BIOL PSYCHIAT, V43, P540, DOI 10.1016/S0006-3223(97)00506-4
   McCance-Katz EF, 1998, DRUG ALCOHOL DEPEN, V52, P27, DOI 10.1016/S0376-8716(98)00050-7
   Mitchell HA, 2006, BIOL PSYCHIAT, V60, P1046, DOI 10.1016/j.biopsych.2006.03.057
   Mitrano DA, 2012, NEUROPSYCHOPHARMACOL
   Mutschler J, 2009, J CLIN PSYCHOPHARM, V29, P99, DOI 10.1097/JCP.0b013e3181934451
   Nich C, 2004, ADDICT BEHAV, V29, P1123, DOI 10.1016/j.addbeh.2004.03.004
   NOUSIAINEN U, 1984, GEN PHARMACOL, V15, P223, DOI 10.1016/0306-3623(84)90163-0
   Oliveto A, 2011, DRUG ALCOHOL DEPEN, V113, P184, DOI 10.1016/j.drugalcdep.2010.07.022
   Pani PP, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007024.pub2
   PARADISI R, 1991, ACTA ENDOCRINOL-COP, V125, P246, DOI 10.1530/acta.0.1250246
   Petrakis IL, 2000, ADDICTION, V95, P219, DOI 10.1046/j.1360-0443.2000.9522198.x
   Pettinati HM, 2008, ADDICT BEHAV, V33, P651, DOI 10.1016/j.addbeh.2007.11.011
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   ROGERS WK, 1979, CLIN PHARMACOL THER, V25, P469
   SAVOLAINEN K, 1984, ACTA PHARMACOL TOX, V55, P339
   Schank JR, 2008, BIOL PSYCHIAT, V63, P1007, DOI 10.1016/j.biopsych.2007.10.018
   Schank JR, 2006, NEUROPSYCHOPHARMACOL, V31, P2221, DOI 10.1038/sj.npp.1301000
   Schlussman SD, 1998, PHARMACOL BIOCHEM BE, V60, P593, DOI 10.1016/S0091-3057(98)00047-1
   Schroeder JP, 2010, NEUROPSYCHOPHARMACOL, V35, P2440, DOI 10.1038/npp.2010.127
   Smith RJ, 2011, BIOL PSYCHIAT, V70, P712, DOI 10.1016/j.biopsych.2011.06.010
   Sofuoglu M, 2008, PHARMACOL BIOCHEM BE, V90, P394, DOI 10.1016/j.pbb.2008.03.021
   Stanley WC, 1997, BRIT J PHARMACOL, V121, P1803, DOI 10.1038/sj.bjp.0701315
   Steketee Jeffery D., 2005, Critical Reviews in Neurobiology, V17, P69
   Szot P, 1999, J NEUROSCI, V19, P10985
   Thomas SA, 1998, J NEUROCHEM, V70, P2468
   Thomas SA, 1997, BEHAV NEUROSCI, V111, P579, DOI 10.1037/0735-7044.111.3.579
   TOLLIVER BK, 1994, PHARMACOL BIOCHEM BE, V48, P733, DOI 10.1016/0091-3057(94)90340-9
   VESELL ES, 1971, CLIN PHARMACOL THER, V12, P785
   Weinshenker D, 2002, P NATL ACAD SCI USA, V99, P13873, DOI 10.1073/pnas.212519999
   Weinshenker D, 2008, J NEUROCHEM, V105, P471, DOI 10.1111/j.1471-4159.2007.05145.x
   Weinshenker D, 2007, NEUROPSYCHOPHARMACOL, V32, P1433, DOI 10.1038/sj.npp.1301263
   ZEMAITIS MA, 1976, BIOCHEM PHARMACOL, V25, P1355, DOI 10.1016/0006-2952(76)90104-0
   Zhang XY, 2005, BIOL PSYCHIAT, V57, P1202, DOI 10.1016/j.biopsych.2005.02.003
NR 61
TC 8
Z9 8
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 27
PY 2012
VL 7
IS 11
AR e50583
DI 10.1371/journal.pone.0050583
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 048BS
UT WOS:000311885800085
PM 23209785
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Heldmann, M
   Berding, G
   Voges, J
   Bogerts, B
   Galazky, I
   Muller, U
   Baillot, G
   Heinze, HJ
   Munte, TF
AF Heldmann, Marcus
   Berding, Georg
   Voges, Juergen
   Bogerts, Bernhard
   Galazky, Imke
   Mueller, Ulf
   Baillot, Gunther
   Heinze, Hans-Jochen
   Muente, Thomas F.
TI Deep Brain Stimulation of Nucleus Accumbens Region in Alcoholism Affects
   Reward Processing
SO PLOS ONE
LA English
DT Article
ID OBSESSIVE-COMPULSIVE DISORDER; ANTERIOR CINGULATE CORTEX;
   DECISION-MAKING; PSYCHOLOGICAL DEPENDENCE; ORBITOFRONTAL CORTEX;
   STEREOTACTIC SURGERY; EMISSION-TOMOGRAPHY; DOPAMINE AGONISTS;
   PARKINSON-DISEASE; MAJOR DEPRESSION
AB The influence of bilateral deep brain stimulation (DBS) of the nucleus nucleus (NAcc) on the processing of reward in a gambling paradigm was investigated using H-2[O-15]-PET (positron emission tomography) in a 38-year-old man treated for severe alcohol addiction. Behavioral data analysis revealed a less risky, more careful choice behavior under active DBS compared to DBS switched off. PET showed win-and loss-related activations in the paracingulate cortex, temporal poles, precuneus and hippocampus under active DBS, brain areas that have been implicated in action monitoring and behavioral control. Except for the temporal pole these activations were not seen when DBS was deactivated. These findings suggest that DBS of the NAcc may act partially by improving behavioral control.
C1 [Heldmann, Marcus; Galazky, Imke; Heinze, Hans-Jochen] Univ Magdeburg, Dept Neurol, D-39106 Magdeburg, Germany.
   [Heldmann, Marcus; Muente, Thomas F.] Univ Lubeck, Dept Neurol, Lubeck, Germany.
   [Berding, Georg; Baillot, Gunther] Hannover Med Sch, Dept Nucl Med, D-3000 Hannover, Germany.
   [Voges, Juergen] Univ Magdeburg, Dept Stereotact Neurosurg, D-39106 Magdeburg, Germany.
   [Bogerts, Bernhard; Mueller, Ulf] Univ Magdeburg, Dept Psychiat, D-39106 Magdeburg, Germany.
RP Heldmann, M (reprint author), Univ Magdeburg, Dept Neurol, D-39106 Magdeburg, Germany.
EM marcus.heldmann@neuro.uni-luebeck.de
RI Munte, Thomas/C-2077-2014
OI Mueller, Ulf/0000-0002-4066-662X
FU DFG [SFB779]
FX This work was supported by grants from the DFG (SFB779) to TFM, BB, and
   HJH. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abler B, 2009, BRAIN, V132, P2396, DOI 10.1093/brain/awp170
   Asari T, 2008, NEUROIMAGE, V41, P145, DOI 10.1016/j.neuroimage.2008.01.059
   Axmacher N, 2010, NEURON, V65, P541, DOI 10.1016/j.neuron.2010.02.006
   Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295
   Blaizot X, 2010, CEREB CORTEX, V20, P2198, DOI 10.1093/cercor/bhp289
   Buckner RL, 2010, ANNU REV PSYCHOL, V61, P27, DOI 10.1146/annurev.psych.60.110707.163508
   Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2
   Camara E, 2009, FRONT HUM NEUROSCI, V2, DOI 10.3389/neuro.09.019.2008
   Cohen MX, 2009, J NEUROSCI, V29, P7591, DOI 10.1523/JNEUROSCI.5335-08.2009
   Cohen MX, 2009, NEUROPSYCHOPHARMACOL, V34, P1649, DOI 10.1038/npp.2008.222
   Cooper JC, 2008, NEUROIMAGE, V39, P538, DOI 10.1016/j.neuroimage.2007.08.009
   Coricelli G, 2005, NAT NEUROSCI, V8, P1255, DOI 10.1038/nn1514
   di Pellegrino G, 2007, J COGNITIVE NEUROSCI, V19, P275, DOI 10.1162/jocn.2007.19.2.275
   Ernst M, 2002, NEUROPSYCHOPHARMACOL, V26, P682, DOI 10.1016/S0893-133X(01)00414-6
   Gao GD, 2003, STEREOT FUNCT NEUROS, V81, P96, DOI 10.1159/000075111
   Gehring WJ, 2002, SCIENCE, V295, P2279, DOI 10.1126/science.1066893
   Geworski L, 2000, EUR J NUCL MED, V27, P161, DOI 10.1007/s002590050022
   Goto Y, 2005, NAT NEUROSCI, V8, P805, DOI 10.1038/nn1471
   Goto Y, 2002, P NATL ACAD SCI USA, V99, P13189, DOI 10.1073/pnas.202303199
   Grace AA, 2000, BRAIN RES REV, V31, P330, DOI 10.1016/S0165-0173(99)00049-1
   Greenberg BD, 2006, NEUROPSYCHOPHARMACOL, V31, P2384, DOI 10.1038/sj.npp.1301165
   Heinze HJ, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.022.2009
   Huettel SA, 2006, COGN AFFECT BEHAV NE, V6, P141, DOI 10.3758/CABN.6.2.141
   Huff W, 2010, CLIN NEUROL NEUROSUR, V112, P137, DOI 10.1016/j.clineuro.2009.11.006
   Huijbers W, 2010, NEUROPSYCHOLOGIA, V48, P491, DOI 10.1016/j.neuropsychologia.2009.10.006
   Ikemoto S, 2010, NEUROSCI BIOBEHAV RE
   Jalabert M, 2009, PROG NEURO-PSYCHOPH, V33, P1336, DOI 10.1016/j.pnpbp.2009.07.010
   Kampe KKW, 2003, J NEUROSCI, V23, P5258
   Kanske P, 2010, CEREB CORTEX, P157
   Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110
   Longe O, 2010, NEUROIMAGE, V49, P1849, DOI 10.1016/j.neuroimage.2009.09.019
   Magno E, 2009, J COGNITIVE NEUROSCI, V21, P2328, DOI 10.1162/jocn.2008.21169
   Marco-Pallares J, 2010, BRAIN RES
   Munte T.F., 2007, FRONT HUM NEUROSCI, V1, P1
   Ochsner KN, 2009, J COGNITIVE NEUROSCI, V21, P1841, DOI 10.1162/jocn.2009.21129
   Olson IR, 2007, BRAIN, V130, P1718, DOI 10.1093/brain/awm052
   Paulus MP, 2006, NEUROIMAGE, V30, P668, DOI 10.1016/j.neuroimage.2005.09.061
   Paulus MP, 2002, NEUROIMAGE, V15, P836, DOI 10.1006/nimg.2001.1031
   Piefke M, 2003, BRAIN, V126, P650, DOI 10.1093/brain/awg064
   Qin JG, 2009, HUM BRAIN MAPP, V30, P1338, DOI 10.1002/hbm.20604
   RANCK JB, 1975, BRAIN RES, V98, P417, DOI 10.1016/0006-8993(75)90364-9
   Redish AD, 2007, ANN NY ACAD SCI, V1104, P324, DOI 10.1196/annals.1390.014
   Riba J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002479
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Royet JP, 2000, J NEUROSCI, V20, P7752
   Schlaepfer TE, 2008, NEUROPSYCHOPHARMACOL, V33, P368, DOI 10.1038/sj.npp.1301408
   Schroeter ML, 2010, NEUROPSYCHOLOGIA, V48, P185, DOI 10.1016/j.neuropsychologia.2009.09.004
   Smith KS, 2009, BEHAV BRAIN RES, V196, P155, DOI 10.1016/j.bbr.2008.09.038
   SPM2, 2012, SPM2
   Steele JD, 2008, BIOL PSYCHIAT, V63, P670, DOI 10.1016/j.biopsych.2007.07.019
   Takahashi H, 2008, CEREB CORTEX, V18, P898, DOI 10.1093/cercor/bhm120
   Tindell AJ, 2005, EUR J NEUROSCI, V22, P2617, DOI 10.1111/j.1460-9568.2005.04411.x
   van Eimeren T, 2009, NEUROPSYCHOPHARMACOL, V34, P2758, DOI [10.1038/sj.npp.npp2009124, 10.1038/npp.2009.124]
   Voon V, 2007, ARCH NEUROL-CHICAGO, V64, P212, DOI 10.1001/archneur.64.2.212
   Weintraub D, 2006, ARCH NEUROL-CHICAGO, V63, P969, DOI 10.1001/archneur.63.7.969
   Willems RM, 2010, SOC COGN AFFECT NEUR
   Wu HM, 2010, NEUROSCI LETT, V473, P77, DOI 10.1016/j.neulet.2010.02.019
NR 57
TC 32
Z9 32
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 22
PY 2012
VL 7
IS 5
AR e36572
DI 10.1371/journal.pone.0036572
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959VQ
UT WOS:000305345300008
PM 22629317
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Petit, G
   Kornreich, C
   Noel, X
   Verbanck, P
   Campanella, S
AF Petit, Geraldine
   Kornreich, Charles
   Noel, Xavier
   Verbanck, Paul
   Campanella, Salvatore
TI Alcohol-Related Context Modulates Performance of Social Drinkers in a
   Visual Go/No-Go Task: A Preliminary Assessment of Event-Related
   Potentials
SO PLOS ONE
LA English
DT Article
ID RESPONSE-INHIBITION; CUE-REACTIVITY; ADDICTIVE BEHAVIORS; ATTENTIONAL
   BIAS; LIGHT DRINKERS; USE DISORDERS; IMPULSIVITY; SENSITIVITY; DRINKING;
   CORTEX
AB Background: Increased alcohol cue-reactivity and altered inhibitory processing have been reported in heavy social drinkers and alcohol-dependent patients, and are associated with relapse. In social drinkers, these two processes have been usually studied separately by recording event-related potentials (ERPs) during rapid picture presentation. The aim of our study was to confront social drinkers to a task triggering high alcohol cue-reactivity, to verify whether it specifically altered inhibitory performance, by using long-lasting background picture presentation.
   Methods: ERP were recorded during visual Go/No-Go tasks performed by social drinkers, in which a frequent Go signal (letter "M''), and a rare No-Go signal (letter "W'') were superimposed on three different types of background pictures: neutral (black background), alcohol-related and non alcohol-related.
   Results: Our data suggested that heavy social drinkers made more commission errors than light drinkers, but only in the alcohol-related context. Neurophysiologically, this was reflected by a delayed No-Go P3 component.
   Conclusions: Elevated alcohol cue-reactivity may lead to poorer inhibitory performance in heavy social drinkers, and may be considered as an important vulnerability factor in developing alcohol misuse. Prevention programs should be designed to decrease the high arousal of alcohol stimuli and strengthen cognitive control in young, at-risk individuals.
C1 [Petit, Geraldine; Kornreich, Charles; Noel, Xavier; Verbanck, Paul; Campanella, Salvatore] Free Univ Brussels, Lab Psychol Med, Brussels, Belgium.
RP Petit, G (reprint author), Free Univ Brussels, Lab Psychol Med, Brussels, Belgium.
EM salvatore.campanella@chu-brugmann.be
FU FNRS
FX Geraldine Petit is Research Fellow, and Xavier Noel as well as Salvatore
   Campanella are Research Associates at the Belgian Fund of Scientific
   Research (FNRS). This study was financially supported by FNRS. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Albert J, 2010, NEUROIMAGE, V49, P914, DOI 10.1016/j.neuroimage.2009.08.045
   Babor T, LEXICON ALCOHOL DRUG
   Bartholow BD, 2007, PSYCHOL ADDICT BEHAV, V21, P555, DOI 10.1037/0893-164X.21.4.555
   Bartholow BD, 2010, PSYCHOL ADDICT BEHAV, V24, P220, DOI 10.1037/a0017705
   Beck A. T., 1987, BECK DEPRESSION INVE
   BERTRAND O, 1985, ELECTROEN CLIN NEURO, V62, P462, DOI 10.1016/0168-5597(85)90058-9
   Beste C, 2008, NEUROPSYCHOLOGIA, V46, P1290, DOI 10.1016/j.neuropsychologia.2007.12.008
   Bonomo YA, 2004, ADDICTION, V99, P1520, DOI 10.1111/j.1360-0443.2004.00846.x
   Carretie L, 2006, EXP BRAIN RES, V174, P630, DOI 10.1007/s00221-006-0510-y
   Chiu PH, 2008, NEUROIMAGE, V42, P988, DOI 10.1016/j.neuroimage.2008.04.248
   Cirilli L, 2011, PLOS ONE, V10
   Cox WM, 1999, DRUG ALCOHOL DEPEN, V55, P85, DOI 10.1016/S0376-8716(98)00186-0
   Crego A, 2009, BINGE DRINKING AFFEC
   Dawe S, 2004, ADDICT BEHAV, V29, P1389, DOI 10.1016/j.addbeh.2004.06.004
   Euser AS, 2012, PSYCHOPHARMACOLOGY, V222, P459, DOI 10.1007/s00213-012-2664-6
   Field M, 2008, DRUG ALCOHOL DEPEN, V97, P1, DOI 10.1016/j.drugalcdep.2008.03.030
   Garland EL, 2012, PSYCHOPHARMACOLOGY, V222, P17, DOI 10.1007/s00213-011-2618-4
   GREELEY JD, 1993, J STUD ALCOHOL, V54, P359, DOI 10.15288/jsa.1993.54.359
   Grusser SM, 2004, PSYCHOPHARMACOLOGY, V175, P296, DOI 10.1007/s00213-004-1828-4
   Herrmann MJ, 2000, ALCOHOL CLIN EXP RES, V24, P1724, DOI 10.1097/00000374-200011000-00015
   Herrmann MJ, 2001, ALCOHOL ALCOHOLISM, V36, P588, DOI 10.1093/alcalc/36.6.588
   KAHLER CW, 1995, ADDICTION, V90, P1025, DOI 10.1046/j.1360-0443.1995.90810252.x
   Kamarajan C, 2005, BIOL PSYCHOL, V69, P353, DOI 10.1016/j.biopsycho.2004.08.004
   Kamarajan C, 2005, CLIN NEUROPHYSIOL, V116, P1049, DOI 10.1016/j.clinph.2004.12.015
   Kiefer M, 1998, NEUROREPORT, V9, P765, DOI 10.1097/00001756-199803090-00037
   Korpelainen JT, 2000, ACTA NEUROL SCAND, V101, P202, DOI 10.1034/j.1600-0404.2000.101003202.x
   Lang P. J., 2005, A6 U FLOR
   Maurage P, 2007, CLIN NEUROPHYSIOL, V118, P633, DOI 10.1016/j.clinph.2006.11.007
   Maurage P, 2009, J PSYCHIATR NEUROSCI, V34, P111
   McKenzie M, 2011, MED J AUSTRALIA, V195, pS27
   Mechtcheriakov S, 2007, J NEUROL NEUROSUR PS, V78, P610, DOI 10.1136/jnnp.2006.095869
   Miller MA, 2011, DRUG ALCOHOL DEPEN, V117, P184, DOI 10.1016/j.drugalcdep.2011.01.016
   Noel X, 2001, ARCH GEN PSYCHIAT, V58, P1152, DOI 10.1001/archpsyc.58.12.1152
   Noel X, 2007, PSYCHOPHARMACOLOGY, V192, P291, DOI 10.1007/s00213-006-0695-6
   Oddy BW, 2009, INT J PSYCHOPHYSIOL, V72, P323, DOI 10.1016/j.ijpsycho.2009.02.002
   Pandey AK, 2012, BIOL PSYCHOL, V89, P170, DOI 10.1016/j.biopsycho.2011.10.009
   Papachristou H, 2012, PSYCHOPHARMACOLOGY, V219, P511, DOI 10.1007/s00213-011-2240-5
   Petit G, 2012, CLIN NEUROPHYSIOL, V123, P925, DOI 10.1016/j.clinph.2011.10.042
   Ridderinkhof KR, 2002, SCIENCE, V298, P2209, DOI 10.1126/science.1076929
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Rugg MD, 1995, ELECTROPHYSIOLOGY MI
   SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x
   SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P695, DOI 10.1111/j.1469-8986.1986.tb00696.x
   Shin E, 2010, PSYCHOL ADDICT BEHAV, V24, P508, DOI 10.1037/a0019663
   Smith JL, 2008, CLIN NEUROPHYSIOL, V119, P704, DOI 10.1016/j.clinph.2007.11.042
   Smith LA, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-51
   Smolka MN, 2006, PSYCHOPHARMACOLOGY, V184, P577, DOI 10.1007/s00213-005-0080-x
   Spielberger CD, 1983, MANUAL STATE TRAIT A
   Stacy AW, 2010, ANNU REV CLIN PSYCHO, V6, P551, DOI 10.1146/annurev.clinpsy.121208.131444
   Thomas SE, 2005, J STUD ALCOHOL, V66, P354, DOI 10.15288/jsa.2005.66.354
   Verdejo-Garcia A, 2010, PSYCHOPHARMACOLOGY, V210, P377, DOI 10.1007/s00213-010-1833-8
   Vollstadt-Klein S, 2011, BIOL PSYCHIAT, V69, P1060, DOI 10.1016/j.biopsych.2010.12.016
   Wessa M, 2007, AM J PSYCHIAT, V164, P638, DOI 10.1176/appi.ajp.164.4.638
   Whiteside SP, 2003, EXP CLIN PSYCHOPHARM, V11, P210, DOI 10.1037/1064-1297.11.3.210
   Wiers RW, 2007, PHARMACOL BIOCHEM BE, V86, P263, DOI 10.1016/j.pbb.2006.09.021
   World Health Organization, 1993, ICD 10 CLASS MENT BE
   Wrase J, 2002, EUR PSYCHIAT, V17, P287, DOI 10.1016/S0924-9338(02)00676-4
   YEE CM, 1994, J ABNORM PSYCHOL, V103, P625, DOI 10.1037/0021-843X.103.4.625
   Yeung N, 2006, PSYCHOL SCI, V17, P164, DOI 10.1111/j.1467-9280.2006.01680.x
   Zhang WH, 2012, BIOL PSYCHOL, V89, P444, DOI 10.1016/j.biopsycho.2011.12.011
   Zironi I, 2006, BEHAV BRAIN RES, V167, P150, DOI 10.1016/j.bbr.2005.09.007
NR 61
TC 51
Z9 53
U1 1
U2 23
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 17
PY 2012
VL 7
IS 5
AR e37466
DI 10.1371/journal.pone.0037466
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959UQ
UT WOS:000305341200077
PM 22616012
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Anderson, BA
   Laurent, PA
   Yantis, S
AF Anderson, Brian A.
   Laurent, Patryk A.
   Yantis, Steven
TI Learned Value Magnifies Salience-Based Attentional Capture
SO PLOS ONE
LA English
DT Article
ID SELECTIVE VISUAL-ATTENTION; CONTROL SETTINGS; HUMAN VISION; CORTEX;
   REWARD; TASK; REPRESENTATIONS; CONSEQUENCES; CONTINGENT; SINGLETONS
AB Visual attention is captured by physically salient stimuli (termed salience-based attentional capture), and by otherwise task-irrelevant stimuli that contain goal-related features (termed contingent attentional capture). Recently, we reported that physically nonsalient stimuli associated with value through reward learning also capture attention involuntarily (Anderson, Laurent, & Yantis, PNAS, 2011). Although it is known that physical salience and goal-relatedness both influence attentional priority, it is unknown whether or how attentional capture by a salient stimulus is modulated by its associated value. Here we show that a physically salient, task-irrelevant distractor previously associated with a large reward slows visual search more than an equally salient distractor previously associated with a smaller reward. This magnification of salience-based attentional capture by learned value extinguishes over several hundred trials. These findings reveal a broad influence of learned value on involuntary attentional capture.
C1 [Anderson, Brian A.; Laurent, Patryk A.; Yantis, Steven] Johns Hopkins Univ, Dept Psychol & Brain Sci, Baltimore, MD 21218 USA.
RP Anderson, BA (reprint author), Johns Hopkins Univ, Dept Psychol & Brain Sci, Baltimore, MD 21218 USA.
EM bander33@jhu.edu
OI Lauwereyns, Jan/0000-0003-0551-2550
FU National Institutes of Health [R01-DA013165]
FX The research was supported by the National Institutes of Health grant
   R01-DA013165 to Steven Yantis. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Anderson BA, 2011, P NATL ACAD SCI USA, V108, P10367, DOI 10.1073/pnas.1104047108
   Anderson BA, 2010, ATTEN PERCEPT PSYCHO, V72, P342, DOI 10.3758/APP.72.2.342
   BACON WF, 1994, PERCEPT PSYCHOPHYS, V55, P485, DOI 10.3758/BF03205306
   Belopolsky AV, 2010, ATTEN PERCEPT PSYCHO, V72, P326, DOI 10.3758/APP.72.2.326
   BUNDESEN C, 1990, PSYCHOL REV, V97, P523, DOI 10.1037/0033-295X.97.4.523
   Bush G, 2010, NEUROPSYCHOPHARMACOL, V35, P278, DOI 10.1038/npp.2009.120
   Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755
   Davis C, 2010, CURR PSYCHIAT REP, V12, P389, DOI 10.1007/s11920-010-0133-7
   Della Libera C, 2006, PSYCHOL SCI, V17, P222
   Della Libera C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019460
   Della Libera C, 2009, PSYCHOL SCI, V20, P778, DOI 10.1111/j.1467-9280.2009.02360.x
   DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.neuro.18.1.193
   DUNCAN J, 1994, NATURE, V369, P313, DOI 10.1038/369313a0
   Field M, 2008, DRUG ALCOHOL DEPEN, V97, P1, DOI 10.1016/j.drugalcdep.2008.03.030
   Folk CL, 1998, J EXP PSYCHOL HUMAN, V24, P847, DOI 10.1037/0096-1523.24.3.847
   FOLK CL, 1992, J EXP PSYCHOL HUMAN, V18, P1030, DOI 10.1037/0096-1523.18.4.1030
   Garavan H, 2007, NEUROPSYCHOL REV, V17, P337, DOI 10.1007/s11065-007-9034-x
   Hickey C, 2006, J COGNITIVE NEUROSCI, V18, P604, DOI 10.1162/jocn.2006.18.4.604
   Hickey C, 2011, VIS COGN, V19, P117, DOI 10.1080/13506285.2010.503946
   Hickey C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014087
   Hickey C, 2010, J NEUROSCI, V30, P11096, DOI 10.1523/JNEUROSCI.1026-10.2010
   Krebs RM, 2010, COGNITION, V117, P341, DOI 10.1016/j.cognition.2010.08.018
   Kyllingsbaek S, 2001, PERCEPT PSYCHOPHYS, V63, P85, DOI 10.3758/BF03200505
   Lamy D, 2004, J EXP PSYCHOL HUMAN, V30, P1019, DOI 10.1037/0096-1523.30.6.1019
   Laurent PA, 2008, NEURAL NETWORKS, V21, P1493, DOI 10.1016/j.neunet.2008.09.004
   Lien MC, 2010, J EXP PSYCHOL HUMAN, V36, P1, DOI 10.1037/a0015875
   Maunsell JHR, 2004, TRENDS COGN SCI, V8, P261, DOI 10.1016/j.tics.2004.04.003
   Navalpakkam V, 2010, P NATL ACAD SCI USA, V107, P5232, DOI 10.1073/pnas.0911972107
   Peck CJ, 2009, J NEUROSCI, V29, P11182, DOI 10.1523/JNEUROSCI.1929-09.2009
   Raymond JE, 2009, PSYCHOL SCI, V20, P981, DOI 10.1111/j.1467-9280.2009.02391.x
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Serences JT, 2007, CEREB CORTEX, V17, P284, DOI 10.1093/cercor/bhj146
   Serences JT, 2010, J NEUROPHYSIOL, V104, P76, DOI 10.1152/jn.01090.2009
   Serences JT, 2008, NEURON, V60, P1169, DOI 10.1016/j.neuron.2008.10.051
   Serences JT, 2005, PSYCHOL SCI, V16, P114, DOI 10.1111/j.0956-7976.2005.00791.x
   Sheppard B, 2010, DEPRESS ANXIETY, V27, P667, DOI 10.1002/da.20691
   SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127
   Shuler MG, 2006, SCIENCE, V311, P1606, DOI 10.1126/science.1123513
   Theeuwes J, 2002, PERCEPT PSYCHOPHYS, V64, P764, DOI 10.3758/BF03194743
   THEEUWES J, 1992, PERCEPT PSYCHOPHYS, V51, P599, DOI 10.3758/BF03211656
   Theeuwes J, 2010, ACTA PSYCHOL, V135, P77, DOI 10.1016/j.actpsy.2010.02.006
   Yantis S., 1984, J EXPT PSYCHOL HUMAN, V10, P350, DOI DOI 10.1037/0096-1523.10.5.601
NR 42
TC 136
Z9 140
U1 1
U2 39
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 21
PY 2011
VL 6
IS 11
AR e27926
DI 10.1371/journal.pone.0027926
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 858IO
UT WOS:000297789900034
PM 22132170
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Agarwal, M
   Guzman, MG
   Morales-Matos, C
   Diaz, RAD
   Abramson, CI
   Giray, T
AF Agarwal, Maitreyi
   Guzman, Manuel Giannoni
   Morales-Matos, Carla
   Del Valle Diaz, Rafael Alejandro
   Abramson, Charles I.
   Giray, Tugrul
TI Dopamine and Octopamine Influence Avoidance Learning of Honey Bees in a
   Place Preference Assay
SO PLOS ONE
LA English
DT Article
ID DIVISION-OF-LABOR; STING EXTENSION REFLEX; APIS-MELLIFERA BRAIN;
   JUVENILE-HORMONE; DROSOPHILA-MELANOGASTER; BEHAVIORAL-DEVELOPMENT;
   FUNCTIONAL EXPRESSION; PERIPLANETA-AMERICANA; OLFACTORY MEMORIES;
   RECEPTOR
AB Biogenic amines are widely characterized in pathways evaluating reward and punishment, resulting in appropriate aversive or appetitive responses of vertebrates and invertebrates. We utilized the honey bee model and a newly developed spatial avoidance conditioning assay to probe effects of biogenic amines octopamine (OA) and dopamine (DA) on avoidance learning. In this new protocol non-harnessed bees associate a spatial color cue with mild electric shock punishment. After a number of experiences with color and shock the bees no longer enter the compartment associated with punishment. Intrinsic aspects of avoidance conditioning are associated with natural behavior of bees such as punishment (lack of food, explosive pollination mechanisms, danger of predation, heat, etc.) and their association to floral traits or other spatial cues during foraging. The results show that DA reduces the punishment received whereas octopamine OA increases the punishment received. These effects are dose-dependent and specific to the acquisition phase of training. The effects during acquisition are specific as shown in experiments using the antagonists Pimozide and Mianserin for DA and OA receptors, respectively. This study demonstrates the integrative role of biogenic amines in aversive learning in the honey bee as modeled in a novel non-appetitive avoidance learning assay.
C1 [Agarwal, Maitreyi] Univ Puerto Rico, Dept Chem, San Juan, PR 00936 USA.
   [Guzman, Manuel Giannoni; Morales-Matos, Carla; Del Valle Diaz, Rafael Alejandro; Giray, Tugrul] Univ Puerto Rico, Dept Biol, San Juan, PR 00936 USA.
   [Abramson, Charles I.] Oklahoma State Univ, Lab Behav Biol & Comparat Psychol, Stillwater, OK 74078 USA.
RP Agarwal, M (reprint author), Univ Puerto Rico, Dept Chem, San Juan, PR 00936 USA.
EM tgiray2@yahoo.com
RI Giray, Tugrul/K-9570-2013
FU National Science Foundation, United States of America [OISE-1043057,
   DBI-0851651]; National Aeronautics and Space Administration Puerto Rico
   Space Grant Consortium [NASA-IDEAS-PR-08]
FX Parts of this work and its publication have been supported by grants
   from National Science Foundation, United States of America (OISE-1043057
   to CA and TG and DBI-0851651), and National Aeronautics and Space
   Administration Puerto Rico Space Grant Consortium (NASA-IDEAS-PR-08 to
   TG). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Abbott KR, 2009, ANIM BEHAV, V78, P633, DOI 10.1016/j.anbehav.2009.05.029
   ABRAMSON CI, 1988, J EXP ANAL BEHAV, V50, P483, DOI 10.1901/jeab.1988.50-483
   ABRAMSON CI, 1995, J COMP PSYCHOL, V109, P390, DOI 10.1037/0735-7036.109.4.390
   ABRAMSON CI, 1986, J COMP PSYCHOL, V100, P108, DOI 10.1037/0735-7036.100.2.108
   ABRAMSON CI, 2010, J INSECT SCI, V10
   ABRAMSON CI, 1981, J GEN PSYCHOL, V104, P229
   Arenas A, 2008, J COMP PHYSIOL A, V194, P629, DOI 10.1007/s00359-008-0337-z
   Avargues-Weber A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015370
   Barron AB, 2005, J COMP PHYSIOL A, V191, P659, DOI 10.1007/s00359-005-0619-7
   Barron AB, 2007, J INSECT PHYSIOL, V53, P187, DOI 10.1016/j.jinsphys.2006.11.009
   Barron AB, 2007, P NATL ACAD SCI USA, V104, P1703, DOI 10.1073/pnas.0610506104
   Barron AB, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00163
   Berridge KC, 2007, PSYCHOPHARMACOLOGY, V191, P391, DOI 10.1007/s00213-006-0578-x
   Berridge KC, 2009, CURR OPIN PHARMACOL, V9, P65, DOI 10.1016/j.coph.2008.12.014
   Bischof LJ, 2004, INSECT BIOCHEM MOLEC, V34, P511, DOI 10.1016/j.ibmb.2004.02.003
   Blenau W, 2000, J NEUROCHEM, V74, P900, DOI 10.1046/j.1471-4159.2000.0740900.x
   Blenau W, 1998, J NEUROCHEM, V70, P15
   Cakmak I, 2010, J INSECT BEHAV, V23, P100, DOI 10.1007/s10905-009-9199-7
   CAMPBELL BA, PUNISHMENT AVERSIVE
   Carcaud J, 2009, J EXP BIOL, V212, P620, DOI 10.1242/jeb.026641
   CHEN WY, 1970, ANIM BEHAV, V18, P725, DOI 10.1016/0003-3472(70)90018-7
   De Marco RJ, 2006, J EXP BIOL, V209, P421, DOI 10.1242/je6.02025
   DISTERHOFT JF, 1971, PHYSIOL BEHAV, V7, P359, DOI 10.1016/0031-9384(71)90314-3
   DISTERHOFT JF, 1972, J COMP PHYSIOL PSYCH, V79, P1, DOI 10.1037/h0032557
   Farooqui T, 2004, J INSECT PHYSIOL, V50, P701, DOI 10.1016/j.jinsphys.2004.04.014
   Farooqui T, 2003, J NEUROSCI, V23, P5370
   Fussnecker BL, 2006, J INSECT PHYSIOL, V52, P1083, DOI 10.1016/j.jinsphys.2006.07.008
   Giray T, 1996, P NATL ACAD SCI USA, V93, P11718, DOI 10.1073/pnas.93.21.11718
   Giray T, 2005, P NATL ACAD SCI USA, V102, P3330, DOI 10.1073/pnas.0409560102
   GIRAY T, 1994, BEHAV ECOL SOCIOBIOL, V35, P13, DOI 10.1007/s002650050064
   Giray T, 2007, J INSECT PHYSIOL, V53, P691, DOI 10.1016/j.jinsphys.2007.03.016
   Giurfa M, 2007, J COMP PHYSIOL A, V193, P801, DOI 10.1007/s00359-007-0235-9
   Giurfa M, 2009, LEARN MEMORY, V16, P761, DOI 10.1101/lm.1603009
   Grohmann L, 2000, EUR J NEUROSCI, V12, P94
   Harano K, 2008, J INSECT PHYSIOL, V54, P848, DOI 10.1016/j.jinsphys.2008.03.003
   Hawes JJ, 2008, NEUROPSYCHOPHARMACOL, V33, P1864, DOI 10.1038/sj.npp.1301579
   Hunt GJ, 2007, J INSECT PHYSIOL, V53, P399, DOI 10.1016/j.jinsphys.2007.01.010
   Kim YC, 2007, J NEUROSCI, V27, P7640, DOI 10.1523/JNEUROSCI.1167-07.2007
   KOLMES SA, 1989, J NEW YORK ENTOMOL S, V97, P218
   Lange AB, 2009, GEN COMP ENDOCR, V162, P18, DOI 10.1016/j.ygcen.2008.05.021
   Libersat F, 2004, BIOSCIENCE, V54, P17, DOI 10.1641/0006-3568(2004)054[0017:MATOOB]2.0.CO;2
   Mackintosh N. J., 1974, PSYCHOL ANIMAL LEARN
   Maqueira B, 2005, J NEUROCHEM, V94, P547, DOI 10.1111/j.1471-4159.2005.03251.x
   Menzel R, 2001, LEARN MEMORY, V8, P53, DOI 10.1101/lm.38801
   Menzel R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004694
   Mustard JA, 2010, J INSECT PHYSIOL, V56, P422, DOI 10.1016/j.jinsphys.2009.11.018
   Nagaya Y, 2002, NEUROSCI LETT, V329, P324, DOI 10.1016/S0304-3940(02)00596-7
   Niggebrugge C, 2009, J EXP BIOL, V212, P1344, DOI 10.1242/jeb.021881
   OSHEA M, 1979, J EXP BIOL, V79, P169
   PAGE JRE, 1998, J COMP PHYSIOL A, V182, P489
   QUINN WG, 1974, P NATL ACAD SCI USA, V71, P708, DOI 10.1073/pnas.71.3.708
   RAGLAND RS, 1965, PSYCHON SCI, V3, P117
   Robinson GE, 2008, SCIENCE, V322, P896, DOI 10.1126/science.1159277
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   ROEDER T, 1990, EUR J PHARMACOL, V191, P221, DOI 10.1016/0014-2999(90)94151-M
   Sandoz JC, 2001, LEARN MEMORY, V8, P286, DOI 10.1101/lm.41401
   Scheiner R, 2002, BEHAV BRAIN RES, V136, P545, DOI 10.1016/S0166-4328(02)00205-X
   Schulz DJ, 2002, HORM BEHAV, V42, P222, DOI 10.1006/hbeh.2002.1806
   Schwaerzel M, 2003, J NEUROSCI, V23, P10495
   Seefeldt S, 2008, J EXP BIOL, V211, P3392, DOI 10.1242/jeb.017624
   Selcho M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005897
   SMITH BH, 1991, J COMP PSYCHOL, V105, P345, DOI 10.1037/0735-7036.105.4.345
   Sokal RR, 1995, BIOMETRY PRINCIPLES
   Srinivasan MV, 2010, ANNU REV ENTOMOL, V55, P267, DOI 10.1146/annurev.ento.010908.164537
   Takahashi T, 2009, J NEUROSCI METH, V179, P9, DOI 10.1016/j.jneumeth.2009.01.002
   TAYLOR R C, 1971, Journal of Biological Psychology, V13, P36
   TEMPEL BL, 1984, P NATL ACAD SCI-BIOL, V81, P3577, DOI 10.1073/pnas.81.11.3577
   Tzschentke TM, 2007, ADDICT BIOL, V12, P227, DOI 10.1111/j.1369-1600.2007.00070.x
   Unoki S, 2006, EUR J NEUROSCI, V24, P2031, DOI 10.1111/j.1460-9568.2006.05099.x
   Vergoz V, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000288
   Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406
   Younger J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013309
NR 72
TC 44
Z9 45
U1 0
U2 36
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 30
PY 2011
VL 6
IS 9
AR e25371
DI 10.1371/journal.pone.0025371
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 834ED
UT WOS:000295941300026
PM 21980435
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

PT J
AU Shin, R
   Cao, JR
   Webb, SM
   Ikemoto, S
AF Shin, Rick
   Cao, Junran
   Webb, Sierra M.
   Ikemoto, Satoshi
TI Amphetamine Administration into the Ventral Striatum Facilitates
   Behavioral Interaction with Unconditioned Visual Signals in Rats
SO PLOS ONE
LA English
DT Article
ID NUCLEUS-ACCUMBENS SHELL; FREELY-MOVING RATS; OLFACTORY TUBERCLE;
   LOCOMOTOR-ACTIVITY; PLACE PREFERENCE; TEGMENTAL AREA; CONDITIONED
   REINFORCEMENT; DOPAMINERGIC-NEURONS; INCENTIVE SALIENCE; DRUG SEEKING
AB Background: Administration of psychomotor stimulants like amphetamine facilitates behavior in the presence of incentive distal stimuli, which have acquired the motivational properties of primary rewards through associative learning. This facilitation appears to be mediated by the mesolimbic dopamine system, which may also be involved in facilitating behavior in the presence of distal stimuli that have not been previously paired with primary rewards. However, it is unclear whether psychomotor stimulants facilitate behavioral interaction with unconditioned distal stimuli.
   Principal Findings: We found that noncontingent administration of amphetamine into subregions of the rat ventral striatum, particularly in the vicinity of the medial olfactory tubercle, facilitates lever pressing followed by visual signals that had not been paired with primary rewards. Noncontingent administration of amphetamine failed to facilitate lever pressing when it was followed by either tones or delayed presentation or absence of visual signals, suggesting that visual signals are key for enhanced behavioral interaction. Systemic administration of amphetamine markedly increased locomotor activity, but did not necessarily increase lever pressing rewarded by visual signals, suggesting that lever pressing is not a byproduct of heightened locomotor activity. Lever pressing facilitated by amphetamine was reduced by co-administration of the dopamine receptor antagonists SCH 23390 (D1 selective) or sulpiride (D2 selective).
   Conclusions: Our results suggest that amphetamine administration into the ventral striatum, particularly in the vicinity of the medial olfactory tubercle, activates dopaminergic mechanisms that strongly enhance behavioral interaction with unconditioned visual stimuli.
C1 [Shin, Rick; Cao, Junran; Webb, Sierra M.; Ikemoto, Satoshi] Natl Inst Drug Abuse, Behav Neurosci Res Branch, NIH, US Dept HHS, Baltimore, MD USA.
RP Shin, R (reprint author), Natl Inst Drug Abuse, Behav Neurosci Res Branch, NIH, US Dept HHS, Baltimore, MD USA.
EM Satoshi.Ikemoto@nih.gov
RI Cao, Junran/E-7354-2013
OI Ikemoto, Satoshi/0000-0002-0732-7386
FU Intramural Research Program of the National Institute on Drug Abuse;
   National Institutes of Health [DA000439-10]
FX Funding: This research was supported by the Intramural Research Program
   of the National Institute on Drug Abuse, National Institutes of Health
   (Project number: DA000439-10). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Aragona BJ, 2009, EUR J NEUROSCI, V30, P1889, DOI 10.1111/j.1460-9568.2009.07027.x
   BADIANI A, 1995, PSYCHOPHARMACOLOGY, V117, P443, DOI 10.1007/BF02246217
   Bardo MT, 1996, BEHAV BRAIN RES, V77, P23, DOI 10.1016/0166-4328(95)00203-0
   BARDO MT, 1989, PHARMACOL BIOCHEM BE, V32, P683, DOI 10.1016/0091-3057(89)90018-X
   BERLYNE DE, 1969, ANN NY ACAD SCI, V159, P1059, DOI 10.1111/j.1749-6632.1969.tb12997.x
   Berridge KC, 1998, BRAIN RES REV, V28, P309, DOI 10.1016/S0165-0173(98)00019-8
   Besheer J, 1999, BEHAV BRAIN RES, V103, P35, DOI 10.1016/S0166-4328(99)00021-2
   Cadoni C, 2000, EUR J PHARMACOL, V387, pR23, DOI 10.1016/S0014-2999(99)00843-2
   Chaudhri N, 2006, PSYCHOPHARMACOLOGY, V184, P353, DOI 10.1007/s00213-005-0178-1
   CLARKE PBS, 1985, BRAIN RES, V348, P355, DOI 10.1016/0006-8993(85)90456-1
   CORRIGALL WA, 1992, PSYCHOPHARMACOLOGY, V107, P285, DOI 10.1007/BF02245149
   Crombag HS, 1996, BRAIN RES, V722, P227, DOI 10.1016/0006-8993(96)00066-2
   CROW TJ, 1973, PSYCHOL MED, V3, P66, DOI 10.1017/S0033291700046353
   David V, 2006, NEUROPHARMACOLOGY, V50, P1030, DOI 10.1016/j.neuropharm.2006.02.003
   Dommett E, 2005, SCIENCE, V307, P1476, DOI 10.1126/science.1107026
   Donny EC, 2003, PSYCHOPHARMACOLOGY, V169, P68, DOI 10.1007/s00213-003-1473-3
   FIBIGER HC, 1986, HDB PHYSL NERVOUS SY, V4, P647
   FINK JS, 1979, J COMP PHYSIOL PSYCH, V93, P34, DOI 10.1037/h0077587
   Gray JA, 1995, BEHAV BRAIN RES, V71, P19, DOI 10.1016/0166-4328(95)00154-9
   Haber SN, 2003, J CHEM NEUROANAT, V26, P317, DOI 10.1016/j.jchemneu.2003.10.003
   Heimer L, 1975, GOLGI CENTENNIAL S P, P177
   Heimer L., 1978, LIMBIC MECHANISMS CO, P95
   Hernandez PJ, 2002, NAT NEUROSCI, V5, P1327, DOI 10.1038/nn973
   Horvitz JC, 2000, NEUROSCIENCE, V96, P651, DOI 10.1016/S0306-4522(00)00019-1
   HUSTON JP, 1989, NEUROSCI BIOBEHAV R, V13, P171, DOI 10.1016/S0149-7634(89)80027-2
   Ikemoto S, 1999, BRAIN RES REV, V31, P6, DOI 10.1016/S0165-0173(99)00023-5
   Ikemoto S, 2006, J NEUROSCI, V26, P723, DOI 10.1523/JNEUROSCI.4542-05.2006
   Ikemoto S, 2005, J NEUROSCI, V25, P5061, DOI 10.1523/JNEUROSCI.0892-05.2005
   Ikemoto S, 2005, SYNAPSE, V56, P57, DOI 10.1002/syn.20124
   Ikemoto S, 2003, J NEUROSCI, V23, P9305
   Ikemoto S, 2002, NEUROSCIENCE, V113, P939, DOI 10.1016/S0306-4522(02)00247-6
   Ikemoto S, 2001, J NEUROSCI METH, V110, P135, DOI 10.1016/S0165-0270(01)00428-9
   Ikemoto S, 2007, BRAIN RES REV, V56, P27, DOI 10.1016/j.brainresrev.2007.05.004
   KAVANAU JL, 1967, SCIENCE, V155, P1623, DOI 10.1126/science.155.3770.1623
   KELLEY AE, 1991, PSYCHOPHARMACOLOGY, V103, P187, DOI 10.1007/BF02244202
   KISH GB, 1955, J COMP PHYSIOL PSYCH, V48, P261, DOI 10.1037/h0040782
   Kish GB, 1966, OPERANT BEHAVIOR ARE, P109
   LANDAUER TK, 1969, PSYCHOL REV, V76, P82, DOI 10.1037/h0026746
   MARX MH, 1955, J COMP PHYSIOL PSYCH, V48, P73, DOI 10.1037/h0045062
   Miller CA, 2005, NEURON, V47, P873, DOI 10.1016/j.neuron.2005.08.006
   NICHOLLS B, 1992, J NEUROSCI METH, V43, P171, DOI 10.1016/0165-0270(92)90026-A
   NISELL M, 1995, PHARMACOL TOXICOL, V76, P157, DOI 10.1111/j.1600-0773.1995.tb00123.x
   NISELL M, 1994, SYNAPSE, V16, P36, DOI 10.1002/syn.890160105
   Olsen CM, 2009, NEUROPSYCHOPHARMACOL, V34, P1685, DOI 10.1038/npp.2008.226
   PIJNENBURG AJJ, 1975, PSYCHOPHARMACOLOGIA, V41, P87, DOI 10.1007/BF00421062
   Rebec GV, 1997, BRAIN RES, V776, P61, DOI 10.1016/S0006-8993(97)01004-4
   Rebec GV, 1997, NEUROSCIENCE, V76, P707, DOI 10.1016/S0306-4522(96)00382-X
   ROBBINS T, 1973, PSYCHOPHARMACOLOGIA, V28, P155, DOI 10.1007/BF00421400
   ROBBINS TW, 1978, PSYCHOPHARMACOLOGY, V58, P79, DOI 10.1007/BF00426794
   ROBBINS TW, 1982, INT REV NEUROBIOL, V23, P303, DOI 10.1016/S0074-7742(08)60628-5
   ROBBINS TW, 1989, NEUROSCI BIOBEHAV R, V13, P155, DOI 10.1016/S0149-7634(89)80025-9
   Robinson DL, 2004, J NEUROCHEM, V90, P894, DOI 10.1111/j.1471-4159.2004.02559.x
   Robinson TE, 2008, PHILOS T R SOC B, V363, P3137, DOI 10.1098/rstb.2008.0093
   Schultz W, 1998, J NEUROPHYSIOL, V80, P1
   Sellings LHL, 2006, NEUROSCIENCE, V141, P1457, DOI 10.1016/j.neuroscience.2006.04.040
   Sellings LHL, 2008, EUR J NEUROSCI, V28, P342, DOI 10.1111/j.1460-9568.2008.06341.x
   Shin R, 2008, PSYCHOPHARMACOLOGY, V198, P261, DOI 10.1007/s00213-008-1131-x
   SKINNER BF, 1948, J EXP PSYCHOL, V38, P168, DOI 10.1037/h0055873
   Spina L, 2006, PSYCHOPHARMACOLOGY, V184, P447, DOI 10.1007/s00213-005-0211-4
   Staddon JER, 1977, HDB OPERANT BEHAVIOR, P125
   STEWART J, 1958, Q J EXP PSYCHOL, V10, P56, DOI 10.1080/17470215808416254
   STEWART J, 1984, PSYCHOL REV, V91, P251, DOI 10.1037/0033-295X.91.2.251
   TAGHZOUTI K, 1985, BRAIN RES, V344, P9, DOI 10.1016/0006-8993(85)91184-9
   TAYLOR JR, 1986, PSYCHOPHARMACOLOGY, V90, P390
   TAYLOR JR, 1984, PSYCHOPHARMACOLOGY, V84, P405, DOI 10.1007/BF00555222
   Voorn P, 2004, TRENDS NEUROSCI, V27, P468, DOI 10.1016/j.tins.2004.06.006
   White NM, 1996, ADDICTION, V91, P921, DOI 10.1046/j.1360-0443.1996.9179212.x
   Wise RA, 2004, NAT REV NEUROSCI, V5, P483, DOI 10.1038/nrn1406
   Wyvell CL, 2000, J NEUROSCI, V20, P8122
NR 69
TC 26
Z9 26
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 15
PY 2010
VL 5
IS 1
AR e8741
DI 10.1371/journal.pone.0008741
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 545EI
UT WOS:000273714900021
PM 20090902
OA DOAJ Gold, Green Published
DA 2019-07-08
ER

EF